

Table 19.1  
Non-Hodgkin Lymphoma

Trends in SEER Incidence<sup>ab</sup> and U.S. Mortality<sup>c</sup> Using the Joinpoint Regression Program,  
1975-2013 With up to Five Joinpoints, 1992-2013 With up to Four Joinpoints,  
Both Sexes by Race/Ethnicity

|                                                                | JP Trend 1 |       | JP Trend 2 |       | JP Trend 3 |       | JP Trend 4 |       | JP Trend 5 |     | JP Trend 6 |     | AAPC <sup>d</sup> |         |
|----------------------------------------------------------------|------------|-------|------------|-------|------------|-------|------------|-------|------------|-----|------------|-----|-------------------|---------|
|                                                                | Years      | APC   | Years      | APC   | Years      | APC   | Years      | APC   | Years      | APC | Years      | APC | 2004-13           | 2009-13 |
| <u>SEER 9 Delay-Adjusted Incidence<sup>a</sup>, 1975-2013</u>  |            |       |            |       |            |       |            |       |            |     |            |     |                   |         |
| All Races                                                      | 1975-91    | 3.6*  | 1991-09    | 0.7*  | 2009-13    | -1.5  |            |       |            |     |            |     | -0.3              | -1.5    |
| White                                                          | 1975-90    | 3.8*  | 1990-07    | 0.8*  | 2007-13    | -0.8* |            |       |            |     |            |     | -0.3              | -0.8*   |
| Black                                                          | 1975-94    | 4.6*  | 1994-13    | 0.5   |            |       |            |       |            |     |            |     | 0.5               | 0.5     |
| <u>SEER 13 Delay-Adjusted Incidence<sup>b</sup>, 1992-2013</u> |            |       |            |       |            |       |            |       |            |     |            |     |                   |         |
| All Races                                                      | 1992-09    | 0.6*  | 2009-13    | -1.4  |            |       |            |       |            |     |            |     | -0.3              | -1.4    |
| White                                                          | 1992-09    | 0.6*  | 2009-13    | -1.5  |            |       |            |       |            |     |            |     | -0.3              | -1.5    |
| Black                                                          | 1992-13    | 0.6*  |            |       |            |       |            |       |            |     |            |     | 0.6*              | 0.6*    |
| <u>SEER 9 Observed Incidence<sup>a</sup>, 1975-2013</u>        |            |       |            |       |            |       |            |       |            |     |            |     |                   |         |
| All Races                                                      | 1975-91    | 3.6*  | 1991-09    | 0.6*  | 2009-13    | -2.1* |            |       |            |     |            |     | -0.6              | -2.1*   |
| White                                                          | 1975-90    | 3.8*  | 1990-07    | 0.8*  | 2007-13    | -1.3* |            |       |            |     |            |     | -0.6*             | -1.3*   |
| Black                                                          | 1975-95    | 4.4*  | 1995-13    | 0.2   |            |       |            |       |            |     |            |     | 0.2               | 0.2     |
| <u>SEER 13 Observed Incidence<sup>b</sup>, 1992-2013</u>       |            |       |            |       |            |       |            |       |            |     |            |     |                   |         |
| All Races                                                      | 1992-09    | 0.5*  | 2009-13    | -2.0* |            |       |            |       |            |     |            |     | -0.6              | -2.0*   |
| White                                                          | 1992-09    | 0.6*  | 2009-13    | -2.2* |            |       |            |       |            |     |            |     | -0.7              | -2.2*   |
| White NH <sup>ef</sup>                                         | 1992-07    | 0.8*  | 2007-13    | -1.2* |            |       |            |       |            |     |            |     | -0.6*             | -1.2*   |
| Black                                                          | 1992-97    | 4.0*  | 1997-00    | -4.3  | 2000-04    | 3.9   | 2004-13    | -1.0* |            |     |            |     | -1.0*             | -1.0*   |
| Black NH <sup>ef</sup>                                         | 1992-97    | 3.8*  | 1997-00    | -4.2  | 2000-04    | 4.0   | 2004-13    | -0.9  |            |     |            |     | -0.9              | -0.9    |
| API <sup>e</sup>                                               | 1992-13    | 0.2   |            |       |            |       |            |       |            |     |            |     | 0.2               | 0.2     |
| AI/AN <sup>eg</sup>                                            | 1992-13    | 1.7*  |            |       |            |       |            |       |            |     |            |     | 1.7*              | 1.7*    |
| Hispanic <sup>f</sup>                                          | 1992-10    | 0.6*  | 2010-13    | -2.9  |            |       |            |       |            |     |            |     | -0.6              | -2.0    |
| <u>U.S. Cancer Mortality<sup>c</sup>, 1975-2013</u>            |            |       |            |       |            |       |            |       |            |     |            |     |                   |         |
| All Races                                                      | 1975-91    | 2.5*  | 1991-97    | 1.6*  | 1997-06    | -3.1* | 2006-13    | -2.2* |            |     |            |     | -2.4*             | -2.2*   |
| White                                                          | 1975-91    | 2.5*  | 1991-97    | 1.6*  | 1997-06    | -3.1* | 2006-13    | -2.2* |            |     |            |     | -2.4*             | -2.2*   |
| Black                                                          | 1975-96    | 2.7*  | 1996-13    | -2.4* |            |       |            |       |            |     |            |     | -2.4*             | -2.4*   |
| <u>U.S. Cancer Mortality<sup>c</sup>, 1992-2013</u>            |            |       |            |       |            |       |            |       |            |     |            |     |                   |         |
| All Races                                                      | 1992-97    | 1.7*  | 1997-06    | -3.1* | 2006-13    | -2.2* |            |       |            |     |            |     | -2.4*             | -2.2*   |
| White                                                          | 1992-97    | 1.7*  | 1997-06    | -3.1* | 2006-13    | -2.2* |            |       |            |     |            |     | -2.4*             | -2.2*   |
| White NH <sup>ef</sup>                                         | 1992-97    | 1.9*  | 1997-06    | -3.1* | 2006-13    | -2.3* |            |       |            |     |            |     | -2.5*             | -2.3*   |
| Black                                                          | 1992-96    | 2.6   | 1996-13    | -2.3* |            |       |            |       |            |     |            |     | -2.3*             | -2.3*   |
| Black NH <sup>ef</sup>                                         | 1992-96    | 3.0   | 1996-13    | -2.3* |            |       |            |       |            |     |            |     | -2.3*             | -2.3*   |
| API <sup>e</sup>                                               | 1992-13    | -1.9* |            |       |            |       |            |       |            |     |            |     | -1.9*             | -1.9*   |
| AI/AN <sup>eg</sup>                                            | 1992-13    | -0.6  |            |       |            |       |            |       |            |     |            |     | -0.6              | -0.6    |
| Hispanic <sup>f</sup>                                          | 1992-97    | 3.1*  | 1997-03    | -3.6* | 2003-13    | -1.3* |            |       |            |     |            |     | -1.3*             | -1.3*   |

Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

\* The APC/AAPC is significantly different from zero ( $p < .05$ ).

- Joinpoint regression line analysis could not be performed on data series.

Table 19.2  
Non-Hodgkin Lymphoma

Trends in SEER Incidence<sup>ab</sup> and U.S. Mortality<sup>c</sup> Using the Joinpoint Regression Program,  
1975-2013 With up to Five Joinpoints, 1992-2013 With up to Four Joinpoints,  
Males by Race/Ethnicity

|                                                                | JP Trend 1 |       | JP Trend 2 |       | JP Trend 3 |       | JP Trend 4 |       | JP Trend 5 |     | JP Trend 6 |     | AAPC <sup>d</sup> |         |
|----------------------------------------------------------------|------------|-------|------------|-------|------------|-------|------------|-------|------------|-----|------------|-----|-------------------|---------|
|                                                                | Years      | APC   | Years      | APC   | Years      | APC   | Years      | APC   | Years      | APC | Years      | APC | 2004-13           | 2009-13 |
| <u>SEER 9 Delay-Adjusted Incidence<sup>a</sup>, 1975-2013</u>  |            |       |            |       |            |       |            |       |            |     |            |     |                   |         |
| All Races                                                      | 1975-91    | 4.2*  | 1991-13    | 0.3*  |            |       |            |       |            |     |            |     | 0.3*              | 0.3*    |
| White                                                          | 1975-90    | 4.4*  | 1990-09    | 0.6*  | 2009-13    | -1.2  |            |       |            |     |            |     | -0.2              | -1.2    |
| Black                                                          | 1975-94    | 5.5*  | 1994-13    | -0.3  |            |       |            |       |            |     |            |     | -0.3              | -0.3    |
| <u>SEER 13 Delay-Adjusted Incidence<sup>b</sup>, 1992-2013</u> |            |       |            |       |            |       |            |       |            |     |            |     |                   |         |
| All Races                                                      | 1992-13    | 0.2   |            |       |            |       |            |       |            |     |            |     | 0.2               | 0.2     |
| White                                                          | 1992-95    | 2.7   | 1995-98    | -2.1  | 1998-09    | 0.8*  | 2009-13    | -1.4  |            |     |            |     | -0.2              | -1.4    |
| Black                                                          | 1992-13    | -0.1  |            |       |            |       |            |       |            |     |            |     | -0.1              | -0.1    |
| <u>SEER 9 Observed Incidence<sup>a</sup>, 1975-2013</u>        |            |       |            |       |            |       |            |       |            |     |            |     |                   |         |
| All Races                                                      | 1975-91    | 4.2*  | 1991-10    | 0.4*  | 2010-13    | -2.6  |            |       |            |     |            |     | -0.6              | -1.9    |
| White                                                          | 1975-90    | 4.4*  | 1990-09    | 0.6*  | 2009-13    | -1.9* |            |       |            |     |            |     | -0.5              | -1.9*   |
| Black                                                          | 1975-94    | 5.5*  | 1994-13    | -0.5  |            |       |            |       |            |     |            |     | -0.5              | -0.5    |
| <u>SEER 13 Observed Incidence<sup>b</sup>, 1992-2013</u>       |            |       |            |       |            |       |            |       |            |     |            |     |                   |         |
| All Races                                                      | 1992-10    | 0.2*  | 2010-13    | -2.2  |            |       |            |       |            |     |            |     | -0.6              | -1.6    |
| White                                                          | 1992-95    | 2.7   | 1995-98    | -2.0  | 1998-09    | 0.7*  | 2009-13    | -2.1* |            |     |            |     | -0.5              | -2.1*   |
| White NH <sup>ef</sup>                                         | 1992-09    | 0.5*  | 2009-13    | -1.7  |            |       |            |       |            |     |            |     | -0.5              | -1.7    |
| Black                                                          | 1992-13    | -0.3  |            |       |            |       |            |       |            |     |            |     | -0.3              | -0.3    |
| Black NH <sup>ef</sup>                                         | 1992-13    | -0.3  |            |       |            |       |            |       |            |     |            |     | -0.3              | -0.3    |
| API <sup>e</sup>                                               | 1992-13    | 0.3   |            |       |            |       |            |       |            |     |            |     | 0.3               | 0.3     |
| AI/AN <sup>eg</sup>                                            | 1992-13    | 0.8   |            |       |            |       |            |       |            |     |            |     | 0.8               | 0.8     |
| Hispanic <sup>f</sup>                                          | 1992-13    | 0.1   |            |       |            |       |            |       |            |     |            |     | 0.1               | 0.1     |
| <u>U.S. Cancer Mortality<sup>c</sup>, 1975-2013</u>            |            |       |            |       |            |       |            |       |            |     |            |     |                   |         |
| All Races                                                      | 1975-91    | 2.7*  | 1991-97    | 1.6*  | 1997-06    | -2.9* | 2006-13    | -2.0* |            |     |            |     | -2.2*             | -2.0*   |
| White                                                          | 1975-96    | 2.5*  | 1996-13    | -2.5* |            |       |            |       |            |     |            |     | -2.5*             | -2.5*   |
| Black                                                          | 1975-96    | 2.7*  | 1996-13    | -2.5* |            |       |            |       |            |     |            |     | -2.5*             | -2.5*   |
| <u>U.S. Cancer Mortality<sup>c</sup>, 1992-2013</u>            |            |       |            |       |            |       |            |       |            |     |            |     |                   |         |
| All Races                                                      | 1992-97    | 1.7*  | 1997-06    | -2.9* | 2006-13    | -2.0* |            |       |            |     |            |     | -2.2*             | -2.0*   |
| White                                                          | 1992-97    | 1.7*  | 1997-06    | -2.8* | 2006-13    | -1.9* |            |       |            |     |            |     | -2.1*             | -1.9*   |
| White NH <sup>ef</sup>                                         | 1992-97    | 1.7*  | 1997-13    | -2.5* |            |       |            |       |            |     |            |     | -2.5*             | -2.5*   |
| Black                                                          | 1992-96    | 2.7   | 1996-13    | -2.4* |            |       |            |       |            |     |            |     | -2.4*             | -2.4*   |
| Black NH <sup>ef</sup>                                         | 1992-96    | 3.0   | 1996-13    | -2.3* |            |       |            |       |            |     |            |     | -2.3*             | -2.3*   |
| API <sup>e</sup>                                               | 1992-13    | -2.1* |            |       |            |       |            |       |            |     |            |     | -2.1*             | -2.1*   |
| AI/AN <sup>eg</sup>                                            | 1992-13    | -0.4  |            |       |            |       |            |       |            |     |            |     | -0.4              | -0.4    |
| Hispanic <sup>f</sup>                                          | 1992-96    | 4.5   | 1996-03    | -3.9* | 2003-13    | -0.9  |            |       |            |     |            |     | -0.9              | -0.9    |

Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

\* The APC/AAPC is significantly different from zero ( $p < .05$ ).

- Joinpoint regression line analysis could not be performed on data series.

a  
b  
c  
d  
e  
f

g

\*

-

Table 19.3  
Non-Hodgkin Lymphoma

Trends in SEER Incidence<sup>ab</sup> and U.S. Mortality<sup>c</sup> Using the Joinpoint Regression Program,  
1975-2013 With up to Five Joinpoints, 1992-2013 With up to Four Joinpoints,  
Females by Race/Ethnicity

|                                                                | JP Trend 1 |       | JP Trend 2 |       | JP Trend 3 |       | JP Trend 4 |       | JP Trend 5 |       | JP Trend 6 |     | AAPC <sup>d</sup> |         |
|----------------------------------------------------------------|------------|-------|------------|-------|------------|-------|------------|-------|------------|-------|------------|-----|-------------------|---------|
|                                                                | Years      | APC   | Years      | APC   | Years      | APC   | Years      | APC   | Years      | APC   | Years      | APC | 2004-13           | 2009-13 |
| <u>SEER 9 Delay-Adjusted Incidence<sup>a</sup>, 1975-2013</u>  |            |       |            |       |            |       |            |       |            |       |            |     |                   |         |
| All Races                                                      | 1975-88    | 3.0*  | 1988-04    | 1.4*  | 2004-13    | -0.6* |            |       |            |       |            |     | -0.6*             | -0.6*   |
| White                                                          | 1975-88    | 3.0*  | 1988-04    | 1.4*  | 2004-13    | -0.7* |            |       |            |       |            |     | -0.7*             | -0.7*   |
| Black                                                          | 1975-04    | 2.9*  | 2004-13    | -0.2  |            |       |            |       |            |       |            |     | -0.2              | -0.2    |
| <u>SEER 13 Delay-Adjusted Incidence<sup>b</sup>, 1992-2013</u> |            |       |            |       |            |       |            |       |            |       |            |     |                   |         |
| All Races                                                      | 1992-04    | 1.4*  | 2004-13    | -0.6* |            |       |            |       |            |       |            |     | -0.6*             | -0.6*   |
| White                                                          | 1992-04    | 1.4*  | 2004-13    | -0.5  |            |       |            |       |            |       |            |     | -0.5              | -0.5    |
| Black                                                          | 1992-98    | 5.3*  | 1998-13    | 0.6*  |            |       |            |       |            |       |            |     | 0.6*              | 0.6*    |
| <u>SEER 9 Observed Incidence<sup>a</sup>, 1975-2013</u>        |            |       |            |       |            |       |            |       |            |       |            |     |                   |         |
| All Races                                                      | 1975-88    | 3.0*  | 1988-04    | 1.4*  | 2004-13    | -0.9* |            |       |            |       |            |     | -0.9*             | -0.9*   |
| White                                                          | 1975-88    | 3.0*  | 1988-04    | 1.5*  | 2004-13    | -1.0* |            |       |            |       |            |     | -1.0*             | -1.0*   |
| Black                                                          | 1975-04    | 2.9*  | 2004-13    | -0.6  |            |       |            |       |            |       |            |     | -0.6              | -0.6    |
| <u>SEER 13 Observed Incidence<sup>b</sup>, 1992-2013</u>       |            |       |            |       |            |       |            |       |            |       |            |     |                   |         |
| All Races                                                      | 1992-04    | 1.4*  | 2004-13    | -0.9* |            |       |            |       |            |       |            |     | -0.9*             | -0.9*   |
| White                                                          | 1992-04    | 1.4*  | 2004-13    | -0.9* |            |       |            |       |            |       |            |     | -0.9*             | -0.9*   |
| White NH <sup>ef</sup>                                         | 1992-04    | 1.5*  | 2004-13    | -1.0* |            |       |            |       |            |       |            |     | -1.0*             | -1.0*   |
| Black                                                          | 1992-98    | 5.5*  | 1998-13    | 0.4   |            |       |            |       |            |       |            |     | 0.4               | 0.4     |
| Black NH <sup>ef</sup>                                         | 1992-98    | 5.4*  | 1998-13    | 0.5   |            |       |            |       |            |       |            |     | 0.5               | 0.5     |
| API <sup>e</sup>                                               | 1992-13    | 0.2   |            |       |            |       |            |       |            |       |            |     | 0.2               | 0.2     |
| AI/AN <sup>eg</sup>                                            | 1992-13    | 2.4*  |            |       |            |       |            |       |            |       |            |     | 2.4*              | 2.4*    |
| Hispanic <sup>f</sup>                                          | 1992-13    | 0.7*  |            |       |            |       |            |       |            |       |            |     | 0.7*              | 0.7*    |
| <u>U.S. Cancer Mortality<sup>c</sup>, 1975-2013</u>            |            |       |            |       |            |       |            |       |            |       |            |     |                   |         |
| All Races                                                      | 1975-94    | 2.2*  | 1994-97    | 0.8   | 1997-13    | -3.1* |            |       |            |       |            |     | -3.1*             | -3.1*   |
| White                                                          | 1975-94    | 2.2*  | 1994-97    | 0.8   | 1997-13    | -3.1* |            |       |            |       |            |     | -3.1*             | -3.1*   |
| Black                                                          | 1975-96    | 2.7*  | 1996-13    | -2.3* |            |       |            |       |            |       |            |     | -2.3*             | -2.3*   |
| <u>U.S. Cancer Mortality<sup>c</sup>, 1992-2013</u>            |            |       |            |       |            |       |            |       |            |       |            |     |                   |         |
| All Races                                                      | 1992-94    | 3.0*  | 1994-97    | 0.7   | 1997-00    | -2.7* | 2000-04    | -3.8* | 2004-13    | -2.8* |            |     | -2.8*             | -2.8*   |
| White                                                          | 1992-94    | 3.3*  | 1994-97    | 0.6   | 1997-00    | -2.5* | 2000-03    | -4.3* | 2003-13    | -2.8* |            |     | -2.8*             | -2.8*   |
| White NH <sup>ef</sup>                                         | 1992-94    | 4.0*  | 1994-97    | 0.6   | 1997-00    | -2.5* | 2000-03    | -4.3* | 2003-13    | -2.9* |            |     | -2.9*             | -2.9*   |
| Black                                                          | 1992-97    | 1.8   | 1997-13    | -2.4* |            |       |            |       |            |       |            |     | -2.4*             | -2.4*   |
| Black NH <sup>ef</sup>                                         | 1992-97    | 2.1   | 1997-13    | -2.3* |            |       |            |       |            |       |            |     | -2.3*             | -2.3*   |
| API <sup>e</sup>                                               | 1992-13    | -1.7* |            |       |            |       |            |       |            |       |            |     | -1.7*             | -1.7*   |
| AI/AN <sup>eg</sup>                                            | 1992-01    | 5.6   | 2001-13    | -4.5* |            |       |            |       |            |       |            |     | -4.5*             | -4.5*   |
| Hispanic <sup>f</sup>                                          | 1992-97    | 2.9   | 1997-13    | -2.1* |            |       |            |       |            |       |            |     | -2.1*             | -2.1*   |

Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

\* The APC/AAPC is significantly different from zero ( $p < .05$ ).

- Joinpoint regression line analysis could not be performed on data series.

Table 19.4  
Non-Hodgkin Lymphoma

Delay-adjusted SEER Incidence<sup>a</sup> Rates by Year, Race and Sex

|                    | All Races |       |         | Whites |       |         | Blacks |       |         |
|--------------------|-----------|-------|---------|--------|-------|---------|--------|-------|---------|
|                    | Total     | Males | Females | Total  | Males | Females | Total  | Males | Females |
| Year of Diagnosis: |           |       |         |        |       |         |        |       |         |
| 1975               | 11.07     | 12.89 | 9.59    | 11.61  | 13.49 | 10.11   | 6.36   | 7.31  | 5.31    |
| 1976               | 11.22     | 12.82 | 10.06   | 11.65  | 13.27 | 10.51   | 6.04   | 7.45  | 5.03    |
| 1977               | 11.18     | 12.93 | 9.82    | 11.64  | 13.52 | 10.20   | 6.64   | 7.23  | 6.10    |
| 1978               | 11.92     | 14.26 | 10.12   | 12.47  | 14.74 | 10.74   | 7.15   | 9.46  | 5.17    |
| 1979               | 12.53     | 14.21 | 11.21   | 12.99  | 14.59 | 11.77   | 8.46   | 11.95 | 5.91    |
| 1980               | 12.62     | 15.01 | 10.81   | 12.97  | 15.26 | 11.22   | 8.77   | 10.89 | 7.20    |
| 1981               | 13.58     | 15.90 | 11.81   | 14.06  | 16.34 | 12.35   | 7.42   | 10.59 | 4.98    |
| 1982               | 13.39     | 15.56 | 11.61   | 14.02  | 16.42 | 12.05   | 10.27  | 10.22 | 10.01   |
| 1983               | 13.99     | 16.62 | 11.95   | 14.63  | 17.52 | 12.40   | 10.28  | 10.88 | 9.62    |
| 1984               | 15.20     | 18.29 | 12.79   | 15.97  | 19.10 | 13.55   | 9.46   | 12.52 | 6.92    |
| 1985               | 15.51     | 18.39 | 13.17   | 16.28  | 19.24 | 13.86   | 9.95   | 11.96 | 8.43    |
| 1986               | 15.91     | 19.43 | 13.01   | 16.82  | 20.56 | 13.75   | 10.66  | 13.13 | 8.52    |
| 1987               | 16.74     | 20.79 | 13.42   | 17.70  | 22.14 | 14.00   | 10.40  | 10.55 | 9.95    |
| 1988               | 17.25     | 21.33 | 14.08   | 18.21  | 22.42 | 14.90   | 11.58  | 15.79 | 8.49    |
| 1989               | 17.35     | 21.65 | 13.84   | 18.35  | 23.02 | 14.50   | 11.62  | 14.17 | 9.72    |
| 1990               | 18.50     | 22.97 | 14.81   | 19.33  | 23.93 | 15.50   | 13.92  | 17.63 | 11.02   |
| 1991               | 18.80     | 23.73 | 14.60   | 19.68  | 24.80 | 15.30   | 14.03  | 18.72 | 10.37   |
| 1992               | 18.62     | 23.04 | 14.94   | 19.55  | 23.94 | 15.83   | 13.68  | 18.87 | 9.65    |
| 1993               | 18.86     | 23.47 | 15.01   | 19.65  | 24.29 | 15.72   | 14.11  | 19.37 | 9.78    |
| 1994               | 19.95     | 24.96 | 15.80   | 20.68  | 25.58 | 16.56   | 14.43  | 21.52 | 8.77    |
| 1995               | 19.97     | 25.41 | 15.42   | 20.67  | 26.15 | 16.01   | 16.70  | 23.54 | 11.38   |
| 1996               | 19.42     | 24.23 | 15.48   | 20.26  | 25.19 | 16.19   | 15.46  | 19.19 | 12.30   |
| 1997               | 19.98     | 24.51 | 16.44   | 20.87  | 25.20 | 17.46   | 16.34  | 24.16 | 10.84   |
| 1998               | 19.61     | 22.95 | 16.84   | 20.57  | 23.98 | 17.74   | 14.49  | 16.96 | 12.54   |
| 1999               | 19.96     | 24.59 | 16.33   | 20.90  | 25.47 | 17.28   | 14.38  | 18.42 | 11.31   |
| 2000               | 19.79     | 24.32 | 16.11   | 20.92  | 25.64 | 17.05   | 13.92  | 18.23 | 10.73   |
| 2001               | 19.99     | 24.38 | 16.44   | 20.79  | 25.42 | 17.03   | 16.01  | 18.33 | 13.92   |
| 2002               | 20.21     | 24.19 | 17.08   | 21.31  | 25.49 | 17.95   | 14.45  | 17.10 | 12.45   |
| 2003               | 20.76     | 25.04 | 17.51   | 21.88  | 26.30 | 18.45   | 16.11  | 19.72 | 13.59   |
| 2004               | 21.39     | 25.87 | 17.94   | 22.32  | 26.80 | 18.83   | 18.48  | 24.03 | 14.47   |
| 2005               | 20.88     | 25.64 | 17.07   | 22.04  | 26.79 | 18.18   | 16.82  | 20.10 | 14.15   |
| 2006               | 20.57     | 24.80 | 17.29   | 21.81  | 26.13 | 18.40   | 16.45  | 21.05 | 13.02   |
| 2007               | 21.36     | 26.26 | 17.45   | 22.65  | 27.69 | 18.52   | 15.80  | 19.33 | 13.12   |
| 2008               | 21.03     | 25.86 | 17.09   | 21.90  | 26.92 | 17.74   | 17.10  | 19.20 | 15.20   |
| 2009               | 21.02     | 25.35 | 17.52   | 22.11  | 26.79 | 18.19   | 15.46  | 18.81 | 13.00   |
| 2010               | 21.56     | 26.80 | 17.30   | 22.46  | 27.54 | 18.29   | 17.93  | 23.43 | 13.55   |
| 2011               | 20.08     | 24.60 | 16.51   | 21.02  | 25.70 | 17.28   | 14.77  | 17.73 | 12.58   |
| 2012               | 20.59     | 25.21 | 16.84   | 21.55  | 26.28 | 17.65   | 17.06  | 19.53 | 14.86   |
| 2013               | 20.17     | 24.72 | 16.48   | 21.31  | 26.00 | 17.42   | 15.85  | 18.52 | 13.83   |

Additional information on the model used to delay-adjust SEER Incidence rates can be found at [\(http://surveillance.cancer.gov/delay/\)](http://surveillance.cancer.gov/delay/).

- <sup>a</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).  
 Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).  
 - Delay-adjusted rate is not shown for observed rates based on less than 16 cases for the time interval.

Table 19.5  
Non-Hodgkin Lymphoma

Age-adjusted SEER Incidence<sup>a</sup> Rates by Year, Race and Sex

|                    | All Races |       |         | Whites |       |         | Blacks |       |         |
|--------------------|-----------|-------|---------|--------|-------|---------|--------|-------|---------|
|                    | Total     | Males | Females | Total  | Males | Females | Total  | Males | Females |
| Year of Diagnosis: |           |       |         |        |       |         |        |       |         |
| 1975-2013          | 18.27     | 22.41 | 15.00   | 19.03  | 23.27 | 15.65   | 13.89  | 17.36 | 11.17   |
| 1975               | 11.07     | 12.89 | 9.59    | 11.61  | 13.49 | 10.11   | 6.36   | 7.31  | 5.31    |
| 1976               | 11.22     | 12.82 | 10.06   | 11.65  | 13.27 | 10.51   | 6.04   | 7.45  | 5.03    |
| 1977               | 11.18     | 12.93 | 9.82    | 11.64  | 13.52 | 10.20   | 6.64   | 7.23  | 6.10    |
| 1978               | 11.92     | 14.26 | 10.12   | 12.47  | 14.74 | 10.74   | 7.15   | 9.46  | 5.17    |
| 1979               | 12.53     | 14.21 | 11.21   | 12.99  | 14.59 | 11.77   | 8.46   | 11.95 | 5.91    |
| 1980               | 12.62     | 15.01 | 10.81   | 12.97  | 15.26 | 11.22   | 8.77   | 10.89 | 7.20    |
| 1981               | 13.58     | 15.90 | 11.81   | 14.06  | 16.34 | 12.35   | 7.42   | 10.59 | 4.98    |
| 1982               | 13.39     | 15.56 | 11.61   | 14.02  | 16.42 | 12.05   | 10.27  | 10.22 | 10.01   |
| 1983               | 13.99     | 16.62 | 11.95   | 14.63  | 17.52 | 12.40   | 10.28  | 10.88 | 9.62    |
| 1984               | 15.20     | 18.29 | 12.79   | 15.97  | 19.10 | 13.55   | 9.46   | 12.52 | 6.92    |
| 1985               | 15.51     | 18.39 | 13.17   | 16.28  | 19.24 | 13.86   | 9.95   | 11.96 | 8.43    |
| 1986               | 15.91     | 19.43 | 13.01   | 16.82  | 20.56 | 13.75   | 10.66  | 13.13 | 8.52    |
| 1987               | 16.74     | 20.79 | 13.42   | 17.70  | 22.14 | 14.00   | 10.40  | 10.55 | 9.95    |
| 1988               | 17.25     | 21.33 | 14.08   | 18.21  | 22.42 | 14.90   | 11.58  | 15.79 | 8.49    |
| 1989               | 17.35     | 21.65 | 13.84   | 18.35  | 23.02 | 14.50   | 11.62  | 14.17 | 9.72    |
| 1990               | 18.50     | 22.97 | 14.81   | 19.33  | 23.93 | 15.50   | 13.92  | 17.63 | 11.02   |
| 1991               | 18.80     | 23.73 | 14.60   | 19.68  | 24.80 | 15.30   | 14.03  | 18.72 | 10.37   |
| 1992               | 18.62     | 23.04 | 14.94   | 19.55  | 23.94 | 15.83   | 13.68  | 18.87 | 9.65    |
| 1993               | 18.86     | 23.47 | 15.01   | 19.65  | 24.29 | 15.72   | 14.11  | 19.37 | 9.78    |
| 1994               | 19.95     | 24.96 | 15.80   | 20.68  | 25.58 | 16.56   | 14.43  | 21.52 | 8.77    |
| 1995               | 19.97     | 25.41 | 15.42   | 20.67  | 26.15 | 16.01   | 16.70  | 23.54 | 11.38   |
| 1996               | 19.42     | 24.23 | 15.48   | 20.26  | 25.19 | 16.19   | 15.46  | 19.19 | 12.30   |
| 1997               | 19.98     | 24.51 | 16.44   | 20.87  | 25.20 | 17.46   | 16.34  | 24.16 | 10.84   |
| 1998               | 19.61     | 22.95 | 16.84   | 20.57  | 23.98 | 17.74   | 14.49  | 16.96 | 12.54   |
| 1999               | 19.96     | 24.59 | 16.33   | 20.90  | 25.47 | 17.28   | 14.38  | 18.42 | 11.31   |
| 2000               | 19.79     | 24.32 | 16.11   | 20.92  | 25.64 | 17.05   | 13.92  | 18.23 | 10.73   |
| 2001               | 19.99     | 24.38 | 16.44   | 20.79  | 25.42 | 17.03   | 16.01  | 18.33 | 13.92   |
| 2002               | 20.21     | 24.19 | 17.08   | 21.31  | 25.49 | 17.95   | 14.45  | 17.10 | 12.45   |
| 2003               | 20.76     | 25.04 | 17.51   | 21.88  | 26.30 | 18.45   | 16.11  | 19.72 | 13.59   |
| 2004               | 21.39     | 25.87 | 17.94   | 22.32  | 26.80 | 18.83   | 18.48  | 24.03 | 14.47   |
| 2005               | 20.83     | 25.59 | 17.04   | 21.99  | 26.74 | 18.14   | 16.76  | 20.03 | 14.10   |
| 2006               | 20.49     | 24.71 | 17.22   | 21.71  | 26.02 | 18.32   | 16.34  | 20.92 | 12.94   |
| 2007               | 21.23     | 26.10 | 17.35   | 22.51  | 27.52 | 18.40   | 15.66  | 19.16 | 13.00   |
| 2008               | 20.87     | 25.65 | 16.96   | 21.72  | 26.69 | 17.59   | 16.87  | 18.94 | 14.99   |
| 2009               | 20.82     | 25.11 | 17.34   | 21.87  | 26.51 | 17.98   | 15.21  | 18.50 | 12.78   |
| 2010               | 21.31     | 26.49 | 17.09   | 22.18  | 27.19 | 18.06   | 17.62  | 23.00 | 13.33   |
| 2011               | 19.77     | 24.23 | 16.26   | 20.67  | 25.27 | 16.99   | 14.43  | 17.30 | 12.29   |
| 2012               | 20.16     | 24.69 | 16.48   | 21.05  | 25.67 | 17.23   | 16.54  | 18.92 | 14.42   |
| 2013               | 19.51     | 23.89 | 15.94   | 20.51  | 25.01 | 16.77   | 15.15  | 17.70 | 13.22   |

<sup>a</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).  
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).  
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.6  
Non-Hodgkin Lymphoma

Age-adjusted U.S. Death<sup>a</sup> Rates by Year, Race and Sex

|                | All Races |       |         | Whites |       |         | Blacks |       |         |
|----------------|-----------|-------|---------|--------|-------|---------|--------|-------|---------|
|                | Total     | Males | Females | Total  | Males | Females | Total  | Males | Females |
| Year of Death: |           |       |         |        |       |         |        |       |         |
| 1975-2013      | 7.18      | 8.99  | 5.85    | 7.48   | 9.33  | 6.11    | 4.87   | 6.26  | 3.87    |
| 1975           | 5.63      | 6.92  | 4.65    | 5.83   | 7.15  | 4.82    | 3.74   | 4.83  | 2.92    |
| 1976           | 5.71      | 6.87  | 4.83    | 5.94   | 7.14  | 5.03    | 3.54   | 4.54  | 2.76    |
| 1977           | 5.77      | 6.88  | 4.92    | 5.96   | 7.10  | 5.10    | 3.89   | 4.89  | 3.12    |
| 1978           | 5.93      | 7.30  | 4.90    | 6.15   | 7.53  | 5.12    | 3.90   | 5.40  | 2.81    |
| 1979           | 5.95      | 7.40  | 4.88    | 6.18   | 7.70  | 5.08    | 3.65   | 4.50  | 2.98    |
| 1980           | 6.23      | 7.47  | 5.29    | 6.47   | 7.74  | 5.52    | 3.99   | 5.15  | 3.12    |
| 1981           | 6.16      | 7.38  | 5.27    | 6.40   | 7.66  | 5.47    | 3.98   | 5.00  | 3.25    |
| 1982           | 6.55      | 7.98  | 5.49    | 6.83   | 8.29  | 5.74    | 4.12   | 5.23  | 3.29    |
| 1983           | 6.66      | 8.11  | 5.58    | 6.92   | 8.39  | 5.85    | 4.30   | 5.79  | 3.23    |
| 1984           | 6.76      | 8.15  | 5.75    | 7.05   | 8.50  | 6.01    | 4.19   | 5.28  | 3.39    |
| 1985           | 7.06      | 8.80  | 5.80    | 7.34   | 9.17  | 6.02    | 4.62   | 5.57  | 3.87    |
| 1986           | 7.31      | 8.98  | 6.05    | 7.59   | 9.25  | 6.33    | 4.95   | 6.64  | 3.70    |
| 1987           | 7.26      | 8.81  | 6.10    | 7.56   | 9.12  | 6.38    | 4.73   | 6.30  | 3.62    |
| 1988           | 7.52      | 9.28  | 6.24    | 7.82   | 9.59  | 6.53    | 5.01   | 6.82  | 3.72    |
| 1989           | 7.83      | 9.73  | 6.43    | 8.12   | 10.04 | 6.71    | 5.33   | 7.10  | 4.07    |
| 1990           | 7.87      | 9.97  | 6.34    | 8.16   | 10.32 | 6.58    | 5.39   | 7.13  | 4.17    |
| 1991           | 8.19      | 10.15 | 6.74    | 8.50   | 10.52 | 7.00    | 5.70   | 7.17  | 4.61    |
| 1992           | 8.22      | 10.30 | 6.69    | 8.53   | 10.66 | 6.96    | 5.64   | 7.23  | 4.45    |
| 1993           | 8.25      | 10.14 | 6.86    | 8.57   | 10.45 | 7.17    | 5.69   | 7.53  | 4.40    |
| 1994           | 8.63      | 10.75 | 7.10    | 9.00   | 11.20 | 7.41    | 5.54   | 6.82  | 4.56    |
| 1995           | 8.72      | 10.81 | 7.16    | 9.09   | 11.21 | 7.49    | 5.79   | 7.62  | 4.45    |
| 1996           | 8.75      | 10.94 | 7.14    | 9.09   | 11.29 | 7.46    | 6.21   | 8.25  | 4.74    |
| 1997           | 8.88      | 11.03 | 7.25    | 9.21   | 11.35 | 7.57    | 6.34   | 8.45  | 4.87    |
| 1998           | 8.69      | 10.85 | 7.10    | 9.03   | 11.27 | 7.38    | 5.99   | 7.50  | 4.89    |
| 1999           | 8.32      | 10.36 | 6.85    | 8.67   | 10.71 | 7.18    | 5.65   | 7.44  | 4.41    |
| 2000           | 8.17      | 10.20 | 6.70    | 8.54   | 10.63 | 7.01    | 5.20   | 6.61  | 4.17    |
| 2001           | 7.91      | 9.98  | 6.42    | 8.21   | 10.31 | 6.68    | 5.61   | 7.28  | 4.47    |
| 2002           | 7.65      | 9.66  | 6.19    | 7.97   | 10.04 | 6.44    | 5.41   | 6.88  | 4.41    |
| 2003           | 7.38      | 9.40  | 5.92    | 7.69   | 9.81  | 6.13    | 4.94   | 5.83  | 4.27    |
| 2004           | 7.09      | 8.94  | 5.73    | 7.38   | 9.28  | 5.96    | 5.01   | 6.23  | 4.13    |
| 2005           | 6.95      | 8.87  | 5.56    | 7.24   | 9.22  | 5.79    | 4.77   | 6.11  | 3.81    |
| 2006           | 6.74      | 8.48  | 5.44    | 7.01   | 8.78  | 5.66    | 4.92   | 6.27  | 3.93    |
| 2007           | 6.59      | 8.36  | 5.26    | 6.86   | 8.67  | 5.49    | 4.52   | 5.77  | 3.62    |
| 2008           | 6.41      | 8.20  | 5.09    | 6.71   | 8.56  | 5.33    | 4.31   | 5.48  | 3.45    |
| 2009           | 6.30      | 8.12  | 4.93    | 6.56   | 8.42  | 5.13    | 4.49   | 6.15  | 3.41    |
| 2010           | 6.14      | 7.83  | 4.85    | 6.37   | 8.11  | 5.04    | 4.57   | 5.84  | 3.64    |
| 2011           | 6.03      | 7.85  | 4.64    | 6.29   | 8.17  | 4.83    | 4.36   | 5.74  | 3.39    |
| 2012           | 5.91      | 7.62  | 4.61    | 6.17   | 7.95  | 4.80    | 4.26   | 5.38  | 3.48    |
| 2013           | 5.70      | 7.37  | 4.44    | 5.94   | 7.66  | 4.62    | 4.11   | 5.27  | 3.32    |

<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.  
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).  
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.7  
Non-Hodgkin LymphomaSEER Incidence<sup>a</sup> and U.S. Death<sup>b</sup> Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex

|                                        | All Races |       |         | Whites |       |         | Blacks |       |         |
|----------------------------------------|-----------|-------|---------|--------|-------|---------|--------|-------|---------|
|                                        | Total     | Males | Females | Total  | Males | Females | Total  | Males | Females |
| <u>SEER Incidence</u>                  |           |       |         |        |       |         |        |       |         |
| <u>Age at Diagnosis</u>                |           |       |         |        |       |         |        |       |         |
| Age-Adjusted Rates, 2009-2013          |           |       |         |        |       |         |        |       |         |
| All ages                               | 19.5      | 23.7  | 16.1    | 20.4   | 24.8  | 16.9    | 14.6   | 17.6  | 12.2    |
| Under 65                               | 9.2       | 10.9  | 7.5     | 9.4    | 11.1  | 7.7     | 9.0    | 11.1  | 7.1     |
| 65 and over                            | 90.9      | 112.6 | 75.4    | 96.7   | 119.2 | 80.3    | 53.0   | 62.6  | 47.2    |
| All ages (IARC world std) <sup>c</sup> | 12.9      | 15.5  | 10.6    | 13.5   | 16.1  | 11.1    | 10.5   | 12.7  | 8.6     |
| Age-Specific Rates, 2009-2013          |           |       |         |        |       |         |        |       |         |
| <1                                     | -         | -     | -       | -      | -     | -       | -      | -     | -       |
| 1-4                                    | 0.7       | 0.8   | 0.5     | 0.7    | 0.8   | 0.5     | 0.6    | -     | -       |
| 5-9                                    | 1.2       | 1.6   | 0.7     | 1.1    | 1.6   | 0.6     | 1.2    | 1.6   | 0.9     |
| 10-14                                  | 1.3       | 1.7   | 1.0     | 1.3    | 1.7   | 1.0     | 1.5    | 1.7   | 1.2     |
| 15-19                                  | 1.8       | 2.4   | 1.1     | 1.8    | 2.4   | 1.1     | 1.6    | 2.4   | 0.8     |
| 20-24                                  | 2.5       | 3.1   | 1.9     | 2.5    | 3.1   | 2.0     | 2.7    | 3.9   | 1.5     |
| 25-29                                  | 3.4       | 3.9   | 2.9     | 3.3    | 3.8   | 2.7     | 4.2    | 4.9   | 3.6     |
| 30-34                                  | 4.9       | 5.7   | 4.0     | 4.7    | 5.4   | 4.0     | 6.3    | 7.7   | 5.0     |
| 35-39                                  | 7.1       | 8.3   | 5.9     | 7.0    | 8.2   | 5.7     | 9.2    | 11.2  | 7.4     |
| 40-44                                  | 9.9       | 11.7  | 8.0     | 10.0   | 11.8  | 8.1     | 10.8   | 13.0  | 8.9     |
| 45-49                                  | 14.5      | 17.1  | 11.9    | 14.9   | 17.4  | 12.4    | 15.1   | 19.4  | 11.3    |
| 50-54                                  | 21.5      | 25.5  | 17.7    | 22.3   | 26.4  | 18.2    | 20.7   | 24.6  | 17.1    |
| 55-59                                  | 30.0      | 35.0  | 25.3    | 31.3   | 36.1  | 26.6    | 26.1   | 33.7  | 19.6    |
| 60-64                                  | 43.8      | 51.9  | 36.4    | 46.0   | 54.4  | 38.2    | 34.4   | 41.3  | 28.8    |
| 65-69                                  | 63.9      | 75.6  | 53.6    | 67.7   | 79.3  | 57.1    | 45.4   | 50.2  | 41.7    |
| 70-74                                  | 82.5      | 99.2  | 68.5    | 88.4   | 105.6 | 73.8    | 48.3   | 56.9  | 42.0    |
| 75-79                                  | 105.2     | 128.9 | 87.1    | 112.2  | 136.7 | 93.0    | 63.1   | 73.4  | 56.5    |
| 80-84                                  | 119.3     | 147.7 | 100.1   | 127.5  | 157.7 | 106.6   | 61.7   | 71.7  | 56.2    |
| 85+                                    | 110.4     | 153.6 | 88.6    | 115.7  | 160.8 | 92.7    | 52.1   | 72.3  | 43.8    |
| <u>U.S. Mortality</u>                  |           |       |         |        |       |         |        |       |         |
| <u>Age at Death</u>                    |           |       |         |        |       |         |        |       |         |
| Age-Adjusted Rates, 2009-2013          |           |       |         |        |       |         |        |       |         |
| All ages                               | 6.0       | 7.7   | 4.7     | 6.3    | 8.1   | 4.9     | 4.4    | 5.7   | 3.5     |
| Under 65                               | 1.5       | 2.0   | 1.1     | 1.5    | 2.0   | 1.0     | 1.8    | 2.3   | 1.3     |
| 65 and over                            | 37.2      | 47.8  | 29.8    | 39.2   | 50.2  | 31.4    | 22.2   | 28.8  | 18.4    |
| All ages (IARC world std) <sup>c</sup> | 3.2       | 4.2   | 2.5     | 3.4    | 4.3   | 2.5     | 2.7    | 3.5   | 2.1     |
| Age-Specific Rates, 2009-2013          |           |       |         |        |       |         |        |       |         |
| <1                                     | -         | -     | -       | -      | -     | -       | -      | -     | -       |
| 1-4                                    | 0.0       | -     | -       | -      | -     | -       | -      | -     | -       |
| 5-9                                    | 0.1       | 0.1   | 0.0     | 0.1    | 0.1   | -       | -      | -     | -       |
| 10-14                                  | 0.1       | 0.1   | 0.1     | 0.1    | 0.1   | 0.1     | -      | -     | -       |
| 15-19                                  | 0.2       | 0.2   | 0.1     | 0.1    | 0.2   | 0.1     | 0.2    | 0.2   | 0.2     |
| 20-24                                  | 0.3       | 0.4   | 0.2     | 0.3    | 0.4   | 0.2     | 0.3    | 0.4   | 0.3     |
| 25-29                                  | 0.4       | 0.5   | 0.3     | 0.4    | 0.5   | 0.3     | 0.7    | 1.0   | 0.5     |
| 30-34                                  | 0.6       | 0.7   | 0.4     | 0.5    | 0.7   | 0.4     | 0.8    | 1.2   | 0.5     |
| 35-39                                  | 0.8       | 1.0   | 0.6     | 0.7    | 0.9   | 0.5     | 1.4    | 1.8   | 1.1     |
| 40-44                                  | 1.2       | 1.6   | 0.9     | 1.2    | 1.6   | 0.8     | 1.9    | 2.1   | 1.7     |
| 45-49                                  | 2.0       | 2.6   | 1.5     | 2.0    | 2.5   | 1.4     | 2.7    | 3.4   | 2.0     |
| 50-54                                  | 3.4       | 4.6   | 2.3     | 3.4    | 4.6   | 2.3     | 4.2    | 5.8   | 2.8     |
| 55-59                                  | 5.9       | 7.8   | 4.1     | 6.0    | 7.9   | 4.2     | 6.0    | 8.0   | 4.2     |
| 60-64                                  | 9.9       | 12.9  | 7.1     | 10.2   | 13.3  | 7.2     | 9.4    | 12.7  | 6.6     |
| 65-69                                  | 15.9      | 20.2  | 12.1    | 16.6   | 21.1  | 12.5    | 12.6   | 15.3  | 10.6    |
| 70-74                                  | 26.0      | 32.8  | 20.1    | 27.4   | 34.5  | 21.2    | 18.4   | 23.9  | 14.4    |
| 75-79                                  | 40.1      | 50.6  | 31.9    | 42.4   | 53.3  | 33.7    | 23.9   | 30.3  | 19.9    |
| 80-84                                  | 59.1      | 76.3  | 47.4    | 62.3   | 80.1  | 50.0    | 33.1   | 45.5  | 26.4    |
| 85+                                    | 77.3      | 101.9 | 65.1    | 81.6   | 107.1 | 68.9    | 36.1   | 47.1  | 31.7    |

<sup>a</sup> SEER 18 areas. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.<sup>b</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.<sup>c</sup> Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

- Rates are per 100,000 and are age-adjusted to the IARC world standard population.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.8  
Non-Hodgkin Lymphoma

## 5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

|                                                            | All Races         |                   |                   | Whites            |                   |                   | Blacks            |                   |                   |
|------------------------------------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
|                                                            | Total             | Males             | Females           | Total             | Males             | Females           | Total             | Males             | Females           |
| 5-Year Relative Survival (Percent)                         |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Year of Diagnosis:                                         |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| 1960-1963 <sup>a</sup>                                     | -                 | -                 | -                 | 31                | 31                | 31                | -                 | -                 | -                 |
| 1970-1973 <sup>a</sup>                                     | -                 | -                 | -                 | 41                | 39                | 43                | -                 | -                 | -                 |
| 1975-1977 <sup>b</sup>                                     | 46.5              | 45.6              | 47.5              | 46.8              | 46.3              | 47.3              | 48.6              | 42.6              | 55.3 <sup>g</sup> |
| 1978-1980 <sup>b</sup>                                     | 47.9              | 46.0              | 49.8              | 47.8              | 46.2              | 49.5              | 51.3              | 47.3              | 56.7              |
| 1981-1983 <sup>b</sup>                                     | 50.6              | 50.2              | 50.9              | 50.8              | 50.5              | 51.1              | 49.5              | 49.2              | 49.8              |
| 1984-1986 <sup>b</sup>                                     | 51.6              | 50.1              | 53.3              | 52.0              | 50.6              | 53.6              | 46.8              | 44.5              | 49.9              |
| 1987-1989 <sup>b</sup>                                     | 50.9              | 47.6              | 54.9              | 51.3              | 48.1              | 55.2              | 46.0              | 41.7              | 51.0              |
| 1990-1992 <sup>b</sup>                                     | 50.7              | 46.6              | 55.7              | 51.5              | 47.5              | 56.4              | 42.2              | 38.2              | 47.7              |
| 1993-1995 <sup>b</sup>                                     | 52.5              | 48.7              | 57.4              | 53.2              | 49.7              | 57.6              | 42.1              | 35.7              | 54.0              |
| 1996-1998 <sup>b</sup>                                     | 58.8              | 57.0              | 60.9              | 59.4              | 57.6              | 61.4              | 54.6              | 53.0              | 56.9              |
| 1999-2001 <sup>b</sup>                                     | 63.9              | 61.4              | 66.9              | 64.9              | 62.8              | 67.5              | 55.7              | 48.9              | 63.8              |
| 2002-2005 <sup>b</sup>                                     | 70.2              | 68.8              | 71.7              | 71.5              | 70.5              | 72.6              | 63.3              | 59.3              | 67.9              |
| 2006-2012 <sup>b</sup>                                     | 72.6 <sup>f</sup> | 71.7 <sup>f</sup> | 73.7 <sup>f</sup> | 73.6 <sup>f</sup> | 72.9 <sup>f</sup> | 74.5 <sup>f</sup> | 65.2 <sup>f</sup> | 61.3 <sup>f</sup> | 69.2 <sup>f</sup> |
| 5-Year Period Survival (Percent) <sup>cd</sup>             |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| 2012                                                       | 71.4              | 69.9              | 73.1              | 71.8              | 70.4              | 73.6              | 65.6              | 63.4              | 67.9              |
| Stage Distribution (%) 2006-2012 <sup>ce</sup>             |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| All Stages                                                 |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Number of cases                                            | 94,683            | 51,367            | 43,316            | 78,649            | 42,785            | 35,864            | 7,765             | 4,170             | 3,595             |
| Percent                                                    | 100%              | 100%              | 100%              | 100%              | 100%              | 100%              | 100%              | 100%              | 100%              |
| Localized                                                  | 28                | 27                | 29                | 27                | 27                | 28                | 28                | 25                | 31                |
| Regional                                                   | 15                | 15                | 15                | 15                | 15                | 15                | 15                | 14                | 15                |
| Distant                                                    | 50                | 51                | 48                | 50                | 52                | 48                | 51                | 55                | 47                |
| Unstaged                                                   | 8                 | 7                 | 8                 | 7                 | 7                 | 8                 | 6                 | 6                 | 7                 |
| 5-Year Relative Survival (Percent), 2006-2012 <sup>c</sup> |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Age at Diagnosis:                                          |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Ages <45                                                   | 81.6              | 79.4              | 85.1              | 83.4              | 81.0              | 87.4              | 69.1              | 67.1              | 72.2              |
| Ages 45-54                                                 | 79.0              | 76.0              | 83.3              | 80.8              | 78.1              | 84.7              | 64.2              | 60.0              | 70.1              |
| Ages 55-64                                                 | 76.0              | 73.2              | 79.7              | 77.1              | 74.5              | 80.6              | 65.5              | 60.3              | 71.9              |
| Ages 65-74                                                 | 70.8              | 68.2              | 73.8              | 71.5              | 69.0              | 74.4              | 63.6              | 55.5              | 70.3              |
| Ages 75+                                                   | 55.1              | 53.1              | 56.7              | 55.7              | 53.3              | 57.6              | 47.0              | 41.4              | 49.6              |
| Ages <65                                                   | 78.4              | 75.8              | 82.1              | 79.8              | 77.3              | 83.4              | 66.5              | 62.8              | 71.5              |
| Ages 65+                                                   | 62.4              | 60.7              | 63.9              | 62.9              | 61.2              | 64.5              | 56.6              | 50.4              | 60.4              |
| Stage <sup>e</sup> :                                       |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| All Stages                                                 | 70.7              | 69.2              | 72.4              | 71.3              | 69.9              | 72.9              | 63.6              | 60.0              | 67.5              |
| Localized                                                  | 82.6              | 82.3              | 83.0              | 83.0              | 82.9              | 83.1              | 78.2              | 74.1              | 81.8              |
| Regional                                                   | 74.4              | 73.3              | 75.6              | 75.0              | 74.2              | 76.0              | 67.7              | 65.5              | 69.7              |
| Distant                                                    | 63.1              | 61.5              | 65.1              | 64.2              | 62.6              | 66.2              | 54.5              | 52.1              | 57.6              |
| Unstaged                                                   | 69.6              | 67.6              | 71.6              | 68.3              | 66.2              | 70.5              | 63.3              | 59.6              | 66.2              |

<sup>a</sup> Based on End Results data from a series of hospital registries and one population-based registry.<sup>b</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2013.

<sup>c</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2013.

<sup>d</sup> Period survival provides a 2012 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).<sup>e</sup> Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.<sup>f</sup> The difference between 1975-1977 and 2006-2012 is statistically significant (p<.05).<sup>g</sup> The standard error is between 5 and 10 percentage points.<sup>h</sup> The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 19.9  
Non-Hodgkin Lymphoma  
SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

|               | 1975-<br>1979 | 1980-<br>1984 | 1985-<br>1989 | 1990-<br>1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---------------|---------------|---------------|---------------|---------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| Survival Time |               |               |               |               |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 1-year        | 70.2          | 73.0          | 71.3          | 70.4          | 70.2 | 73.2 | 75.6 | 76.7 | 77.4 | 77.3 | 78.7 | 81.0 | 80.3 | 81.1 | 81.6 | 81.0 | 81.6 | 84.0 | 83.9 | 84.2 | 83.3 | 84.0 |
| 2-year        | 60.2          | 63.7          | 62.8          | 62.2          | 61.7 | 65.8 | 68.5 | 70.0 | 71.0 | 71.4 | 73.3 | 76.0 | 75.6 | 76.0 | 77.2 | 76.9 | 77.4 | 78.9 | 79.4 | 79.4 | 79.5 |      |
| 3-year        | 54.6          | 58.5          | 58.2          | 57.7          | 57.4 | 62.0 | 64.8 | 66.3 | 66.9 | 67.8 | 70.0 | 73.1 | 73.0 | 73.5 | 74.7 | 74.5 | 74.9 | 76.0 | 77.1 | 77.2 |      |      |
| 4-year        | 50.5          | 54.6          | 54.3          | 54.4          | 54.6 | 58.6 | 62.1 | 63.5 | 64.4 | 65.4 | 68.0 | 71.1 | 71.5 | 71.4 | 72.8 | 72.6 | 73.0 | 74.2 | 75.3 |      |      |      |
| 5-year        | 46.8          | 50.7          | 51.0          | 51.6          | 51.9 | 56.0 | 59.4 | 60.9 | 62.0 | 63.8 | 65.9 | 69.2 | 69.9 | 70.1 | 71.4 | 70.5 | 71.1 | 72.5 |      |      |      |      |
| 6-year        | 43.6          | 47.5          | 48.3          | 49.2          | 49.8 | 54.1 | 57.1 | 58.3 | 59.4 | 62.0 | 64.6 | 68.0 | 68.2 | 68.7 | 70.2 | 68.8 | 70.0 |      |      |      |      |      |
| 7-year        | 40.8          | 45.0          | 45.8          | 46.9          | 47.8 | 52.1 | 55.1 | 56.4 | 57.7 | 60.4 | 62.8 | 66.2 | 67.0 | 67.1 | 68.2 | 67.2 |      |      |      |      |      |      |
| 8-year        | 38.5          | 42.8          | 43.4          | 45.0          | 46.3 | 50.4 | 52.8 | 55.1 | 56.2 | 58.8 | 61.2 | 65.0 | 65.6 | 66.5 | 66.7 |      |      |      |      |      |      |      |
| 9-year        | 36.6          | 40.8          | 41.4          | 43.4          | 45.1 | 49.3 | 51.4 | 53.4 | 54.7 | 57.4 | 59.8 | 63.9 | 64.6 | 64.7 |      |      |      |      |      |      |      |      |
| 10-year       | 35.0          | 38.9          | 39.8          | 42.0          | 44.2 | 48.0 | 50.0 | 52.1 | 53.5 | 56.2 | 58.8 | 63.1 | 63.1 |      |      |      |      |      |      |      |      |      |
| 11-year       | 33.5          | 37.4          | 38.4          | 40.5          | 43.2 | 46.6 | 48.6 | 50.9 | 52.5 | 54.6 | 57.9 | 61.7 |      |      |      |      |      |      |      |      |      |      |
| 12-year       | 32.3          | 35.9          | 36.9          | 39.5          | 42.1 | 45.6 | 48.0 | 50.0 | 51.1 | 53.3 | 56.6 |      |      |      |      |      |      |      |      |      |      |      |
| 13-year       | 31.4          | 34.7          | 35.7          | 38.3          | 41.3 | 44.8 | 46.7 | 49.0 | 49.9 | 51.8 |      |      |      |      |      |      |      |      |      |      |      |      |
| 14-year       | 30.2          | 33.5          | 34.7          | 37.1          | 40.4 | 44.2 | 45.4 | 48.3 | 48.7 |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 15-year       | 28.8          | 32.2          | 33.5          | 36.4          | 39.6 | 43.6 | 44.4 | 47.2 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 16-year       | 27.9          | 31.1          | 32.7          | 35.5          | 39.0 | 43.5 | 43.0 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 17-year       | 27.3          | 30.3          | 32.1          | 34.7          | 38.5 | 42.7 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 18-year       | 26.7          | 29.5          | 31.3          | 33.9          | 37.5 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 19-year       | 26.0          | 28.7          | 30.5          | 33.1          |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 20-year       | 25.1          | 27.9          | 30.1          |               |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

<sup>a</sup>

Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.10  
Non-Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

|               | 1975-<br>1979 | 1980-<br>1984 | 1985-<br>1989 | 1990-<br>1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---------------|---------------|---------------|---------------|---------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| Survival Time |               |               |               |               |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 1-year        | 69.4          | 72.7          | 68.9          | 67.1          | 66.6 | 71.2 | 74.7 | 74.9 | 75.8 | 76.5 | 77.6 | 80.6 | 79.6 | 80.1 | 81.0 | 81.0 | 81.4 | 83.5 | 82.7 | 83.6 | 83.6 | 83.8 |
| 2-year        | 59.4          | 63.7          | 60.5          | 58.2          | 58.3 | 63.6 | 67.1 | 68.2 | 69.1 | 70.3 | 71.2 | 75.2 | 74.8 | 75.4 | 76.1 | 76.5 | 77.8 | 77.7 | 78.0 | 78.6 | 79.5 |      |
| 3-year        | 53.4          | 58.0          | 55.7          | 53.7          | 54.5 | 59.8 | 63.8 | 64.5 | 64.4 | 66.7 | 67.9 | 72.0 | 72.5 | 72.6 | 73.0 | 73.6 | 75.3 | 75.0 | 75.5 | 76.3 |      |      |
| 4-year        | 49.3          | 53.9          | 51.6          | 50.4          | 51.5 | 56.1 | 61.0 | 61.9 | 61.5 | 63.9 | 65.6 | 70.0 | 70.8 | 70.0 | 70.9 | 71.4 | 73.3 | 73.1 | 73.4 |      |      |      |
| 5-year        | 45.4          | 50.1          | 48.2          | 47.6          | 48.5 | 53.6 | 58.2 | 59.1 | 59.0 | 61.7 | 63.5 | 67.9 | 68.8 | 68.7 | 69.7 | 68.9 | 70.9 | 71.9 |      |      |      |      |
| 6-year        | 42.6          | 46.6          | 45.5          | 45.5          | 46.8 | 51.0 | 56.1 | 56.4 | 56.2 | 60.2 | 61.9 | 66.7 | 66.8 | 67.4 | 68.2 | 67.0 | 69.5 |      |      |      |      |      |
| 7-year        | 39.9          | 44.2          | 43.1          | 43.6          | 44.8 | 49.1 | 54.2 | 54.4 | 54.6 | 58.6 | 60.0 | 65.2 | 65.6 | 65.3 | 66.6 | 65.1 |      |      |      |      |      |      |
| 8-year        | 37.8          | 42.0          | 40.9          | 41.7          | 43.2 | 47.4 | 52.0 | 53.2 | 53.5 | 56.6 | 58.1 | 63.7 | 64.3 | 64.7 | 64.7 |      |      |      |      |      |      |      |
| 9-year        | 35.7          | 40.1          | 39.1          | 40.1          | 42.2 | 46.4 | 50.4 | 51.3 | 52.3 | 55.2 | 57.1 | 62.8 | 63.1 | 62.9 |      |      |      |      |      |      |      |      |
| 10-year       | 34.0          | 38.0          | 37.7          | 39.1          | 41.5 | 45.4 | 48.8 | 50.2 | 51.5 | 54.1 | 55.9 | 61.7 | 61.5 |      |      |      |      |      |      |      |      |      |
| 11-year       | 32.8          | 36.3          | 36.4          | 38.0          | 40.7 | 43.7 | 47.5 | 49.2 | 50.7 | 52.6 | 54.5 | 60.2 |      |      |      |      |      |      |      |      |      |      |
| 12-year       | 31.9          | 35.2          | 35.1          | 37.1          | 39.4 | 42.6 | 47.0 | 48.0 | 49.8 | 51.3 | 53.5 |      |      |      |      |      |      |      |      |      |      |      |
| 13-year       | 30.7          | 34.2          | 34.2          | 36.1          | 38.8 | 41.9 | 45.4 | 46.5 | 49.0 | 50.0 |      |      |      |      |      |      |      |      |      |      |      |      |
| 14-year       | 29.4          | 33.0          | 33.2          | 34.9          | 37.6 | 41.3 | 44.2 | 45.9 | 47.9 |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 15-year       | 28.0          | 31.9          | 32.3          | 34.3          | 36.7 | 40.8 | 43.3 | 45.1 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 16-year       | 27.1          | 30.7          | 31.5          | 33.2          | 35.9 | 40.8 | 42.3 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 17-year       | 26.5          | 29.9          | 30.8          | 32.5          | 35.6 | 40.3 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 18-year       | 26.0          | 29.3          | 30.2          | 31.8          | 34.8 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 19-year       | 25.5          | 28.7          | 29.3          | 31.1          |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 20-year       | 24.9          | 27.9          | 29.1          |               |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

<sup>a</sup>

Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.11  
Non-Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

|               | 1975-<br>1979 | 1980-<br>1984 | 1985-<br>1989 | 1990-<br>1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---------------|---------------|---------------|---------------|---------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| Survival Time |               |               |               |               |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 1-year        | 71.0          | 73.4          | 74.0          | 74.7          | 75.1 | 75.8 | 76.7 | 78.6 | 79.2 | 78.2 | 80.0 | 81.4 | 81.0 | 82.2 | 82.4 | 80.9 | 81.9 | 84.6 | 85.3 | 85.0 | 82.8 | 84.1 |
| 2-year        | 61.1          | 63.7          | 65.6          | 67.2          | 66.3 | 68.7 | 70.1 | 72.0 | 73.3 | 72.7 | 75.7 | 76.8 | 76.5 | 76.7 | 78.4 | 77.3 | 77.1 | 80.3 | 81.1 | 80.6 | 79.4 |      |
| 3-year        | 55.9          | 58.9          | 61.1          | 62.8          | 61.4 | 64.9 | 66.1 | 68.4 | 69.9 | 69.2 | 72.6 | 74.3 | 73.6 | 74.6 | 76.7 | 75.5 | 74.5 | 77.3 | 79.0 | 78.3 |      |      |
| 4-year        | 51.9          | 55.2          | 57.6          | 59.5          | 58.8 | 61.8 | 63.4 | 65.3 | 68.0 | 67.4 | 70.9 | 72.4 | 72.3 | 73.0 | 75.0 | 73.9 | 72.8 | 75.4 | 77.6 |      |      |      |
| 5-year        | 48.2          | 51.3          | 54.3          | 56.7          | 56.3 | 59.0 | 60.7 | 62.9 | 65.6 | 66.4 | 68.8 | 70.7 | 71.2 | 71.6 | 73.4 | 72.4 | 71.3 | 73.3 |      |      |      |      |
| 6-year        | 44.6          | 48.4          | 51.7          | 53.9          | 53.8 | 57.9 | 58.3 | 60.3 | 63.3 | 64.3 | 67.8 | 69.4 | 69.9 | 70.2 | 72.4 | 70.8 | 70.5 |      |      |      |      |      |
| 7-year        | 41.7          | 45.8          | 49.0          | 51.1          | 51.7 | 55.9 | 56.2 | 58.5 | 61.3 | 62.5 | 66.2 | 67.2 | 68.6 | 69.2 | 70.1 | 69.6 |      |      |      |      |      |      |
| 8-year        | 39.2          | 43.7          | 46.3          | 49.1          | 50.3 | 54.1 | 53.9 | 57.3 | 59.4 | 61.4 | 64.8 | 66.6 | 67.1 | 68.4 | 69.0 |      |      |      |      |      |      |      |
| 9-year        | 37.5          | 41.6          | 44.3          | 47.5          | 48.9 | 52.8 | 52.7 | 55.7 | 57.6 | 60.2 | 63.1 | 65.2 | 66.3 | 66.8 |      |      |      |      |      |      |      |      |
| 10-year       | 36.0          | 39.8          | 42.4          | 45.8          | 47.7 | 51.3 | 51.5 | 54.1 | 56.0 | 58.6 | 62.3 | 64.6 | 64.9 |      |      |      |      |      |      |      |      |      |
| 11-year       | 34.2          | 38.5          | 40.9          | 43.8          | 46.6 | 50.2 | 49.9 | 52.7 | 54.5 | 57.0 | 61.9 | 63.3 |      |      |      |      |      |      |      |      |      |      |
| 12-year       | 32.9          | 36.8          | 39.0          | 42.4          | 45.7 | 49.3 | 49.2 | 52.2 | 52.7 | 55.7 | 60.3 |      |      |      |      |      |      |      |      |      |      |      |
| 13-year       | 32.1          | 35.2          | 37.5          | 41.0          | 44.6 | 48.4 | 48.3 | 51.6 | 50.8 | 53.9 |      |      |      |      |      |      |      |      |      |      |      |      |
| 14-year       | 31.0          | 34.0          | 36.5          | 39.9          | 43.9 | 47.7 | 46.8 | 51.0 | 49.4 |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 15-year       | 29.7          | 32.5          | 34.9          | 39.0          | 43.3 | 47.0 | 45.7 | 49.5 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 16-year       | 28.7          | 31.5          | 34.2          | 38.4          | 43.1 | 46.4 | 43.7 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 17-year       | 28.2          | 30.6          | 33.6          | 37.6          | 42.4 | 45.6 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 18-year       | 27.4          | 29.8          | 32.7          | 36.6          | 40.8 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 19-year       | 26.5          | 28.7          | 32.0          | 35.6          |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 20-year       | 25.4          | 28.0          | 31.2          |               |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

<sup>a</sup>

Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.12  
Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2013

All Races, Males, All Ages

Year of Diagnosis

| SEER Location                               | 1975-<br>1979 | 1980-<br>1981 | 1982-<br>1983 | 1984-<br>1985 | 1986-<br>1987 | 1988-<br>1989 | 1990-<br>1991 | 1992-<br>1993 | 1994-<br>1995 | 1996-<br>1997 | 1998-<br>1999 | 2000-<br>2001 | 2002-<br>2003 | 2004-<br>2005 | 2006-<br>2007 | 2008-<br>2009 | 2010-<br>2011 | 2012-<br>2013 |
|---------------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| SEER 9 <sup>b</sup>                         | 5,222         | 2,506         | 2,704         | 3,176         | 3,627         | 3,991         | 4,568         | 4,729         | 5,324         | 5,256         | 5,261         | 5,556         | 5,772         | 6,218         | 6,392         | 6,677         | 6,962         | 7,000         |
| SEER 9 except<br>SF-Oakland                 | 4,285         | 2,088         | 2,267         | 2,603         | 2,819         | 3,089         | 3,505         | 3,694         | 4,158         | 4,246         | 4,363         | 4,509         | 4,817         | 5,201         | 5,392         | 5,606         | 5,813         | 5,956         |
| San Francisco-<br>Oakland SMSA <sup>c</sup> | 937           | 418           | 437           | 573           | 808           | 902           | 1,063         | 1,035         | 1,166         | 1,010         | 898           | 1,047         | 955           | 1,017         | 1,000         | 1,071         | 1,149         | 1,044         |
| San Francisco<br>City/County                | 245           | 96            | 123           | 210           | 326           | 393           | 467           | 410           | 450           | 353           | 213           | 256           | 220           | 283           | 219           | 215           | 239           | 224           |

Age-Adjusted Cancer Incidence Rates<sup>a</sup>

By SEER Location and Year of Diagnosis, 1975-2013

All Races, Males, All Ages

Year of Diagnosis

| SEER Location                               | 1975-<br>1979 | 1980-<br>1981 | 1982-<br>1983 | 1984-<br>1985 | 1986-<br>1987 | 1988-<br>1989 | 1990-<br>1991 | 1992-<br>1993 | 1994-<br>1995 | 1996-<br>1997 | 1998-<br>1999 | 2000-<br>2001 | 2002-<br>2003 | 2004-<br>2005 | 2006-<br>2007 | 2008-<br>2009 | 2010-<br>2011 | 2012-<br>2013 |
|---------------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| SEER 9 <sup>b</sup>                         | 13.4          | 15.5          | 16.1          | 18.3          | 20.1          | 21.5          | 23.3          | 23.3          | 25.2          | 24.4          | 23.8          | 24.4          | 24.6          | 25.7          | 25.4          | 25.4          | 25.4          | 24.3          |
| SEER 9 except<br>SF-Oakland                 | 13.2          | 15.4          | 16.1          | 18.1          | 18.8          | 20.0          | 21.6          | 21.8          | 23.6          | 23.5          | 23.5          | 23.5          | 24.4          | 25.6          | 25.4          | 25.2          | 25.1          | 24.5          |
| San Francisco-<br>Oakland SMSA <sup>c</sup> | 14.7          | 15.8          | 16.0          | 19.4          | 26.7          | 28.4          | 31.7          | 30.5          | 33.5          | 28.8          | 25.1          | 28.6          | 25.5          | 26.6          | 25.6          | 26.2          | 26.6          | 23.3          |
| San Francisco<br>City/County                | 14.3          | 14.4          | 17.6          | 29.3          | 44.4          | 51.9          | 61.0          | 52.3          | 57.4          | 44.6          | 27.4          | 32.5          | 26.9          | 35.4          | 26.5          | 25.5          | 27.2          | 25.1          |

<sup>a</sup>

Rates are per 100,000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup>

The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

<sup>c</sup>

The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

-

Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.13  
Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2013

All Races, Males, Ages 0-19

Year of Diagnosis

| SEER Location                               | 1975-<br>1979 | 1980-<br>1981 | 1982-<br>1983 | 1984-<br>1985 | 1986-<br>1987 | 1988-<br>1989 | 1990-<br>1991 | 1992-<br>1993 | 1994-<br>1995 | 1996-<br>1997 | 1998-<br>1999 | 2000-<br>2001 | 2002-<br>2003 | 2004-<br>2005 | 2006-<br>2007 | 2008-<br>2009 | 2010-<br>2011 | 2012-<br>2013 |
|---------------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| SEER 9 <sup>b</sup>                         | 223           | 87            | 108           | 91            | 94            | 85            | 100           | 89            | 120           | 105           | 104           | 119           | 127           | 106           | 106           | 142           | 133           | 152           |
| SEER 9 except<br>SF-Oakland                 | 191           | 78            | 95            | 82            | 80            | 77            | 86            | 74            | 107           | 84            | 93            | 100           | 115           | 89            | 87            | 114           | 118           | 127           |
| San Francisco-<br>Oakland SMSA <sup>c</sup> | 32            | 9             | 13            | 9             | 14            | 8             | 14            | 15            | 13            | 21            | 11            | 19            | 12            | 17            | 19            | 28            | 15            | 25            |
| San Francisco<br>City/County                | 9             | <4            | <4            | <4            | <4            | <4            | <4            | <4            | <4            | <4            | <4            | <4            | <4            | <4            | <4            | 5             | <4            | 5             |

Age-Adjusted Cancer Incidence Rates<sup>a</sup>

By SEER Location and Year of Diagnosis, 1975-2013

All Races, Males, Ages 0-19

Year of Diagnosis

| SEER Location                               | 1975-<br>1979 | 1980-<br>1981 | 1982-<br>1983 | 1984-<br>1985 | 1986-<br>1987 | 1988-<br>1989 | 1990-<br>1991 | 1992-<br>1993 | 1994-<br>1995 | 1996-<br>1997 | 1998-<br>1999 | 2000-<br>2001 | 2002-<br>2003 | 2004-<br>2005 | 2006-<br>2007 | 2008-<br>2009 | 2010-<br>2011 | 2012-<br>2013 |
|---------------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| SEER 9 <sup>b</sup>                         | 1.2           | 1.2           | 1.6           | 1.4           | 1.4           | 1.3           | 1.5           | 1.3           | 1.7           | 1.4           | 1.4           | 1.5           | 1.6           | 1.4           | 1.3           | 1.8           | 1.7           | 1.9           |
| SEER 9 except<br>SF-Oakland                 | 1.2           | 1.3           | 1.6           | 1.4           | 1.4           | 1.3           | 1.5           | 1.2           | 1.7           | 1.3           | 1.4           | 1.5           | 1.7           | 1.3           | 1.3           | 1.6           | 1.7           | 1.8           |
| San Francisco-<br>Oakland SMSA <sup>c</sup> | 1.4           | 1.0           | 1.5           | 1.0           | 1.6           | 0.9           | 1.5           | 1.6           | 1.3           | 2.1           | 1.1           | 1.8           | 1.2           | 1.7           | 1.9           | 2.7           | 1.4           | 2.4           |
| San Francisco<br>City/County                | 2.3           | -             | -             | -             | -             | -             | -             | -             | -             | -             | -             | -             | -             | -             | -             | 4.0           | -             | 4.0           |

<sup>a</sup> Rates are per 100,000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

<sup>c</sup> The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.14  
Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2013

All Races, Males, Ages 20-54

Year of Diagnosis

| SEER Location                               | 1975-<br>1979 | 1980-<br>1981 | 1982-<br>1983 | 1984-<br>1985 | 1986-<br>1987 | 1988-<br>1989 | 1990-<br>1991 | 1992-<br>1993 | 1994-<br>1995 | 1996-<br>1997 | 1998-<br>1999 | 2000-<br>2001 | 2002-<br>2003 | 2004-<br>2005 | 2006-<br>2007 | 2008-<br>2009 | 2010-<br>2011 | 2012-<br>2013 |
|---------------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| SEER 9 <sup>b</sup>                         | 1,464         | 687           | 723           | 958           | 1,211         | 1,411         | 1,764         | 1,830         | 2,089         | 1,767         | 1,606         | 1,692         | 1,623         | 1,717         | 1,652         | 1,690         | 1,667         | 1,575         |
| SEER 9 except<br>SF-Oakland                 | 1,208         | 563           | 588           | 730           | 827           | 922           | 1,193         | 1,294         | 1,483         | 1,323         | 1,269         | 1,323         | 1,309         | 1,405         | 1,380         | 1,398         | 1,396         | 1,313         |
| San Francisco-<br>Oakland SMSA <sup>c</sup> | 256           | 124           | 135           | 228           | 384           | 489           | 571           | 536           | 606           | 444           | 337           | 369           | 314           | 312           | 272           | 292           | 271           | 262           |
| San Francisco<br>City/County                | 58            | 29            | 34            | 105           | 215           | 288           | 333           | 303           | 317           | 224           | 105           | 115           | 111           | 111           | 86            | 75            | 72            | 71            |

Age-Adjusted Cancer Incidence Rates<sup>a</sup>

By SEER Location and Year of Diagnosis, 1975-2013

All Races, Males, Ages 20-54

Year of Diagnosis

| SEER Location                               | 1975-<br>1979 | 1980-<br>1981 | 1982-<br>1983 | 1984-<br>1985 | 1986-<br>1987 | 1988-<br>1989 | 1990-<br>1991 | 1992-<br>1993 | 1994-<br>1995 | 1996-<br>1997 | 1998-<br>1999 | 2000-<br>2001 | 2002-<br>2003 | 2004-<br>2005 | 2006-<br>2007 | 2008-<br>2009 | 2010-<br>2011 | 2012-<br>2013 |
|---------------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| SEER 9 <sup>b</sup>                         | 6.9           | 7.9           | 8.2           | 10.4          | 12.4          | 13.5          | 15.9          | 15.6          | 16.9          | 13.8          | 12.1          | 12.3          | 11.7          | 12.3          | 11.6          | 11.8          | 11.5          | 10.9          |
| SEER 9 except<br>SF-Oakland                 | 6.9           | 7.8           | 8.1           | 9.7           | 10.3          | 10.9          | 13.1          | 13.4          | 14.4          | 12.3          | 11.5          | 11.5          | 11.2          | 11.9          | 11.5          | 11.6          | 11.5          | 10.8          |
| San Francisco-<br>Oakland SMSA <sup>c</sup> | 6.9           | 8.4           | 8.9           | 13.9          | 22.6          | 26.4          | 29.5          | 26.7          | 29.8          | 21.2          | 15.5          | 16.4          | 13.9          | 14.1          | 12.3          | 13.0          | 11.7          | 11.2          |
| San Francisco<br>City/County                | 6.7           | 8.8           | 9.4           | 27.2          | 56.5          | 71.5          | 81.3          | 72.4          | 74.4          | 50.7          | 23.0          | 25.2          | 23.9          | 24.8          | 19.4          | 16.2          | 15.0          | 14.5          |

<sup>a</sup> Rates are per 100,000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

<sup>c</sup> The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.15  
Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2013

All Races, Males, Ages 55+

Year of Diagnosis

| SEER Location                               | 1975-<br>1979 | 1980-<br>1981 | 1982-<br>1983 | 1984-<br>1985 | 1986-<br>1987 | 1988-<br>1989 | 1990-<br>1991 | 1992-<br>1993 | 1994-<br>1995 | 1996-<br>1997 | 1998-<br>1999 | 2000-<br>2001 | 2002-<br>2003 | 2004-<br>2005 | 2006-<br>2007 | 2008-<br>2009 | 2010-<br>2011 | 2012-<br>2013 |
|---------------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| SEER 9 <sup>b</sup>                         | 3,535         | 1,732         | 1,873         | 2,127         | 2,322         | 2,495         | 2,704         | 2,810         | 3,115         | 3,384         | 3,551         | 3,745         | 4,022         | 4,395         | 4,634         | 4,845         | 5,162         | 5,273         |
| SEER 9 except<br>SF-Oakland                 | 2,886         | 1,447         | 1,584         | 1,791         | 1,912         | 2,090         | 2,226         | 2,326         | 2,568         | 2,839         | 3,001         | 3,086         | 3,393         | 3,707         | 3,925         | 4,094         | 4,299         | 4,516         |
| San Francisco-<br>Oakland SMSA <sup>c</sup> | 649           | 285           | 289           | 336           | 410           | 405           | 478           | 484           | 547           | 545           | 550           | 659           | 629           | 688           | 709           | 751           | 863           | 757           |
| San Francisco<br>City/County                | 178           | 65            | 88            | 104           | 109           | 105           | 132           | 106           | 130           | 126           | 106           | 141           | 108           | 169           | 131           | 135           | 164           | 148           |

Age-Adjusted Cancer Incidence Rates<sup>a</sup>

By SEER Location and Year of Diagnosis, 1975-2013

All Races, Males, Ages 55+

Year of Diagnosis

| SEER Location                               | 1975-<br>1979 | 1980-<br>1981 | 1982-<br>1983 | 1984-<br>1985 | 1986-<br>1987 | 1988-<br>1989 | 1990-<br>1991 | 1992-<br>1993 | 1994-<br>1995 | 1996-<br>1997 | 1998-<br>1999 | 2000-<br>2001 | 2002-<br>2003 | 2004-<br>2005 | 2006-<br>2007 | 2008-<br>2009 | 2010-<br>2011 | 2012-<br>2013 |
|---------------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| SEER 9 <sup>b</sup>                         | 45.1          | 52.2          | 54.0          | 59.6          | 63.3          | 67.2          | 70.1          | 70.6          | 76.1          | 80.0          | 81.1          | 83.1          | 85.8          | 90.0          | 90.0          | 88.7          | 89.5          | 85.6          |
| SEER 9 except<br>SF-Oakland                 | 44.0          | 52.1          | 54.4          | 60.1          | 62.0          | 66.7          | 68.7          | 69.2          | 74.4          | 79.6          | 81.3          | 81.2          | 85.8          | 90.1          | 90.3          | 88.8          | 88.4          | 86.7          |
| San Francisco-<br>Oakland SMSA <sup>c</sup> | 50.8          | 52.8          | 52.0          | 57.1          | 70.2          | 70.3          | 77.3          | 78.3          | 85.4          | 82.1          | 80.1          | 93.2          | 85.4          | 89.4          | 88.4          | 88.5          | 95.2          | 79.6          |
| San Francisco<br>City/County                | 48.2          | 44.6          | 59.8          | 72.7          | 73.9          | 75.7          | 93.4          | 74.7          | 91.4          | 87.2          | 72.7          | 93.4          | 69.0          | 104.7         | 76.4          | 76.3          | 89.0          | 78.0          |

<sup>a</sup> Rates are per 100,000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

<sup>c</sup> The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.16  
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,  
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and  
Lifetime Risk of Dying from Cancer Given Alive at Current Age  
Both Sexes, 2011-2013 By Race/Ethnicity

| Race/<br>Ethnicity | Current<br>Age | Risk of Being<br>Diagnosed with Cancer |         |         |      | Risk of Dying<br>from Cancer | Race/<br>Ethnicity                                   | Current<br>Age | Risk of Being<br>Diagnosed with Cancer |         |         |      | Risk of Dying<br>from Cancer |
|--------------------|----------------|----------------------------------------|---------|---------|------|------------------------------|------------------------------------------------------|----------------|----------------------------------------|---------|---------|------|------------------------------|
|                    |                | +10 yrs                                | +20 yrs | +30 yrs | Ever |                              |                                                      |                | +10 yrs                                | +20 yrs | +30 yrs | Ever |                              |
| All Races          | 0              | 0.01                                   | 0.02    | 0.05    | 2.10 | 0.75                         | Asian/<br>Pacific<br>Islander                        | 0              | 0.01                                   | 0.02    | 0.05    | 1.84 | 0.73                         |
|                    | 10             | 0.02                                   | 0.05    | 0.10    | 2.11 | 0.76                         |                                                      | 10             | 0.02                                   | 0.04    | 0.08    | 1.85 | 0.74                         |
|                    | 20             | 0.03                                   | 0.09    | 0.20    | 2.10 | 0.76                         |                                                      | 20             | 0.03                                   | 0.07    | 0.15    | 1.83 | 0.74                         |
|                    | 30             | 0.06                                   | 0.17    | 0.41    | 2.09 | 0.77                         |                                                      | 30             | 0.04                                   | 0.12    | 0.28    | 1.82 | 0.74                         |
|                    | 40             | 0.12                                   | 0.35    | 0.80    | 2.06 | 0.77                         |                                                      | 40             | 0.08                                   | 0.24    | 0.56    | 1.79 | 0.74                         |
|                    | 50             | 0.24                                   | 0.70    | 1.36    | 1.99 | 0.78                         |                                                      | 50             | 0.16                                   | 0.48    | 1.00    | 1.73 | 0.74                         |
|                    | 60             | 0.49                                   | 1.18    | 1.73    | 1.86 | 0.78                         |                                                      | 60             | 0.33                                   | 0.86    | 1.37    | 1.61 | 0.73                         |
|                    | 70             | 0.79                                   | 1.41    | -       | 1.55 | 0.75                         |                                                      | 70             | 0.57                                   | 1.12    | -       | 1.37 | 0.69                         |
| White              | 80             | 0.83                                   | -       | -       | 1.03 | 0.63                         | American<br>Indian/<br>Alaska<br>Native <sup>a</sup> | 80             | 0.66                                   | -       | -       | 0.96 | 0.56                         |
|                    | 0              | 0.01                                   | 0.02    | 0.05    | 2.20 | 0.79                         |                                                      | 0              | 0.01                                   | 0.02    | 0.04    | 1.63 | 0.49                         |
|                    | 10             | 0.02                                   | 0.04    | 0.10    | 2.21 | 0.80                         |                                                      | 10             | 0.01                                   | 0.03    | 0.07    | 1.64 | 0.50                         |
|                    | 20             | 0.03                                   | 0.08    | 0.20    | 2.20 | 0.80                         |                                                      | 20             | 0.01                                   | 0.05    | 0.13    | 1.63 | 0.50                         |
|                    | 30             | 0.06                                   | 0.17    | 0.42    | 2.19 | 0.81                         |                                                      | 30             | 0.04                                   | 0.12    | 0.25    | 1.65 | 0.51                         |
|                    | 40             | 0.12                                   | 0.37    | 0.84    | 2.16 | 0.81                         |                                                      | 40             | 0.08                                   | 0.22    | 0.55    | 1.64 | 0.52                         |
|                    | 50             | 0.25                                   | 0.74    | 1.44    | 2.09 | 0.82                         |                                                      | 50             | 0.15                                   | 0.50    | 0.96    | 1.63 | 0.53                         |
|                    | 60             | 0.51                                   | 1.25    | 1.82    | 1.95 | 0.82                         |                                                      | 60             | 0.37                                   | 0.87    | 1.41    | 1.59 | 0.55                         |
| Black              | 70             | 0.84                                   | 1.48    | -       | 1.63 | 0.78                         | Hispanic <sup>b</sup>                                | 70             | 0.57                                   | 1.18    | -       | 1.39 | 0.54                         |
|                    | 80             | 0.88                                   | -       | -       | 1.07 | 0.66                         |                                                      | 80             | 0.84                                   | -       | -       | 1.12 | 0.47                         |
|                    | 0              | 0.01                                   | 0.02    | 0.06    | 1.29 | 0.44                         |                                                      | 0              | 0.01                                   | 0.02    | 0.04    | 2.13 | 0.76                         |
|                    | 10             | 0.02                                   | 0.05    | 0.12    | 1.30 | 0.45                         |                                                      | 10             | 0.01                                   | 0.04    | 0.08    | 2.14 | 0.76                         |
|                    | 20             | 0.03                                   | 0.11    | 0.22    | 1.29 | 0.45                         |                                                      | 20             | 0.02                                   | 0.07    | 0.17    | 2.14 | 0.77                         |
|                    | 30             | 0.08                                   | 0.19    | 0.40    | 1.28 | 0.45                         |                                                      | 30             | 0.05                                   | 0.15    | 0.38    | 2.13 | 0.77                         |
|                    | 40             | 0.12                                   | 0.33    | 0.63    | 1.22 | 0.45                         |                                                      | 40             | 0.10                                   | 0.33    | 0.75    | 2.10 | 0.77                         |
|                    | 50             | 0.22                                   | 0.53    | 0.88    | 1.15 | 0.45                         |                                                      | 50             | 0.23                                   | 0.66    | 1.31    | 2.03 | 0.77                         |
|                    | 60             | 0.34                                   | 0.72    | 0.96    | 1.02 | 0.44                         |                                                      | 60             | 0.45                                   | 1.13    | 1.69    | 1.88 | 0.75                         |
|                    | 70             | 0.45                                   | 0.74    | -       | 0.81 | 0.41                         |                                                      | 70             | 0.75                                   | 1.37    | -       | 1.58 | 0.71                         |
|                    | 80             | 0.42                                   | -       | -       | 0.52 | 0.33                         |                                                      | 80             | 0.79                                   | -       | -       | 1.05 | 0.58                         |

Devcan 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

<sup>a</sup> Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

- Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 19.17  
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,  
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and  
Lifetime Risk of Dying from Cancer Given Alive at Current Age  
Males, 2011-2013 By Race/Ethnicity

| Race/<br>Ethnicity | Current<br>Age | Risk of Being<br>Diagnosed with Cancer |         |         |      | Risk of Dying<br>from Cancer | Race/<br>Ethnicity                                   | Current<br>Age | Risk of Being<br>Diagnosed with Cancer |         |         |      | Risk of Dying<br>from Cancer |
|--------------------|----------------|----------------------------------------|---------|---------|------|------------------------------|------------------------------------------------------|----------------|----------------------------------------|---------|---------|------|------------------------------|
|                    |                | +10 yrs                                | +20 yrs | +30 yrs | Ever |                              |                                                      |                | +10 yrs                                | +20 yrs | +30 yrs | Ever |                              |
| All Races          | 0              | 0.01                                   | 0.03    | 0.07    | 2.36 | 0.86                         | Asian/<br>Pacific<br>Islander                        | 0              | 0.01                                   | 0.03    | 0.06    | 2.11 | 0.84                         |
|                    | 10             | 0.02                                   | 0.06    | 0.12    | 2.37 | 0.87                         |                                                      | 10             | 0.02                                   | 0.05    | 0.09    | 2.12 | 0.85                         |
|                    | 20             | 0.04                                   | 0.10    | 0.23    | 2.36 | 0.87                         |                                                      | 20             | 0.03                                   | 0.07    | 0.16    | 2.10 | 0.85                         |
|                    | 30             | 0.07                                   | 0.20    | 0.47    | 2.36 | 0.88                         |                                                      | 30             | 0.04                                   | 0.14    | 0.33    | 2.09 | 0.85                         |
|                    | 40             | 0.14                                   | 0.41    | 0.92    | 2.33 | 0.88                         |                                                      | 40             | 0.10                                   | 0.29    | 0.68    | 2.06 | 0.85                         |
|                    | 50             | 0.28                                   | 0.81    | 1.56    | 2.26 | 0.89                         |                                                      | 50             | 0.20                                   | 0.59    | 1.21    | 2.00 | 0.85                         |
|                    | 60             | 0.57                                   | 1.37    | 1.99    | 2.13 | 0.90                         |                                                      | 60             | 0.41                                   | 1.06    | 1.64    | 1.87 | 0.84                         |
|                    | 70             | 0.93                                   | 1.66    | -       | 1.82 | 0.87                         |                                                      | 70             | 0.70                                   | 1.34    | -       | 1.60 | 0.80                         |
| White              | 80             | 1.03                                   | -       | -       | 1.27 | 0.75                         | American<br>Indian/<br>Alaska<br>Native <sup>a</sup> | 80             | 0.80                                   | -       | -       | 1.11 | 0.67                         |
|                    | 0              | 0.01                                   | 0.03    | 0.06    | 2.46 | 0.90                         |                                                      | 0              | 0.01                                   | 0.03    | 0.05    | 1.73 | 0.60                         |
|                    | 10             | 0.02                                   | 0.05    | 0.12    | 2.47 | 0.91                         |                                                      | 10             | 0.02                                   | 0.04    | 0.08    | 1.74 | 0.61                         |
|                    | 20             | 0.03                                   | 0.10    | 0.23    | 2.46 | 0.91                         |                                                      | 20             | 0.02                                   | 0.06    | 0.14    | 1.73 | 0.61                         |
|                    | 30             | 0.06                                   | 0.20    | 0.48    | 2.46 | 0.92                         |                                                      | 30             | 0.05                                   | 0.12    | 0.24    | 1.75 | 0.63                         |
|                    | 40             | 0.14                                   | 0.42    | 0.96    | 2.43 | 0.92                         |                                                      | 40             | 0.08                                   | 0.20    | 0.57    | 1.75 | 0.64                         |
|                    | 50             | 0.29                                   | 0.85    | 1.64    | 2.37 | 0.93                         |                                                      | 50             | 0.13                                   | 0.52    | 0.98    | 1.76 | 0.66                         |
|                    | 60             | 0.60                                   | 1.45    | 2.10    | 2.24 | 0.94                         |                                                      | 60             | 0.43                                   | 0.93    | 1.51    | 1.79 | 0.69                         |
| Black              | 70             | 0.99                                   | 1.74    | -       | 1.91 | 0.91                         | Hispanic <sup>b</sup>                                | 70             | 0.60                                   | 1.28    | -       | 1.61 | 0.69                         |
|                    | 80             | 1.09                                   | -       | -       | 1.32 | 0.78                         |                                                      | 80             | 0.99                                   | -       | -       | 1.47 | 0.67                         |
|                    | 0              | 0.01                                   | 0.03    | 0.07    | 1.38 | 0.49                         |                                                      | 0              | 0.01                                   | 0.03    | 0.05    | 2.34 | 0.85                         |
|                    | 10             | 0.02                                   | 0.06    | 0.15    | 1.40 | 0.50                         |                                                      | 10             | 0.02                                   | 0.04    | 0.10    | 2.35 | 0.86                         |
|                    | 20             | 0.04                                   | 0.13    | 0.27    | 1.39 | 0.50                         |                                                      | 20             | 0.03                                   | 0.08    | 0.20    | 2.35 | 0.86                         |
|                    | 30             | 0.09                                   | 0.23    | 0.47    | 1.37 | 0.50                         |                                                      | 30             | 0.05                                   | 0.17    | 0.42    | 2.34 | 0.87                         |
|                    | 40             | 0.14                                   | 0.39    | 0.72    | 1.32 | 0.50                         |                                                      | 40             | 0.12                                   | 0.37    | 0.84    | 2.32 | 0.87                         |
|                    | 50             | 0.26                                   | 0.60    | 0.96    | 1.23 | 0.50                         |                                                      | 50             | 0.26                                   | 0.74    | 1.47    | 2.25 | 0.87                         |
|                    | 60             | 0.38                                   | 0.78    | 1.02    | 1.08 | 0.49                         |                                                      | 60             | 0.51                                   | 1.28    | 1.92    | 2.11 | 0.87                         |
|                    | 70             | 0.51                                   | 0.81    | -       | 0.89 | 0.46                         |                                                      | 70             | 0.87                                   | 1.59    | -       | 1.80 | 0.83                         |
|                    | 80             | 0.49                                   | -       | -       | 0.61 | 0.39                         |                                                      | 80             | 0.95                                   | -       | -       | 1.24 | 0.70                         |

Devcan 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

<sup>a</sup> Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

- Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 19.18  
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,  
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and  
Lifetime Risk of Dying from Cancer Given Alive at Current Age  
Females, 2011-2013 By Race/Ethnicity

| Race/<br>Ethnicity | Current<br>Age | Risk of Being<br>Diagnosed with Cancer |         |         |      | Risk of Dying<br>from Cancer | Race/<br>Ethnicity                                   | Current<br>Age | Risk of Being<br>Diagnosed with Cancer |         |         |      | Risk of Dying<br>from Cancer |
|--------------------|----------------|----------------------------------------|---------|---------|------|------------------------------|------------------------------------------------------|----------------|----------------------------------------|---------|---------|------|------------------------------|
|                    |                | +10 yrs                                | +20 yrs | +30 yrs | Ever |                              |                                                      |                | +10 yrs                                | +20 yrs | +30 yrs | Ever |                              |
| All Races          | 0              | 0.01                                   | 0.02    | 0.04    | 1.87 | 0.67                         | Asian/<br>Pacific<br>Islander                        | 0              | 0.00                                   | 0.01    | 0.04    | 1.61 | 0.65                         |
|                    | 10             | 0.01                                   | 0.03    | 0.08    | 1.88 | 0.67                         |                                                      | 10             | 0.01                                   | 0.03    | 0.07    | 1.62 | 0.66                         |
|                    | 20             | 0.02                                   | 0.07    | 0.17    | 1.87 | 0.67                         |                                                      | 20             | 0.03                                   | 0.06    | 0.13    | 1.61 | 0.66                         |
|                    | 30             | 0.05                                   | 0.15    | 0.35    | 1.86 | 0.68                         |                                                      | 30             | 0.04                                   | 0.10    | 0.24    | 1.59 | 0.66                         |
|                    | 40             | 0.10                                   | 0.30    | 0.68    | 1.82 | 0.68                         |                                                      | 40             | 0.07                                   | 0.21    | 0.45    | 1.56 | 0.66                         |
|                    | 50             | 0.21                                   | 0.60    | 1.17    | 1.76 | 0.68                         |                                                      | 50             | 0.14                                   | 0.39    | 0.82    | 1.51 | 0.65                         |
|                    | 60             | 0.41                                   | 1.01    | 1.50    | 1.63 | 0.68                         |                                                      | 60             | 0.26                                   | 0.70    | 1.16    | 1.40 | 0.64                         |
|                    | 70             | 0.66                                   | 1.21    | -       | 1.34 | 0.65                         |                                                      | 70             | 0.46                                   | 0.95    | -       | 1.20 | 0.60                         |
| White              | 80             | 0.70                                   | -       | -       | 0.87 | 0.55                         | American<br>Indian/<br>Alaska<br>Native <sup>a</sup> | 80             | 0.56                                   | -       | -       | 0.85 | 0.49                         |
|                    | 0              | 0.00                                   | 0.02    | 0.04    | 1.95 | 0.70                         |                                                      | 0              | 0.00                                   | 0.01    | 0.02    | 1.56 | 0.41                         |
|                    | 10             | 0.01                                   | 0.03    | 0.08    | 1.97 | 0.71                         |                                                      | 10             | 0.01                                   | 0.02    | 0.05    | 1.57 | 0.41                         |
|                    | 20             | 0.02                                   | 0.07    | 0.17    | 1.96 | 0.71                         |                                                      | 20             | 0.01                                   | 0.04    | 0.12    | 1.56 | 0.41                         |
|                    | 30             | 0.05                                   | 0.15    | 0.36    | 1.95 | 0.71                         |                                                      | 30             | 0.04                                   | 0.11    | 0.27    | 1.57 | 0.42                         |
|                    | 40             | 0.10                                   | 0.31    | 0.72    | 1.91 | 0.71                         |                                                      | 40             | 0.07                                   | 0.24    | 0.54    | 1.56 | 0.42                         |
|                    | 50             | 0.21                                   | 0.63    | 1.24    | 1.85 | 0.71                         |                                                      | 50             | 0.17                                   | 0.48    | 0.94    | 1.54 | 0.43                         |
|                    | 60             | 0.43                                   | 1.07    | 1.59    | 1.71 | 0.71                         |                                                      | 60             | 0.33                                   | 0.81    | 1.33    | 1.44 | 0.45                         |
| Black              | 70             | 0.71                                   | 1.27    | -       | 1.41 | 0.68                         | Hispanic <sup>b</sup>                                | 70             | 0.54                                   | 1.11    | -       | 1.24 | 0.45                         |
|                    | 80             | 0.73                                   | -       | -       | 0.91 | 0.57                         |                                                      | 80             | 0.74                                   | -       | -       | 0.91 | 0.36                         |
|                    | 0              | 0.01                                   | 0.02    | 0.04    | 1.21 | 0.41                         |                                                      | 0              | 0.00                                   | 0.01    | 0.03    | 1.95 | 0.68                         |
|                    | 10             | 0.01                                   | 0.03    | 0.09    | 1.22 | 0.42                         |                                                      | 10             | 0.01                                   | 0.03    | 0.07    | 1.97 | 0.69                         |
|                    | 20             | 0.02                                   | 0.08    | 0.18    | 1.21 | 0.42                         |                                                      | 20             | 0.02                                   | 0.06    | 0.15    | 1.96 | 0.69                         |
|                    | 30             | 0.06                                   | 0.16    | 0.33    | 1.20 | 0.41                         |                                                      | 30             | 0.04                                   | 0.13    | 0.33    | 1.95 | 0.69                         |
|                    | 40             | 0.10                                   | 0.28    | 0.56    | 1.15 | 0.41                         |                                                      | 40             | 0.09                                   | 0.29    | 0.67    | 1.92 | 0.69                         |
|                    | 50             | 0.18                                   | 0.47    | 0.80    | 1.08 | 0.41                         |                                                      | 50             | 0.21                                   | 0.58    | 1.17    | 1.85 | 0.68                         |
|                    | 60             | 0.31                                   | 0.67    | 0.91    | 0.97 | 0.40                         |                                                      | 60             | 0.39                                   | 1.00    | 1.51    | 1.70 | 0.67                         |
|                    | 70             | 0.41                                   | 0.69    | -       | 0.76 | 0.37                         |                                                      | 70             | 0.65                                   | 1.21    | -       | 1.41 | 0.63                         |
|                    | 80             | 0.38                                   | -       | -       | 0.48 | 0.30                         |                                                      | 80             | 0.68                                   | -       | -       | 0.92 | 0.50                         |

Devcan 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

<sup>a</sup> Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

- Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 19.19  
Non-Hodgkin Lymphoma

SEER Incidence and U.S. Mortality  
Age-Adjusted Rates and Trends<sup>a</sup>  
By Race/Ethnicity and Sex

| SEER Incidence                    | SEER 18 Areas <sup>b</sup><br>Rate 2009-2013<br>Rate per 100,000 persons |       |         | SEER 13 Areas <sup>b</sup><br>Trend 2004-2013 <sup>c</sup><br>AAPC (%) |       |         | SEER 9 Areas <sup>b</sup><br>Trend 2004-2013 <sup>d</sup><br>AAPC (%) |       |         |
|-----------------------------------|--------------------------------------------------------------------------|-------|---------|------------------------------------------------------------------------|-------|---------|-----------------------------------------------------------------------|-------|---------|
|                                   | Total                                                                    | Males | Females | Total                                                                  | Males | Females | Total                                                                 | Males | Females |
|                                   | RACE/ETHNICITY                                                           |       |         |                                                                        |       |         |                                                                       |       |         |
| All Races                         | 19.5                                                                     | 23.7  | 16.1    | -0.6                                                                   | -0.6  | -0.9*   | -0.6                                                                  | -0.6  | -0.9*   |
| White                             | 20.4                                                                     | 24.8  | 16.9    | -0.7                                                                   | -0.5  | -0.9*   | -0.6*                                                                 | -0.5  | -1.0*   |
| White Hispanic <sup>e</sup>       | 18.3                                                                     | 21.5  | 15.8    | -0.6                                                                   | 0.2   | 0.7*    | -                                                                     | -     | -       |
| White Non-Hispanic <sup>e</sup>   | 20.9                                                                     | 25.4  | 17.1    | -0.6*                                                                  | -0.5  | -1.0*   | -                                                                     | -     | -       |
| Black                             | 14.6                                                                     | 17.6  | 12.2    | -1.0*                                                                  | -0.3  | 0.4     | 0.2                                                                   | -0.5  | -0.6    |
| Asian/Pacific Islander            | 13.5                                                                     | 16.5  | 11.1    | 0.2                                                                    | 0.3   | 0.2     | -                                                                     | -     | -       |
| Amer Ind/Alaska Nat <sup>f</sup>  | 12.9                                                                     | 14.6  | 11.6    | 1.7*                                                                   | 0.8   | 2.4*    | -                                                                     | -     | -       |
| Hispanic <sup>e</sup>             | 17.7                                                                     | 20.7  | 15.3    | -0.6                                                                   | 0.1   | 0.7*    | -                                                                     | -     | -       |
| <u>U.S. Mortality<sup>g</sup></u> |                                                                          |       |         |                                                                        |       |         |                                                                       |       |         |
|                                   | Rate 2009-2013<br>Rate per 100,000 persons                               |       |         | Trend 2004-2013 <sup>h</sup><br>AAPC (%)                               |       |         |                                                                       |       |         |
|                                   | Total                                                                    | Males | Females | Total                                                                  | Males | Females |                                                                       |       |         |
|                                   | RACE/ETHNICITY                                                           |       |         |                                                                        |       |         |                                                                       |       |         |
| All Races                         | 6.0                                                                      | 7.7   | 4.7     | -2.4*                                                                  | -2.2* | -2.8*   |                                                                       |       |         |
| White                             | 6.3                                                                      | 8.1   | 4.9     | -2.4*                                                                  | -2.1* | -2.8*   |                                                                       |       |         |
| White Hispanic <sup>e</sup>       | 5.4                                                                      | 6.7   | 4.4     | -1.1*                                                                  | -0.7  | -1.9*   |                                                                       |       |         |
| White Non-Hispanic <sup>e</sup>   | 6.3                                                                      | 8.1   | 4.9     | -2.5*                                                                  | -2.5* | -2.9*   |                                                                       |       |         |
| Black                             | 4.4                                                                      | 5.7   | 3.5     | -2.3*                                                                  | -2.4* | -2.4*   |                                                                       |       |         |
| Asian/Pacific Islander            | 4.0                                                                      | 4.9   | 3.3     | -1.9*                                                                  | -2.1* | -1.7*   |                                                                       |       |         |
| Amer Ind/Alaska Nat               |                                                                          |       |         |                                                                        |       |         |                                                                       |       |         |
| Total U.S.                        | 3.2                                                                      | 4.1   | 2.5     | -3.4*                                                                  | -1.5  | -5.2*   |                                                                       |       |         |
| CHSDA Counties                    | 4.5                                                                      | 5.7   | 3.5     | -0.6                                                                   | -0.4  | -4.5*   |                                                                       |       |         |
| Non-CHSDA Counties                | 1.7                                                                      | 2.2   | 1.3     | 2.2                                                                    | 4.4   | -4.7*   |                                                                       |       |         |
| Hispanic <sup>e</sup>             | 5.1                                                                      | 6.3   | 4.2     | -1.3*                                                                  | -0.9  | -2.1*   |                                                                       |       |         |

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

a Trend based on less than 10 cases for at least one year within the time interval.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry, and Rural Georgia.

The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG.

c The 2004-2013 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1992-2013.

d The 2004-2013 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints over diagnosis years 1975-2013.

e Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2004-2013 Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

f Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

g US Mortality Files, National Center for Health Statistics, CDC.

h The 2004-2013 mortality AAPCs are based on a Joinpoint analysis using years of death 1992-2013.

\* The APC is significantly different from zero (p<.05).

Table 19.20  
Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Rates<sup>a</sup>  
By Registry, Race and Sex

|                                                    | All Races |       |         | Whites |       |         | Blacks |       |         |
|----------------------------------------------------|-----------|-------|---------|--------|-------|---------|--------|-------|---------|
|                                                    | Total     | Males | Females | Total  | Males | Females | Total  | Males | Females |
| <u>SEER Incidence Rates<sup>a</sup>, 2009-2013</u> |           |       |         |        |       |         |        |       |         |
| California                                         | 18.68     | 22.79 | 15.32   | 19.62  | 23.89 | 16.07   | 14.16  | 16.58 | 12.09   |
| Greater Bay Area                                   | 19.98     | 24.72 | 16.04   | 21.96  | 27.15 | 17.51   | 16.28  | 19.47 | 13.52   |
| San Francisco-Oakland                              | 19.98     | 25.11 | 15.77   | 22.07  | 27.77 | 17.25   | 15.90  | 19.28 | 13.01   |
| San Jose-Monterey                                  | 20.04     | 24.04 | 16.59   | 21.81  | 26.11 | 17.99   | 19.11  | 21.25 | 17.00   |
| Los Angeles                                        | 18.47     | 22.35 | 15.36   | 19.96  | 23.94 | 16.67   | 14.05  | 17.07 | 11.73   |
| Greater California                                 | 18.33     | 22.31 | 15.05   | 18.83  | 22.93 | 15.43   | 13.27  | 14.73 | 11.83   |
| Connecticut                                        | 20.96     | 25.26 | 17.67   | 21.29  | 25.68 | 17.87   | 14.17  | 16.82 | 12.34   |
| Detroit                                            | 21.56     | 26.48 | 17.77   | 23.31  | 28.35 | 19.35   | 15.60  | 19.57 | 12.71   |
| Georgia                                            | 17.74     | 21.74 | 14.56   | 18.77  | 22.78 | 15.42   | 14.32  | 17.74 | 11.92   |
| Atlanta                                            | 18.81     | 23.50 | 15.21   | 20.39  | 25.59 | 16.18   | 16.21  | 19.28 | 13.81   |
| Rural Georgia                                      | 14.69     | 16.27 | 13.49   | 17.25  | 18.30 | 15.62   | 8.72   | -     | -       |
| Greater Georgia                                    | 17.26     | 20.99 | 14.25   | 18.22  | 21.87 | 15.14   | 13.05  | 16.55 | 10.68   |
| Hawaii                                             | 18.05     | 21.79 | 14.87   | 20.90  | 23.73 | 17.69   | -      | -     | -       |
| Iowa                                               | 22.09     | 26.68 | 18.48   | 22.13  | 26.65 | 18.58   | 15.59  | 18.48 | 13.83   |
| Kentucky                                           | 20.76     | 25.39 | 17.08   | 20.96  | 25.40 | 17.44   | 15.82  | 22.03 | 11.13   |
| Louisiana                                          | 19.86     | 23.96 | 16.55   | 21.52  | 25.64 | 18.12   | 14.83  | 18.38 | 12.05   |
| New Jersey                                         | 21.16     | 25.44 | 17.83   | 22.33  | 26.77 | 18.83   | 14.04  | 16.40 | 12.15   |
| New Mexico                                         | 15.25     | 17.32 | 13.50   | 15.30  | 17.46 | 13.47   | 10.46  | 14.45 | -       |
| Seattle-Puget Sound                                | 22.04     | 27.16 | 17.69   | 22.66  | 27.86 | 18.23   | 17.97  | 19.62 | 15.90   |
| Utah                                               | 18.86     | 23.34 | 15.05   | 19.13  | 23.74 | 15.20   | -      | -     | -       |
| SEER 9 Areas <sup>b</sup>                          | 20.30     | 24.87 | 16.61   | 21.25  | 25.92 | 17.40   | 15.77  | 19.03 | 13.22   |
| SEER 13 Areas <sup>b</sup>                         | 19.84     | 24.21 | 16.31   | 20.99  | 25.50 | 17.27   | 15.38  | 18.57 | 12.89   |
| SEER 18 Areas <sup>b</sup>                         | 19.51     | 23.73 | 16.10   | 20.45  | 24.76 | 16.90   | 14.57  | 17.63 | 12.17   |

<sup>a</sup> Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)  
<sup>b</sup> The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.  
The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.  
The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG.  
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.21  
Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Rates<sup>a</sup>  
By Registry, Race and Sex

|                                                | All Races |       |         | Whites |       |         | Blacks |       |         |
|------------------------------------------------|-----------|-------|---------|--------|-------|---------|--------|-------|---------|
|                                                | Total     | Males | Females | Total  | Males | Females | Total  | Males | Females |
| <u>SEER Death Rates<sup>a</sup>, 2009-2013</u> |           |       |         |        |       |         |        |       |         |
| California                                     | 5.69      | 7.27  | 4.48    | 6.12   | 7.87  | 4.77    | 4.39   | 5.39  | 3.62    |
| Greater Bay Area                               | 5.73      | 7.55  | 4.34    | 6.44   | 8.66  | 4.71    | 4.90   | 5.95  | 4.11    |
| San Francisco-Oakland                          | 5.74      | 7.76  | 4.19    | 6.42   | 8.93  | 4.46    | 4.96   | 5.96  | 4.23    |
| San Jose-Monterey                              | 5.72      | 7.16  | 4.63    | 6.47   | 8.18  | 5.14    | -      | -     | -       |
| Los Angeles                                    | 5.60      | 6.91  | 4.60    | 6.09   | 7.48  | 4.98    | 4.63   | 5.58  | 3.90    |
| Greater California                             | 5.71      | 7.33  | 4.46    | 6.04   | 7.78  | 4.69    | 3.86   | 5.03  | 2.95    |
| Connecticut                                    | 5.56      | 7.22  | 4.35    | 5.66   | 7.33  | 4.43    | 3.86   | 5.72  | 2.76    |
| Detroit                                        | 6.70      | 8.83  | 5.14    | 7.20   | 9.44  | 5.52    | 5.00   | 6.81  | 3.79    |
| Georgia                                        | 5.44      | 7.32  | 4.11    | 5.92   | 7.80  | 4.54    | 3.85   | 5.46  | 2.83    |
| Atlanta                                        | 5.02      | 7.19  | 3.66    | 5.45   | 7.96  | 3.79    | 4.07   | 5.33  | 3.33    |
| Rural Georgia                                  | 6.06      | 8.65  | 4.17    | 7.13   | 8.82  | 5.78    | -      | -     | -       |
| Greater Georgia                                | 5.61      | 7.37  | 4.29    | 6.07   | 7.74  | 4.76    | 3.72   | 5.46  | 2.53    |
| Hawaii                                         | 5.40      | 7.10  | 4.04    | 5.56   | 6.81  | 4.28    | -      | -     | -       |
| Iowa                                           | 6.73      | 8.78  | 5.27    | 6.75   | 8.79  | 5.29    | 6.58   | -     | -       |
| Kentucky                                       | 6.89      | 8.94  | 5.38    | 7.07   | 9.09  | 5.56    | 4.27   | 7.02  | 2.53    |
| Louisiana                                      | 6.56      | 8.75  | 4.87    | 6.97   | 9.04  | 5.33    | 5.03   | 7.29  | 3.38    |
| New Jersey                                     | 5.61      | 7.33  | 4.41    | 6.00   | 7.82  | 4.69    | 3.76   | 5.15  | 2.96    |
| New Mexico                                     | 4.95      | 6.13  | 3.97    | 4.98   | 6.18  | 3.96    | -      | -     | -       |
| Seattle-Puget Sound                            | 6.40      | 8.12  | 5.07    | 6.61   | 8.49  | 5.13    | 4.92   | 4.53  | 4.90    |
| Utah                                           | 5.69      | 7.01  | 4.62    | 5.83   | 7.20  | 4.73    | -      | -     | -       |
| SEER 9 Areas <sup>b</sup>                      | 5.94      | 7.75  | 4.58    | 6.24   | 8.15  | 4.78    | 4.55   | 5.96  | 3.58    |
| SEER 13 Areas <sup>b</sup>                     | 5.85      | 7.53  | 4.59    | 6.23   | 8.03  | 4.84    | 4.57   | 5.87  | 3.66    |
| SEER 18 Areas <sup>b</sup>                     | 5.87      | 7.60  | 4.58    | 6.24   | 8.04  | 4.86    | 4.32   | 5.85  | 3.26    |
| Total U.S.                                     | 6.01      | 7.75  | 4.69    | 6.26   | 8.05  | 4.88    | 4.36   | 5.66  | 3.45    |

<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.

The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG.

- Statistic not shown. Rate based on less than 16 cases for the time interval.


Table 19.22  
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death<sup>a</sup> Rates By State, All Races, 2009-2013


Males and Females

| State            | Rate | SE   | Rank(CI) <sup>d</sup> | PD                  |
|------------------|------|------|-----------------------|---------------------|
| TOTAL U.S.       | 6.01 | 0.02 |                       |                     |
| High Five States |      |      |                       |                     |
| Minnesota        | 7.00 | 0.16 | 01(01,11)             | 16.48 <sup>c</sup>  |
| Kentucky         | 6.89 | 0.17 | 02(01,17)             | 14.76               |
| Michigan         | 6.86 | 0.11 | 03(01,11)             | 14.29               |
| Iowa             | 6.73 | 0.19 | 04(01,22)             | 12.11               |
| Oklahoma         | 6.69 | 0.18 | 05(01,22)             | 11.46               |
| Low Five States  |      |      |                       |                     |
| Hawaii           | 5.40 | 0.26 | 47(19,51)             | -10.10              |
| Maryland         | 5.36 | 0.13 | 48(30,51)             | -10.83              |
| Colorado         | 5.28 | 0.15 | 49(32,51)             | -12.17              |
| New Mexico       | 4.95 | 0.21 | 50(37,51)             | -17.53 <sup>c</sup> |
| D.C.             | 4.88 | 0.42 | 51(19,51)             | -18.77 <sup>c</sup> |

| State         | Rate | SE   | Rank(CI) <sup>d</sup> | PD                  | State          | Rate | SE   | Rank(CI) <sup>d</sup> | PD                  |
|---------------|------|------|-----------------------|---------------------|----------------|------|------|-----------------------|---------------------|
| Alabama       | 6.14 | 0.15 | 22(07,35)             | 2.24                | Montana        | 5.77 | 0.31 | 28(05,51)             | -3.91               |
| Alaska        | 5.86 | 0.53 | 26(01,51)             | -2.49               | Nebraska       | 6.18 | 0.25 | 21(03,44)             | 2.94                |
| Arizona       | 5.56 | 0.13 | 38(25,49)             | -7.44               | Nevada         | 5.49 | 0.21 | 43(21,51)             | -8.55               |
| Arkansas      | 6.59 | 0.20 | 08(01,25)             | 9.66                | New Hampshire  | 5.43 | 0.27 | 46(19,51)             | -9.57               |
| California    | 5.69 | 0.06 | 33(26,43)             | -5.26               | New Jersey     | 5.61 | 0.11 | 37(25,48)             | -6.55               |
| Colorado      | 5.28 | 0.15 | 49(32,51)             | -12.17              | New Mexico     | 4.95 | 0.21 | 50(37,51)             | -17.53 <sup>c</sup> |
| Connecticut   | 5.56 | 0.16 | 39(22,50)             | -7.51               | New York       | 5.72 | 0.07 | 31(24,43)             | -4.79               |
| Delaware      | 6.10 | 0.34 | 23(01,49)             | 1.49                | North Carolina | 5.76 | 0.11 | 29(22,44)             | -4.06               |
| D.C.          | 4.88 | 0.42 | 51(19,51)             | -18.77 <sup>c</sup> | North Dakota   | 5.46 | 0.37 | 44(09,51)             | -9.17               |
| Florida       | 5.75 | 0.07 | 30(23,42)             | -4.22               | Ohio           | 6.58 | 0.10 | 09(02,19)             | 9.56                |
| Georgia       | 5.44 | 0.11 | 45(29,50)             | -9.40               | Oklahoma       | 6.69 | 0.18 | 05(01,22)             | 11.46               |
| Hawaii        | 5.40 | 0.26 | 47(19,51)             | -10.10              | Oregon         | 6.34 | 0.17 | 16(03,29)             | 5.60                |
| Idaho         | 6.32 | 0.28 | 18(01,43)             | 5.26                | Pennsylvania   | 6.49 | 0.09 | 11(04,21)             | 8.04                |
| Illinois      | 6.21 | 0.10 | 20(11,28)             | 3.32                | Rhode Island   | 5.52 | 0.30 | 42(13,51)             | -8.06               |
| Indiana       | 6.59 | 0.14 | 07(01,22)             | 9.68                | South Carolina | 5.68 | 0.15 | 36(20,48)             | -5.37               |
| Iowa          | 6.73 | 0.19 | 04(01,22)             | 12.11               | South Dakota   | 5.69 | 0.34 | 35(04,51)             | -5.34               |
| Kansas        | 6.34 | 0.20 | 17(02,32)             | 5.47                | Tennessee      | 6.46 | 0.14 | 14(02,24)             | 7.54                |
| Kentucky      | 6.89 | 0.17 | 02(01,17)             | 14.76               | Texas          | 5.85 | 0.07 | 27(22,39)             | -2.65               |
| Louisiana     | 6.56 | 0.17 | 10(01,24)             | 9.29                | Utah           | 5.69 | 0.24 | 34(15,50)             | -5.30               |
| Maine         | 6.46 | 0.28 | 13(01,38)             | 7.55                | Vermont        | 6.32 | 0.42 | 19(01,49)             | 5.21                |
| Maryland      | 5.36 | 0.13 | 48(30,51)             | -10.83              | Virginia       | 5.92 | 0.12 | 25(17,40)             | -1.52               |
| Massachusetts | 5.54 | 0.12 | 40(25,49)             | -7.72               | Washington     | 6.35 | 0.14 | 15(04,26)             | 5.65                |
| Michigan      | 6.86 | 0.11 | 03(01,11)             | 14.29               | West Virginia  | 6.59 | 0.24 | 06(01,27)             | 9.76                |
| Minnesota     | 7.00 | 0.16 | 01(01,11)             | 16.48 <sup>c</sup>  | Wisconsin      | 6.48 | 0.14 | 12(02,24)             | 7.93                |
| Mississippi   | 5.70 | 0.19 | 32(18,49)             | -5.13               | Wyoming        | 5.54 | 0.44 | 41(03,51)             | -7.72               |
| Missouri      | 6.01 | 0.13 | 24(14,39)             | 0.08                |                |      |      |                       |                     |



Age-Adjusted Death  
Rates per 100,000  
Quantile Interval



<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> Difference between state rate and total U.S. rate is statistically significant ( $p \leq .0002$ ).

<sup>c</sup> Absolute percent difference between state rate and total U.S. rate is 15% or more.

<sup>d</sup> Rank of state level death rate and the 95% confidence intervals (low, high) for the rank.

SE Standard error of the rate.

PD Percent difference between state rate and total U.S. rate.

- Statistic not shown. Rate based on less than 16 cases for the time interval.


Table 19.23  
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death<sup>a</sup> Rates By State, All Races, 2009-2013


Males

| State            | Rate | SE   | Rank(CI) <sup>d</sup> | PD                  |
|------------------|------|------|-----------------------|---------------------|
| TOTAL U.S.       | 7.75 | 0.03 |                       |                     |
| High Five States |      |      |                       |                     |
| Michigan         | 9.05 | 0.20 | 01(01,12)             | 16.76 <sup>c</sup>  |
| Minnesota        | 9.01 | 0.27 | 02(01,15)             | 16.32 <sup>c</sup>  |
| Kentucky         | 8.94 | 0.31 | 03(01,19)             | 15.40 <sup>c</sup>  |
| Iowa             | 8.78 | 0.33 | 04(01,22)             | 13.24               |
| Louisiana        | 8.75 | 0.31 | 05(01,21)             | 12.87               |
| Low Five States  |      |      |                       |                     |
| Wyoming          | 6.53 | 0.74 | 47(02,51)             | -15.69 <sup>c</sup> |
| Rhode Island     | 6.44 | 0.50 | 48(17,51)             | -16.85 <sup>c</sup> |
| North Dakota     | 6.32 | 0.60 | 49(15,51)             | -18.39 <sup>c</sup> |
| New Mexico       | 6.13 | 0.35 | 50(35,51)             | -20.95 <sup>c</sup> |
| D.C.             | 5.95 | 0.72 | 51(14,51)             | -23.28 <sup>c</sup> |

| State         | Rate | SE   | Rank(CI) <sup>d</sup> | PD                  | State          | Rate | SE   | Rank(CI) <sup>d</sup> | PD                  |
|---------------|------|------|-----------------------|---------------------|----------------|------|------|-----------------------|---------------------|
| Alabama       | 7.71 | 0.27 | 20(08,43)             | -0.50               | Montana        | 7.62 | 0.54 | 24(01,50)             | -1.72               |
| Alaska        | 7.18 | 0.86 | 37(01,51)             | -7.29               | Nebraska       | 7.53 | 0.42 | 27(04,49)             | -2.78               |
| Arizona       | 7.06 | 0.21 | 40(22,49)             | -8.95               | Nevada         | 6.97 | 0.35 | 44(17,50)             | -10.09              |
| Arkansas      | 8.23 | 0.34 | 15(01,39)             | 6.21                | New Hampshire  | 6.90 | 0.47 | 45(12,51)             | -10.96              |
| California    | 7.27 | 0.10 | 35(25,44)             | -6.16               | New Jersey     | 7.33 | 0.19 | 33(19,46)             | -5.38               |
| Colorado      | 6.74 | 0.26 | 46(25,51)             | -12.97              | New Mexico     | 6.13 | 0.35 | 50(35,51)             | -20.95 <sup>c</sup> |
| Connecticut   | 7.22 | 0.29 | 36(17,49)             | -6.86               | New York       | 7.38 | 0.13 | 32(21,43)             | -4.73               |
| Delaware      | 7.50 | 0.58 | 28(01,50)             | -3.21               | North Carolina | 7.46 | 0.19 | 30(17,44)             | -3.78               |
| D.C.          | 5.95 | 0.72 | 51(14,51)             | -23.28 <sup>c</sup> | North Dakota   | 6.32 | 0.60 | 49(15,51)             | -18.39 <sup>c</sup> |
| Florida       | 7.41 | 0.11 | 31(21,42)             | -4.35               | Ohio           | 8.55 | 0.18 | 07(02,19)             | 10.27               |
| Georgia       | 7.32 | 0.21 | 34(18,47)             | -5.49               | Oklahoma       | 8.63 | 0.32 | 06(01,25)             | 11.38               |
| Hawaii        | 7.10 | 0.45 | 39(07,51)             | -8.37               | Oregon         | 8.34 | 0.30 | 12(01,29)             | 7.68                |
| Idaho         | 7.67 | 0.47 | 23(02,49)             | -0.96               | Pennsylvania   | 8.45 | 0.16 | 10(03,20)             | 8.98                |
| Illinois      | 8.04 | 0.17 | 19(08,29)             | 3.71                | Rhode Island   | 6.44 | 0.50 | 48(17,51)             | -16.85 <sup>c</sup> |
| Indiana       | 8.48 | 0.24 | 09(01,24)             | 9.47                | South Carolina | 7.58 | 0.27 | 25(11,45)             | -2.20               |
| Iowa          | 8.78 | 0.33 | 04(01,22)             | 13.24               | South Dakota   | 7.04 | 0.57 | 41(06,51)             | -9.09               |
| Kansas        | 8.26 | 0.35 | 13(01,38)             | 6.56                | Tennessee      | 8.53 | 0.25 | 08(01,23)             | 10.12               |
| Kentucky      | 8.94 | 0.31 | 03(01,19)             | 15.40 <sup>c</sup>  | Texas          | 7.55 | 0.13 | 26(18,39)             | -2.54               |
| Louisiana     | 8.75 | 0.31 | 05(01,21)             | 12.87               | Utah           | 7.01 | 0.39 | 43(14,51)             | -9.49               |
| Maine         | 8.18 | 0.48 | 17(01,44)             | 5.55                | Vermont        | 8.22 | 0.73 | 16(01,49)             | 6.02                |
| Maryland      | 7.04 | 0.24 | 42(21,49)             | -9.14               | Virginia       | 7.69 | 0.22 | 22(11,41)             | -0.80               |
| Massachusetts | 7.14 | 0.22 | 38(21,48)             | -7.91               | Washington     | 8.08 | 0.23 | 18(04,32)             | 4.27                |
| Michigan      | 9.05 | 0.20 | 01(01,12)             | 16.76 <sup>c</sup>  | West Virginia  | 8.25 | 0.41 | 14(01,40)             | 6.40                |
| Minnesota     | 9.01 | 0.27 | 02(01,15)             | 16.32 <sup>c</sup>  | Wisconsin      | 8.37 | 0.25 | 11(02,26)             | 7.97                |
| Mississippi   | 7.49 | 0.35 | 29(08,48)             | -3.29               | Wyoming        | 6.53 | 0.74 | 47(02,51)             | -15.69 <sup>c</sup> |
| Missouri      | 7.69 | 0.23 | 21(11,43)             | -0.78               |                |      |      |                       |                     |



Age-Adjusted Death  
Rates per 100,000  
Quantile Interval



- <sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- <sup>b</sup> Difference between state rate and total U.S. rate is statistically significant ( $p \leq .0002$ ).
- <sup>c</sup> Absolute percent difference between state rate and total U.S. rate is 15% or more.
- <sup>d</sup> Rank of state level death rate and the 95% confidence intervals (low, high) for the rank.
- SE Standard error of the rate.
- PD Percent difference between state rate and total U.S. rate.
- Statistic not shown. Rate based on less than 16 cases for the time interval.


Table 19.24  
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death<sup>a</sup> Rates By State, All Races, 2009-2013

Females

| State            | Rate | SE   | Rank(CI) <sup>d</sup> | PD                  |
|------------------|------|------|-----------------------|---------------------|
| TOTAL U.S.       | 4.69 | 0.02 |                       |                     |
| High Five States |      |      |                       |                     |
| Kentucky         | 5.38 | 0.20 | 01(01,23)             | 14.89               |
| Minnesota        | 5.38 | 0.18 | 02(01,23)             | 14.89               |
| West Virginia    | 5.35 | 0.29 | 03(01,33)             | 14.19               |
| Arkansas         | 5.35 | 0.24 | 04(01,28)             | 14.17               |
| Iowa             | 5.27 | 0.23 | 05(01,29)             | 12.53               |
| Low Five States  |      |      |                       |                     |
| Georgia          | 4.11 | 0.13 | 47(32,51)             | -12.22              |
| D.C.             | 4.08 | 0.50 | 48(01,51)             | -13.04              |
| Colorado         | 4.07 | 0.18 | 49(28,51)             | -13.25              |
| Hawaii           | 4.04 | 0.30 | 50(17,51)             | -13.80              |
| New Mexico       | 3.97 | 0.26 | 51(24,51)             | -15.26 <sup>c</sup> |

| State         | Rate | SE   | Rank(CI) <sup>d</sup> | PD     | State          | Rate | SE   | Rank(CI) <sup>d</sup> | PD                  |
|---------------|------|------|-----------------------|--------|----------------|------|------|-----------------------|---------------------|
| Alabama       | 4.99 | 0.18 | 15(02,37)             | 6.51   | Montana        | 4.26 | 0.37 | 44(04,51)             | -9.02               |
| Alaska        | 4.56 | 0.64 | 31(01,51)             | -2.81  | Nebraska       | 5.11 | 0.30 | 11(01,43)             | 8.99                |
| Arizona       | 4.34 | 0.15 | 41(23,50)             | -7.50  | Nevada         | 4.23 | 0.25 | 45(15,51)             | -9.74               |
| Arkansas      | 5.35 | 0.24 | 04(01,28)             | 14.17  | New Hampshire  | 4.32 | 0.32 | 42(06,51)             | -7.72               |
| California    | 4.48 | 0.07 | 35(25,44)             | -4.49  | New Jersey     | 4.41 | 0.12 | 37(22,49)             | -5.90               |
| Colorado      | 4.07 | 0.18 | 49(28,51)             | -13.25 | New Mexico     | 3.97 | 0.26 | 51(24,51)             | -15.26 <sup>c</sup> |
| Connecticut   | 4.35 | 0.19 | 40(16,51)             | -7.22  | New York       | 4.50 | 0.09 | 34(23,44)             | -3.93               |
| Delaware      | 4.97 | 0.42 | 17(01,51)             | 6.04   | North Carolina | 4.53 | 0.13 | 33(18,46)             | -3.35               |
| D.C.          | 4.08 | 0.50 | 48(01,51)             | -13.04 | North Dakota   | 4.78 | 0.46 | 24(01,51)             | 2.00                |
| Florida       | 4.40 | 0.08 | 39(25,47)             | -6.12  | Ohio           | 5.13 | 0.12 | 10(02,25)             | 9.49                |
| Georgia       | 4.11 | 0.13 | 47(32,51)             | -12.22 | Oklahoma       | 5.17 | 0.21 | 08(01,32)             | 10.37               |
| Hawaii        | 4.04 | 0.30 | 50(17,51)             | -13.80 | Oregon         | 4.74 | 0.20 | 26(05,45)             | 1.20                |
| Idaho         | 5.10 | 0.34 | 12(01,47)             | 8.75   | Pennsylvania   | 5.04 | 0.11 | 14(04,27)             | 7.45                |
| Illinois      | 4.89 | 0.11 | 19(07,32)             | 4.36   | Rhode Island   | 4.73 | 0.36 | 27(01,51)             | 1.03                |
| Indiana       | 5.23 | 0.16 | 06(01,26)             | 11.53  | South Carolina | 4.30 | 0.17 | 43(20,51)             | -8.27               |
| Iowa          | 5.27 | 0.23 | 05(01,29)             | 12.53  | South Dakota   | 4.64 | 0.41 | 28(01,51)             | -0.99               |
| Kansas        | 4.84 | 0.23 | 22(02,46)             | 3.32   | Tennessee      | 4.87 | 0.16 | 21(04,39)             | 3.91                |
| Kentucky      | 5.38 | 0.20 | 01(01,23)             | 14.89  | Texas          | 4.55 | 0.09 | 32(21,43)             | -2.98               |
| Louisiana     | 4.87 | 0.19 | 20(03,42)             | 3.92   | Utah           | 4.62 | 0.28 | 29(03,51)             | -1.47               |
| Maine         | 5.15 | 0.32 | 09(01,45)             | 9.94   | Vermont        | 4.81 | 0.48 | 23(01,51)             | 2.55                |
| Maryland      | 4.15 | 0.16 | 46(27,51)             | -11.45 | Virginia       | 4.60 | 0.14 | 30(14,46)             | -1.81               |
| Massachusetts | 4.41 | 0.14 | 38(21,49)             | -5.92  | Washington     | 4.99 | 0.16 | 16(02,33)             | 6.37                |
| Michigan      | 5.21 | 0.13 | 07(01,24)             | 11.16  | West Virginia  | 5.35 | 0.29 | 03(01,33)             | 14.19               |
| Minnesota     | 5.38 | 0.18 | 02(01,23)             | 14.89  | Wisconsin      | 5.06 | 0.17 | 13(02,30)             | 7.99                |
| Mississippi   | 4.45 | 0.23 | 36(11,51)             | -5.10  | Wyoming        | 4.94 | 0.56 | 18(01,51)             | 5.30                |
| Missouri      | 4.77 | 0.16 | 25(06,42)             | 1.80   |                |      |      |                       |                     |



<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> Difference between state rate and total U.S. rate is statistically significant ( $p \leq .0002$ ).

<sup>c</sup> Absolute percent difference between state rate and total U.S. rate is 15% or more.

<sup>d</sup> Rank of state level death rate and the 95% confidence intervals (low, high) for the rank.

SE Standard error of the rate.

PD Percent difference between state rate and total U.S. rate.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.25  
Non-Hodgkin LymphomaEstimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2013  
By Race/Ethnicity, Sex and Years Since Diagnosis

| Years Since Diagnosis                      |            | 0 to <5 | 5 to <10 | 10 to <15 | 15 to <20 | 20 to <25 | 25 to <30 | 0 to <21 <sup>e</sup> | 0 to <38 <sup>e</sup> | >=38 <sup>g</sup> | Complete <sup>h</sup> |
|--------------------------------------------|------------|---------|----------|-----------|-----------|-----------|-----------|-----------------------|-----------------------|-------------------|-----------------------|
| Race                                       | Sex        |         |          |           |           |           |           |                       |                       |                   |                       |
| All Races <sup>b</sup>                     | Both Sexes | 208,024 | 147,198  | 93,446    | 53,791    | 29,696    | 17,350    | 522,304               | 561,810               | 7,726             | 569,536               |
|                                            | Males      | 112,213 | 75,991   | 48,589    | 28,402    | 15,226    | 9,437     | 275,343               | 296,343               | 4,074             | 300,417               |
|                                            | Females    | 95,811  | 71,207   | 44,857    | 25,389    | 14,470    | 7,913     | 246,961               | 265,467               | 3,652             | 269,119               |
| White <sup>b</sup>                         | Both Sexes | 177,772 | 129,114  | 82,376    | 47,190    | 26,689    | 15,706    | 454,266               | 490,081               | 8,097             | 498,178               |
|                                            | Males      | 96,367  | 67,062   | 42,958    | 24,852    | 13,724    | 8,505     | 240,356               | 259,429               | 4,601             | 264,030               |
|                                            | Females    | 81,405  | 62,052   | 39,418    | 22,338    | 12,965    | 7,201     | 213,910               | 230,652               | 3,496             | 234,148               |
| Black <sup>b</sup>                         | Both Sexes | 17,916  | 11,753   | 7,007     | 4,000     | 1,905     | 1,053     | 41,985                | 44,379                | 657               | 45,036                |
|                                            | Males      | 9,210   | 5,685    | 3,495     | 2,144     | 951       | 608       | 21,173                | 22,442                | 275               | 22,717                |
|                                            | Females    | 8,706   | 6,068    | 3,512     | 1,856     | 954       | 445       | 20,812                | 21,937                | 382               | 22,319                |
| Asian/<br>Pacific<br>Islander <sup>c</sup> | Both Sexes | 6,610   | 4,003    | 2,560     | +         | +         | +         | 14,811                | +                     | +                 | +                     |
|                                            | Males      | 3,504   | 2,073    | 1,331     | +         | +         | +         | 7,733                 | +                     | +                 | +                     |
|                                            | Females    | 3,106   | 1,930    | 1,229     | +         | +         | +         | 7,078                 | +                     | +                 | +                     |
| Hispanic <sup>d</sup>                      | Both Sexes | 17,016  | 10,193   | 6,238     | +         | +         | +         | 37,304                | +                     | +                 | +                     |
|                                            | Males      | 8,761   | 5,202    | 3,274     | +         | +         | +         | 19,291                | +                     | +                 | +                     |
|                                            | Females    | 8,255   | 4,991    | 2,964     | +         | +         | +         | 18,013                | +                     | +                 | +                     |

Estimated prevalence percent<sup>a</sup> on January 1, 2013, of the SEER<sup>c</sup> population diagnosed in the previous 21 years  
By Age at Prevalence, Race/Ethnicity and Sex

|                                            |            | Age Specific (Crude) |         |         |         |         |         |         |         |         |         | Age-Adjusted <sup>f</sup> |
|--------------------------------------------|------------|----------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------------------------|
| Age at Prevalence                          |            | All Ages             | 0-9     | 10-19   | 20-29   | 30-39   | 40-49   | 50-59   | 60-69   | 70-79   | 80+     | All Ages                  |
| Race                                       | Sex        |                      |         |         |         |         |         |         |         |         |         |                           |
| All Races <sup>c</sup>                     | Both Sexes | 0.1453%              | 0.0032% | 0.0122% | 0.0261% | 0.0470% | 0.1000% | 0.2003% | 0.3794% | 0.6058% | 0.7099% | 0.1377%                   |
|                                            | Males      | 0.1555%              | 0.0042% | 0.0166% | 0.0316% | 0.0550% | 0.1164% | 0.2326% | 0.4283% | 0.6806% | 0.8179% | 0.1581%                   |
|                                            | Females    | 0.1354%              | 0.0021% | 0.0077% | 0.0203% | 0.0390% | 0.0837% | 0.1694% | 0.3353% | 0.5448% | 0.6453% | 0.1199%                   |
| White <sup>c</sup>                         | Both Sexes | 0.1630%              | 0.0031% | 0.0128% | 0.0274% | 0.0484% | 0.1067% | 0.2145% | 0.4077% | 0.6658% | 0.7634% | 0.1481%                   |
|                                            | Males      | 0.1736%              | 0.0043% | 0.0178% | 0.0333% | 0.0561% | 0.1247% | 0.2487% | 0.4554% | 0.7442% | 0.8736% | 0.1693%                   |
|                                            | Females    | 0.1524%              | 0.0020% | 0.0077% | 0.0211% | 0.0402% | 0.0881% | 0.1806% | 0.3632% | 0.6002% | 0.6968% | 0.1290%                   |
| Black <sup>c</sup>                         | Both Sexes | 0.0927%              | 0.0036% | 0.0112% | 0.0258% | 0.0541% | 0.0949% | 0.1718% | 0.2952% | 0.3768% | 0.3583% | 0.1037%                   |
|                                            | Males      | 0.0985%              | 0.0034% | 0.0139% | 0.0327% | 0.0678% | 0.1074% | 0.1989% | 0.3454% | 0.3815% | 0.3716% | 0.1161%                   |
|                                            | Females    | 0.0875%              | 0.0038% | 0.0083% | 0.0191% | 0.0421% | 0.0839% | 0.1482% | 0.2560% | 0.3735% | 0.3517% | 0.0932%                   |
| Asian/<br>Pacific<br>Islander <sup>c</sup> | Both Sexes | 0.0908%              | 0.0032% | 0.0106% | 0.0191% | 0.0317% | 0.0609% | 0.1261% | 0.2405% | 0.3636% | 0.5004% | 0.0885%                   |
|                                            | Males      | 0.0983%              | 0.0046% | 0.0132% | 0.0216% | 0.0355% | 0.0679% | 0.1475% | 0.2748% | 0.4244% | 0.6218% | 0.1037%                   |
|                                            | Females    | 0.0841%              | 0.0017% | 0.0078% | 0.0165% | 0.0283% | 0.0547% | 0.1077% | 0.2123% | 0.3164% | 0.4260% | 0.0765%                   |
| Hispanic <sup>d</sup>                      | Both Sexes | 0.0716%              | 0.0030% | 0.0101% | 0.0207% | 0.0327% | 0.0790% | 0.1516% | 0.2929% | 0.4728% | 0.5580% | 0.1070%                   |
|                                            | Males      | 0.0729%              | 0.0034% | 0.0131% | 0.0248% | 0.0385% | 0.0890% | 0.1702% | 0.3041% | 0.4833% | 0.6015% | 0.1155%                   |
|                                            | Females    | 0.0702%              | 0.0025% | 0.0069% | 0.0163% | 0.0266% | 0.0685% | 0.1338% | 0.2832% | 0.4651% | 0.5319% | 0.0993%                   |

- <sup>a</sup> US 2013 cancer prevalence counts are based on 2013 cancer prevalence proportions from the SEER registries and 1/1/2013 US population estimates based on the average of 2012 and 2013 population estimates from the US Bureau of the Census.
- <sup>b c d</sup> Prevalence was calculated using the First Malignant Primary Only for a person. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry
- <sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.
- <sup>f</sup> Maximum limited-duration prevalence: 38 years for 1975-2013 SEER 9 data; 21 years for 1992-2013 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.
- <sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 38 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <38 and >=38. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.
- + Not available.

Table 19.26  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>  
SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2004-2013

| Site                                                                          | All Ages |         |       | Ages 0-19 |        |      | Ages 20-64 |         |       | Ages 65+ |         |       |
|-------------------------------------------------------------------------------|----------|---------|-------|-----------|--------|------|------------|---------|-------|----------|---------|-------|
|                                                                               | Rate     | Count   | APC   | Rate      | Count  | APC  | Rate       | Count   | APC   | Rate     | Count   | APC   |
| Lymphoid Neoplasm                                                             | 35.9     | 305,874 | -0.4* | 5.9       | 14,053 | 0.3  | 23.6       | 129,762 | -0.6* | 161.2    | 162,059 | -0.3  |
| 1 Hodgkin Lymphoma                                                            | 2.7      | 23,173  | -1.5* | 1.2       | 2,903  | -0.5 | 3.2        | 16,148  | -1.3* | 4.1      | 4,122   | -2.9* |
| 2 Non-Hodgkin lymphoma                                                        | 32.2     | 274,206 | -0.2  | 4.7       | 11,024 | 0.3  | 19.9       | 110,735 | -0.4* | 151.7    | 152,447 | -0.1  |
| 2(a) Non-Hodgkin lymphoma, B-cell                                             | 29.7     | 253,038 | 0.1   | 3.6       | 8,581  | 2.4* | 18.0       | 100,428 | -0.1  | 143.3    | 144,029 | 0.2   |
| 2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell                                | 1.4      | 11,706  | 3.2*  | 2.9       | 6,914  | 2.4* | 0.7        | 3,563   | 3.9*  | 1.2      | 1,229   | 5.8*  |
| 2(a) 2. Mature Non-Hodgkin lymphoma, B-cell                                   | 26.8     | 228,787 | -0.3  | 0.7       | 1,559  | 2.5* | 16.6       | 92,753  | -0.5* | 133.8    | 134,475 | -0.2  |
| 2(a) 2.1. Chronic/Small/Prolymphocytic/<br>Mantle B-cell Non-Hodgkin lymphoma | 6.6      | 56,488  | -1.4* | 0.0       | 26     | -    | 3.3        | 19,130  | -1.2* | 37.1     | 37,332  | -1.4* |
| 2(a) 2.1.1. Chronic/Small lymphocytic<br>leukemia/lymphoma                    | 5.8      | 49,480  | -1.7* | 0.0       | 23     | -    | 2.9        | 16,551  | -1.5* | 32.7     | 32,906  | -1.8* |
| 2(a) 2.1.2. Prolymphocytic leukemia, B-cell                                   | 0.0      | 201     | -4.9* | -         | -      | -    | 0.0        | 56      | -     | 0.1      | 142     | -4.7* |
| 2(a) 2.1.3. Mantle-cell lymphoma                                              | 0.8      | 6,807   | 1.3*  | 0.0       | 0      | -    | 0.4        | 2,523   | 0.8   | 4.3      | 4,284   | 1.5*  |
| 2(a) 2.2. Lymphoplasmacytic lymphoma/<br>Waldenstrom macroglobulinemia        | 0.6      | 5,304   | -1.2* | -         | -      | -    | 0.3        | 1,595   | -2.4* | 3.7      | 3,706   | -0.8  |
| 2(a) 2.2.1. Lymphoplasmacytic lymphoma                                        | 0.3      | 2,371   | -0.1  | -         | -      | -    | 0.1        | 704     | -1.4  | 1.7      | 1,666   | 0.4   |
| 2(a) 2.2.2. Waldenstrom macroglobulinemia                                     | 0.3      | 2,933   | -2.2* | -         | -      | -    | 0.2        | 891     | -3.2* | 2.0      | 2,040   | -1.8* |
| 2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)                               | 7.0      | 59,315  | 0.4   | 0.3       | 654    | 0.7  | 4.6        | 25,301  | -0.2  | 33.2     | 33,360  | 0.7*  |
| 2(a) 2.3.1. DLBCL, NOS <sup>c</sup>                                           | 6.9      | 58,652  | 0.3   | 0.3       | 623    | 0.4  | 4.5        | 24,775  | -0.4  | 33.1     | 33,254  | 0.7*  |
| 2(a) 2.3.2. Intravascular large B-cell<br>lymphoma                            | 0.0      | 89      | -     | 0.0       | 0      | -    | 0.0        | 40      | -     | 0.0      | 49      | -     |
| 2(a) 2.3.3. Primary effusion lymphoma                                         | 0.0      | 107     | -     | 0.0       | 0      | -    | 0.0        | 78      | -     | 0.0      | 29      | -     |
| 2(a) 2.3.4. Mediastinal large B-cell<br>lymphoma                              | 0.1      | 467     | 8.5*  | 0.0       | 31     | -    | 0.1        | 408     | 8.7*  | 0.0      | 28      | -     |
| 2(a) 2.4. Burkitt lymphoma/leukemia                                           | 0.4      | 3,464   | 0.1   | 0.3       | 700    | 4.1* | 0.4        | 1,990   | -1.2  | 0.8      | 774     | 0.1   |
| 2(a) 2.5. Marginal-zone lymphoma (MZL)                                        | 2.0      | 16,802  | 0.5   | 0.0       | 94     | -    | 1.3        | 7,006   | 0.5   | 9.7      | 9,702   | 0.4   |
| 2(a) 2.5.1. Splenic MZL                                                       | 0.2      | 1,480   | -0.2  | 0.0       | 0      | -    | 0.1        | 576     | 0.2   | 0.9      | 904     | -0.4  |
| 2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type                            | 1.2      | 9,999   | 0.9   | 0.0       | 62     | -    | 0.8        | 4,473   | 0.8   | 5.4      | 5,464   | 0.9   |
| 2(a) 2.5.3. Nodal MZL                                                         | 0.6      | 5,323   | -0.2  | 0.0       | 32     | -    | 0.3        | 1,957   | -0.2  | 3.3      | 3,334   | -0.3  |
| 2(a) 2.6. Follicular lymphoma                                                 | 3.6      | 31,110  | -2.1* | 0.0       | 68     | -    | 2.9        | 15,897  | -2.5* | 15.1     | 15,145  | -1.8* |
| 2(a) 2.7. Hairy-cell leukemia                                                 | 0.3      | 2,582   | -0.2  | -         | -      | -    | 0.3        | 1,644   | 0.3   | 0.9      | 937     | -0.9  |
| 2(a) 2.8. Plasma cell neoplasms                                               | 6.3      | 53,685  | 1.0*  | -         | -      | -    | 3.5        | 20,174  | 1.1*  | 33.4     | 33,499  | 1.0*  |
| 2(a) 2.8.1. Plasmacytoma                                                      | 0.4      | 3,439   | 2.2*  | -         | -      | -    | 0.3        | 1,670   | 2.2*  | 1.7      | 1,759   | 2.1   |
| 2(a) 2.8.2. Multiple myeloma/<br>plasma-cell leukemia                         | 5.9      | 50,246  | 1.0*  | -         | -      | -    | 3.2        | 18,504  | 1.0*  | 31.6     | 31,740  | 1.0*  |
| 2(a) 2.9. Heavy chain disease                                                 | 0.0      | 37      | -     | -         | -      | -    | 0.0        | 16      | -     | 0.0      | 20      | -     |
| 2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>                        | 1.5      | 12,545  | 5.3*  | 0.0       | 108    | -    | 0.7        | 4,112   | 5.1*  | 8.3      | 8,325   | 5.4*  |

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.26 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes  
SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2004-2013

| Site                                                                                             | All Ages |        |        | Ages 0-19 |       |       | Ages 20-64 |       |       | Ages 65+ |       |       |
|--------------------------------------------------------------------------------------------------|----------|--------|--------|-----------|-------|-------|------------|-------|-------|----------|-------|-------|
|                                                                                                  | Rate     | Count  | APC    | Rate      | Count | APC   | Rate       | Count | APC   | Rate     | Count | APC   |
| 2(b) Non-Hodgkin lymphoma, T-cell                                                                | 2.1      | 18,167 | 0.0    | 0.8       | 1,791 | 0.8   | 1.8        | 9,365 | -0.2  | 7.0      | 7,011 | 0.0   |
| 2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell                                                   | 0.1      | 854    | -      | 0.2       | 411   | -     | 0.1        | 380   | -     | 0.1      | 63    | -     |
| 2(b) 2. Mature Non-Hodgkin lymphoma, T-cell                                                      | 2.0      | 17,210 | 1.4*   | 0.6       | 1,377 | 8.7*  | 1.7        | 8,933 | 1.1   | 6.9      | 6,900 | 0.4   |
| 2(b) 2.1. Mycosis fungoides/Sezary syndrome                                                      | 0.5      | 4,296  | 1.3*   | 0.1       | 122   | -     | 0.5        | 2,514 | 0.7   | 1.6      | 1,660 | 1.8*  |
| 2(b) 2.1.1. Mycosis fungoides                                                                    | 0.5      | 4,157  | 1.2    | 0.1       | 122   | -     | 0.5        | 2,470 | 0.6   | 1.5      | 1,565 | 1.7*  |
| 2(b) 2.1.2. Sezary syndrome                                                                      | 0.0      | 139    | -      | 0.0       | 0     | -     | 0.0        | 44    | -     | 0.1      | 95    | -     |
| 2(b) 2.2. Peripheral T-cell lymphoma                                                             | 1.2      | 9,900  | -0.2   | 0.2       | 399   | -0.6  | 0.9        | 5,000 | -0.4  | 4.5      | 4,501 | 0.1   |
| 2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>                                         | 0.4      | 3,550  | 0.8    | 0.0       | 65    | -     | 0.3        | 1,689 | 0.9   | 1.8      | 1,796 | 0.7   |
| 2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma                                                   | 0.2      | 1,272  | 1.5    | -         | -     | -     | 0.1        | 492   | -0.8  | 0.8      | 777   | 2.6   |
| 2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma                                       | 0.0      | 123    | -      | 0.0       | 21    | -     | 0.0        | 74    | -     | 0.0      | 28    | -     |
| 2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type                             | 0.2      | 1,914  | -3.2*  | 0.1       | 241   | -3.1  | 0.2        | 1,082 | -2.3  | 0.6      | 591   | -4.3* |
| 2(b) 2.2.5. Hepatosplenic T-cell lymphoma                                                        | 0.0      | 84     | -      | -         | -     | -     | 0.0        | 63    | -     | -        | -     | -     |
| 2(b) 2.2.6. Enteropathy-type T-cell lymphoma                                                     | 0.0      | 119    | -      | 0.0       | 0     | -     | 0.0        | 58    | -     | 0.1      | 61    | -     |
| 2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>                                          | 0.2      | 1,953  | 0.7    | 0.0       | 30    | -     | 0.2        | 1,061 | 0.7   | 0.9      | 862   | 0.5   |
| 2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma                                     | 0.1      | 885    | -2.2   | 0.0       | 29    | -     | 0.1        | 481   | -3.0  | 0.4      | 375   | -1.7  |
| 2(b) 2.3. Adult T-cell leukemia/lymphoma                                                         | 0.2      | 1,834  | 12.4*  | 0.4       | 830   | 14.4* | 0.1        | 744   | 12.8* | 0.3      | 260   | 4.6   |
| 2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia | 0.1      | 697    | 2.0    | 0.0       | 24    | -     | 0.1        | 476   | 2.5   | 0.2      | 197   | 2.0   |
| 2(b) 2.5. T-cell large granular lymphocytic leukemia                                             | 0.0      | 176    | -      | -         | -     | -     | 0.0        | 68    | -     | 0.1      | 107   | -     |
| 2(b) 2.6. Prolymphocytic leukemia, T-cell                                                        | 0.0      | 307    | 3.6    | -         | -     | -     | 0.0        | 131   | -     | 0.2      | 175   | 3.4*  |
| 2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell                                          | 0.0      | 103    | -      | -         | -     | -     | 0.0        | 52    | -     | 0.0      | 48    | -     |
| 2(c) Non-Hodgkin lymphoma, unknown lineage                                                       | 0.4      | 3,001  | -18.4* | 0.3       | 652   | -     | 0.2        | 942   | -     | 1.4      | 1,407 | -     |
| 2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage                               | 0.1      | 1,199  | -22.1* | 0.3       | 635   | -     | 0.1        | 309   | -     | 0.2      | 255   | -     |
| 2(c) 2. Prolymphocytic leukemia, unknown lineage                                                 | 0.0      | 95     | -      | -         | -     | -     | 0.0        | 27    | -     | 0.1      | 66    | -     |
| 2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage                                 | 0.2      | 1,707  | -      | -         | -     | -     | 0.1        | 606   | -     | 1.1      | 1,086 | -     |
| 2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>                                           | 1.6      | 13,759 | -1.1*  | 3.4       | 7,960 | -1.5* | 0.8        | 4,252 | -0.7  | 1.5      | 1,547 | 0.1   |
| 3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma                                            | 0.0      | 249    | 22.7*  | -         | -     | -     | 0.0        | 132   | -     | 0.1      | 111   | -     |
| 4 Lymphoid neoplasm, NOS <sup>c</sup>                                                            | 1.0      | 8,246  | -5.0*  | 0.1       | 120   | -     | 0.5        | 2,747 | -4.8* | 5.3      | 5,379 | -5.4* |

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.27  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>  
SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Males, 2004-2013

| Site                                                                          | All Ages |         |       | Ages 0-19 |       |      | Ages 20-64 |        |       | Ages 65+ |        |       |
|-------------------------------------------------------------------------------|----------|---------|-------|-----------|-------|------|------------|--------|-------|----------|--------|-------|
|                                                                               | Rate     | Count   | APC   | Rate      | Count | APC  | Rate       | Count  | APC   | Rate     | Count  | APC   |
| Lymphoid Neoplasm                                                             | 44.4     | 170,501 | -0.3  | 6.8       | 8,174 | 0.1  | 28.1       | 75,839 | -0.7* | 205.8    | 86,488 | -0.1  |
| 1 Hodgkin Lymphoma                                                            | 3.1      | 12,673  | -1.3* | 1.3       | 1,566 | 0.3  | 3.5        | 8,934  | -1.2* | 5.1      | 2,173  | -2.5* |
| 2 Non-Hodgkin lymphoma                                                        | 40.2     | 153,352 | -0.1  | 5.4       | 6,527 | -0.2 | 24.0       | 65,193 | -0.5* | 194.1    | 81,632 | 0.2   |
| 2(a) Non-Hodgkin lymphoma, B-cell                                             | 37.0     | 140,909 | 0.2   | 4.1       | 4,923 | 1.9* | 21.6       | 59,006 | -0.3  | 183.1    | 76,980 | 0.4   |
| 2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell                                | 1.5      | 6,368   | 2.9*  | 3.1       | 3,782 | 1.4  | 0.8        | 1,987  | 4.5*  | 1.4      | 599    | 6.7*  |
| 2(a) 2. Mature Non-Hodgkin lymphoma, B-cell                                   | 33.7     | 127,862 | -0.2  | 0.9       | 1,061 | 3.4* | 20.0       | 54,632 | -0.7* | 171.6    | 72,169 | 0.0   |
| 2(a) 2.1. Chronic/Small/Prolymphocytic/<br>Mantle B-cell Non-Hodgkin lymphoma | 9.2      | 34,539  | -1.3* | -         | -     | -    | 4.4        | 12,509 | -1.3* | 52.4     | 22,016 | -1.4* |
| 2(a) 2.1.1. Chronic/Small lymphocytic<br>leukemia/lymphoma                    | 7.9      | 29,622  | -1.7* | -         | -     | -    | 3.8        | 10,607 | -1.6* | 45.3     | 19,002 | -1.8* |
| 2(a) 2.1.2. Prolymphocytic leukemia, B-cell                                   | 0.0      | 135     | -2.9  | -         | -     | -    | 0.0        | 39     | -     | 0.2      | 95     | -     |
| 2(a) 2.1.3. Mantle-cell lymphoma                                              | 1.3      | 4,782   | 1.2   | 0.0       | 0     | -    | 0.7        | 1,863  | 0.7   | 6.9      | 2,919  | 1.5   |
| 2(a) 2.2. Lymphoplasmacytic lymphoma/<br>Waldenstrom macroglobulinemia        | 0.8      | 3,079   | -1.3  | -         | -     | -    | 0.3        | 924    | -2.3* | 5.2      | 2,154  | -1.0  |
| 2(a) 2.2.1. Lymphoplasmacytic lymphoma                                        | 0.4      | 1,315   | -0.1  | 0.0       | 0     | -    | 0.1        | 379    | -2.3  | 2.2      | 936    | 0.6   |
| 2(a) 2.2.2. Waldenstrom macroglobulinemia                                     | 0.5      | 1,764   | -2.2* | -         | -     | -    | 0.2        | 545    | -2.4* | 2.9      | 1,218  | -2.1* |
| 2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)                               | 8.5      | 32,475  | 0.6*  | 0.3       | 379   | 3.0  | 5.7        | 15,185 | -0.3  | 40.5     | 16,911 | 1.2*  |
| 2(a) 2.3.1. DLBCL, NOS <sup>c</sup>                                           | 8.5      | 32,155  | 0.6   | 0.3       | 368   | 2.5  | 5.6        | 14,936 | -0.4  | 40.3     | 16,851 | 1.2*  |
| 2(a) 2.3.2. Intravascular large B-cell<br>lymphoma                            | 0.0      | 42      | -     | 0.0       | 0     | -    | 0.0        | 21     | -     | 0.1      | 21     | -     |
| 2(a) 2.3.3. Primary effusion lymphoma                                         | 0.0      | 97      | -     | 0.0       | 0     | -    | 0.0        | 75     | -     | 0.1      | 22     | -     |
| 2(a) 2.3.4. Mediastinal large B-cell<br>lymphoma                              | 0.0      | 181     | -     | -         | -     | -    | 0.1        | 153    | -     | 0.0      | 17     | -     |
| 2(a) 2.4. Burkitt lymphoma/leukemia                                           | 0.6      | 2,513   | -0.5  | 0.4       | 538   | 3.1  | 0.6        | 1,523  | -1.9  | 1.1      | 452    | 0.1   |
| 2(a) 2.5. Marginal-zone lymphoma (MZL)                                        | 2.1      | 7,884   | 0.5   | 0.1       | 67    | -    | 1.2        | 3,383  | 0.2   | 10.5     | 4,434  | 0.5   |
| 2(a) 2.5.1. Splenic MZL                                                       | 0.2      | 704     | -0.1  | 0.0       | 0     | -    | 0.1        | 282    | 0.4   | 1.0      | 422    | -0.4  |
| 2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type                            | 1.2      | 4,576   | 0.6   | 0.0       | 40    | -    | 0.8        | 2,092  | 0.4   | 5.8      | 2,444  | 0.6   |
| 2(a) 2.5.3. Nodal MZL                                                         | 0.7      | 2,604   | 0.4   | 0.0       | 27    | -    | 0.4        | 1,009  | -0.3  | 3.7      | 1,568  | 0.5   |
| 2(a) 2.6. Follicular lymphoma                                                 | 3.9      | 15,497  | -2.1* | 0.0       | 55    | -    | 3.0        | 8,238  | -3.1* | 16.8     | 7,204  | -1.3* |
| 2(a) 2.7. Hairy-cell leukemia                                                 | 0.5      | 2,047   | -0.5  | -         | -     | -    | 0.5        | 1,330  | 0.1   | 1.7      | 716    | -1.3* |
| 2(a) 2.8. Plasma cell neoplasms                                               | 7.9      | 29,804  | 1.2*  | -         | -     | -    | 4.1        | 11,531 | 1.0*  | 43.4     | 18,268 | 1.3*  |
| 2(a) 2.8.1. Plasmacytoma                                                      | 0.5      | 2,136   | 1.7*  | -         | -     | -    | 0.4        | 1,074  | 1.6   | 2.5      | 1,058  | 1.8   |
| 2(a) 2.8.2. Multiple myeloma/<br>plasma-cell leukemia                         | 7.4      | 27,668  | 1.2*  | -         | -     | -    | 3.7        | 10,457 | 1.0*  | 40.9     | 17,210 | 1.3*  |
| 2(a) 2.9. Heavy chain disease                                                 | 0.0      | 24      | -     | -         | -     | -    | -          | -      | -     | -        | -      | -     |
| 2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>                        | 1.8      | 6,679   | 5.4*  | 0.1       | 80    | -    | 0.9        | 2,387  | 5.1*  | 10.2     | 4,212  | 5.4*  |

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.27 - continued  
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes  
 SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Males, 2004-2013

| Site                                                                                             | All Ages |        |       | Ages 0-19 |       |       | Ages 20-64 |       |       | Ages 65+ |       |       |
|--------------------------------------------------------------------------------------------------|----------|--------|-------|-----------|-------|-------|------------|-------|-------|----------|-------|-------|
|                                                                                                  | Rate     | Count  | APC   | Rate      | Count | APC   | Rate       | Count | APC   | Rate     | Count | APC   |
| 2(b) Non-Hodgkin lymphoma, T-cell                                                                | 2.7      | 10,833 | 0.0   | 1.0       | 1,237 | 0.1   | 2.1        | 5,605 | -0.1  | 9.4      | 3,991 | 0.1   |
| 2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell                                                   | 0.1      | 593    | -     | 0.2       | 299   | -     | 0.1        | 259   | -     | 0.1      | 35    | -     |
| 2(b) 2. Mature Non-Hodgkin lymphoma, T-cell                                                      | 2.6      | 10,184 | 1.5*  | 0.8       | 936   | 8.3*  | 2.0        | 5,320 | 1.3   | 9.3      | 3,928 | 0.5   |
| 2(b) 2.1. Mycosis fungoides/Sezary syndrome                                                      | 0.6      | 2,456  | 1.1   | 0.0       | 60    | -     | 0.5        | 1,411 | 0.8   | 2.3      | 985   | 1.0   |
| 2(b) 2.1.1. Mycosis fungoides                                                                    | 0.6      | 2,376  | 1.0   | 0.0       | 60    | -     | 0.5        | 1,385 | 0.6   | 2.2      | 931   | 0.8   |
| 2(b) 2.1.2. Sezary syndrome                                                                      | 0.0      | 80     | -     | 0.0       | 0     | -     | 0.0        | 26    | -     | 0.1      | 54    | -     |
| 2(b) 2.2. Peripheral T-cell lymphoma                                                             | 1.5      | 5,794  | -0.1  | 0.2       | 245   | -2.1  | 1.1        | 3,015 | -0.2  | 6.0      | 2,534 | 0.2   |
| 2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>                                         | 0.6      | 2,120  | 1.0   | 0.0       | 41    | -     | 0.4        | 1,070 | 1.2   | 2.4      | 1,009 | 0.8   |
| 2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma                                                   | 0.2      | 681    | 2.5*  | -         | -     | -     | 0.1        | 284   | 1.3   | 0.9      | 394   | 3.1   |
| 2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma                                       | 0.0      | 41     | -     | -         | -     | -     | 0.0        | 24    | -     | -        | -     | -     |
| 2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type                             | 0.3      | 1,169  | -3.3* | 0.1       | 151   | -     | 0.3        | 671   | -3.3  | 0.8      | 347   | -2.4  |
| 2(b) 2.2.5. Hepatosplenic T-cell lymphoma                                                        | 0.0      | 58     | -     | -         | -     | -     | 0.0        | 41    | -     | -        | -     | -     |
| 2(b) 2.2.6. Enteropathy-type T-cell lymphoma                                                     | 0.0      | 64     | -     | 0.0       | 0     | -     | 0.0        | 29    | -     | 0.1      | 35    | -     |
| 2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>                                          | 0.3      | 1,150  | 0.6   | 0.0       | 18    | -     | 0.2        | 633   | 0.2   | 1.2      | 499   | 0.6   |
| 2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma                                     | 0.1      | 511    | -2.7  | 0.0       | 16    | -     | 0.1        | 263   | -1.9  | 0.6      | 232   | -3.4  |
| 2(b) 2.3. Adult T-cell leukemia/lymphoma                                                         | 0.3      | 1,226  | 12.5* | 0.5       | 611   | 12.8* | 0.2        | 483   | 13.2* | 0.3      | 132   | -     |
| 2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia | 0.1      | 449    | 1.6   | 0.0       | 19    | -     | 0.1        | 309   | 1.7   | 0.3      | 121   | -     |
| 2(b) 2.5. T-cell large granular lymphocytic leukemia                                             | 0.0      | 85     | -     | 0.0       | 0     | -     | 0.0        | 26    | -     | 0.1      | 59    | -     |
| 2(b) 2.6. Prolymphocytic leukemia, T-cell                                                        | 0.0      | 174    | 6.0*  | -         | -     | -     | 0.0        | 76    | -     | 0.2      | 97    | -     |
| 2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell                                          | 0.0      | 56     | -     | -         | -     | -     | 0.0        | 26    | -     | 0.1      | 28    | -     |
| 2(c) Non-Hodgkin lymphoma, unknown lineage                                                       | 0.4      | 1,610  | -     | 0.3       | 367   | -     | 0.2        | 582   | -     | 1.6      | 661   | -     |
| 2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage                               | 0.2      | 673    | -     | 0.3       | 356   | -     | 0.1        | 179   | -     | 0.3      | 138   | -     |
| 2(c) 2. Prolymphocytic leukemia, unknown lineage                                                 | 0.0      | 56     | -     | -         | -     | -     | 0.0        | 16    | -     | 0.1      | 39    | -     |
| 2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage                                 | 0.2      | 881    | -     | -         | -     | -     | 0.1        | 387   | -     | 1.2      | 484   | -     |
| 2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>                                           | 1.8      | 7,634  | -1.7* | 3.7       | 4,437 | -2.8* | 0.9        | 2,425 | -0.7  | 1.8      | 772   | 0.9   |
| 3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma                                            | 0.0      | 138    | -     | -         | -     | -     | 0.0        | 79    | -     | 0.1      | 54    | -     |
| 4 Lymphoid neoplasm, NOS <sup>c</sup>                                                            | 1.2      | 4,338  | -4.7* | 0.1       | 76    | -     | 0.6        | 1,633 | -5.8* | 6.4      | 2,629 | -4.7* |

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.28  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>  
SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Females, 2004-2013

| Site                                                                          | All Ages |         |       | Ages 0-19 |       |      | Ages 20-64 |        |       | Ages 65+ |        |       |
|-------------------------------------------------------------------------------|----------|---------|-------|-----------|-------|------|------------|--------|-------|----------|--------|-------|
|                                                                               | Rate     | Count   | APC   | Rate      | Count | APC  | Rate       | Count  | APC   | Rate     | Count  | APC   |
| Lymphoid Neoplasm                                                             | 29.1     | 135,373 | -0.6* | 5.1       | 5,879 | 0.5  | 19.3       | 53,923 | -0.4  | 129.5    | 75,571 | -0.8* |
| 1 Hodgkin Lymphoma                                                            | 2.4      | 10,500  | -1.8* | 1.1       | 1,337 | -1.4 | 2.8        | 7,214  | -1.4* | 3.4      | 1,949  | -3.6* |
| 2 Non-Hodgkin lymphoma                                                        | 25.9     | 120,854 | -0.3  | 3.9       | 4,497 | 1.0  | 16.0       | 45,542 | -0.1  | 121.5    | 70,815 | -0.5* |
| 2(a) Non-Hodgkin lymphoma, B-cell                                             | 24.0     | 112,129 | 0.0   | 3.2       | 3,658 | 3.1* | 14.5       | 41,422 | 0.1   | 115.1    | 67,049 | -0.2  |
| 2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell                                | 1.3      | 5,338   | 3.7*  | 2.7       | 3,132 | 3.6* | 0.6        | 1,576  | 3.1*  | 1.1      | 630    | 5.1*  |
| 2(a) 2. Mature Non-Hodgkin lymphoma, B-cell                                   | 21.4     | 100,925 | -0.5* | 0.4       | 498   | 0.6  | 13.3       | 38,121 | -0.3  | 107.0    | 62,306 | -0.6* |
| 2(a) 2.1. Chronic/Small/Prolymphocytic/<br>Mantle B-cell Non-Hodgkin lymphoma | 4.6      | 21,949  | -1.7* | -         | -     | -    | 2.2        | 6,621  | -1.1  | 26.1     | 15,316 | -1.9* |
| 2(a) 2.1.1. Chronic/Small lymphocytic<br>leukemia/lymphoma                    | 4.2      | 19,858  | -1.9* | -         | -     | -    | 2.0        | 5,944  | -1.3* | 23.6     | 13,904 | -2.2* |
| 2(a) 2.1.2. Prolymphocytic leukemia, B-cell                                   | 0.0      | 66      | -     | -         | -     | -    | 0.0        | 17     | -     | 0.1      | 47     | -     |
| 2(a) 2.1.3. Mantle-cell lymphoma                                              | 0.4      | 2,025   | 1.0   | 0.0       | 0     | -    | 0.2        | 660    | 1.0   | 2.4      | 1,365  | 1.0   |
| 2(a) 2.2. Lymphoplasmacytic lymphoma/<br>Waldenstrom macroglobulinemia        | 0.5      | 2,225   | -1.4  | -         | -     | -    | 0.2        | 671    | -2.5  | 2.7      | 1,552  | -0.9  |
| 2(a) 2.2.1. Lymphoplasmacytic lymphoma                                        | 0.2      | 1,056   | -0.1  | -         | -     | -    | 0.1        | 325    | 0.3   | 1.3      | 730    | -0.3  |
| 2(a) 2.2.2. Waldenstrom macroglobulinemia                                     | 0.2      | 1,169   | -2.4* | -         | -     | -    | 0.1        | 346    | -4.3* | 1.4      | 822    | -1.6  |
| 2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)                               | 5.8      | 26,840  | 0.0   | 0.2       | 275   | -2.4 | 3.6        | 10,116 | 0.0   | 28.2     | 16,449 | 0.0   |
| 2(a) 2.3.1. DLBCL, NOS <sup>c</sup>                                           | 5.7      | 26,497  | -0.1  | 0.2       | 255   | -2.5 | 3.5        | 9,839  | -0.3  | 28.1     | 16,403 | 0.0   |
| 2(a) 2.3.2. Intravascular large B-cell<br>lymphoma                            | 0.0      | 47      | -     | 0.0       | 0     | -    | 0.0        | 19     | -     | 0.0      | 28     | -     |
| 2(a) 2.3.3. Primary effusion lymphoma                                         | -        | -       | -     | 0.0       | 0     | -    | -          | -      | -     | -        | -      | -     |
| 2(a) 2.3.4. Mediastinal large B-cell<br>lymphoma                              | 0.1      | 286     | 9.7*  | 0.0       | 20    | -    | 0.1        | 255    | 10.5* | -        | -      | -     |
| 2(a) 2.4. Burkitt lymphoma/leukemia                                           | 0.2      | 951     | 1.6   | 0.1       | 162   | -    | 0.2        | 467    | 1.6   | 0.6      | 322    | -1.1  |
| 2(a) 2.5. Marginal-zone lymphoma (MZL)                                        | 1.9      | 8,918   | 0.5   | 0.0       | 27    | -    | 1.3        | 3,623  | 0.7   | 9.1      | 5,268  | 0.4   |
| 2(a) 2.5.1. Splenic MZL                                                       | 0.2      | 776     | 0.1   | 0.0       | 0     | -    | 0.1        | 294    | -0.1  | 0.8      | 482    | 0.1   |
| 2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type                            | 1.2      | 5,423   | 1.1   | 0.0       | 22    | -    | 0.8        | 2,381  | 1.2   | 5.2      | 3,020  | 1.1   |
| 2(a) 2.5.3. Nodal MZL                                                         | 0.6      | 2,719   | -0.6  | -         | -     | -    | 0.3        | 948    | 0.0   | 3.1      | 1,766  | -0.9  |
| 2(a) 2.6. Follicular lymphoma                                                 | 3.3      | 15,613  | -2.1* | -         | -     | -    | 2.7        | 7,659  | -1.9* | 13.8     | 7,941  | -2.3* |
| 2(a) 2.7. Hairy-cell leukemia                                                 | 0.1      | 535     | 0.1   | 0.0       | 0     | -    | 0.1        | 314    | 1.3   | 0.4      | 221    | -1.9  |
| 2(a) 2.8. Plasma cell neoplasms                                               | 5.0      | 23,881  | 0.7   | -         | -     | -    | 2.9        | 8,643  | 1.1   | 26.2     | 15,231 | 0.5   |
| 2(a) 2.8.1. Plasmacytoma                                                      | 0.3      | 1,303   | 2.9*  | -         | -     | -    | 0.2        | 596    | 3.4   | 1.2      | 701    | 2.2   |
| 2(a) 2.8.2. Multiple myeloma/<br>plasma-cell leukemia                         | 4.8      | 22,578  | 0.6   | -         | -     | -    | 2.7        | 8,047  | 1.0   | 25.0     | 14,530 | 0.4   |
| 2(a) 2.9. Heavy chain disease                                                 | -        | -       | -     | 0.0       | 0     | -    | -          | -      | -     | -        | -      | -     |
| 2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>                        | 1.2      | 5,866   | 5.1*  | 0.0       | 28    | -    | 0.6        | 1,725  | 5.1*  | 6.9      | 4,113  | 5.1*  |

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.28 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes  
SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Females, 2004-2013

| Site                                                                                             | All Ages |       |       | Ages 0-19 |       |      | Ages 20-64 |       |       | Ages 65+ |       |       |
|--------------------------------------------------------------------------------------------------|----------|-------|-------|-----------|-------|------|------------|-------|-------|----------|-------|-------|
|                                                                                                  | Rate     | Count | APC   | Rate      | Count | APC  | Rate       | Count | APC   | Rate     | Count | APC   |
| 2(b) Non-Hodgkin lymphoma, T-cell                                                                | 1.6      | 7,334 | 0.0   | 0.5       | 554   | 2.2  | 1.4        | 3,760 | -0.3  | 5.2      | 3,020 | -0.2  |
| 2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell                                                   | 0.1      | 261   | -     | 0.1       | 112   | -    | 0.0        | 121   | -     | 0.0      | 28    | -     |
| 2(b) 2. Mature Non-Hodgkin lymphoma, T-cell                                                      | 1.5      | 7,026 | 1.1*  | 0.4       | 441   | 8.9* | 1.3        | 3,613 | 0.7   | 5.1      | 2,972 | 0.2   |
| 2(b) 2.1. Mycosis fungoides/Sezary syndrome                                                      | 0.4      | 1,840 | 1.4   | 0.1       | 62    | -    | 0.4        | 1,103 | 0.7   | 1.2      | 675   | 2.6   |
| 2(b) 2.1.1. Mycosis fungoides                                                                    | 0.4      | 1,781 | 1.3   | 0.1       | 62    | -    | 0.4        | 1,085 | 0.6   | 1.1      | 634   | 2.6   |
| 2(b) 2.1.2. Sezary syndrome                                                                      | 0.0      | 59    | -     | 0.0       | 0     | -    | 0.0        | 18    | -     | 0.1      | 41    | -     |
| 2(b) 2.2. Peripheral T-cell lymphoma                                                             | 0.9      | 4,106 | -0.3  | 0.1       | 154   | -    | 0.7        | 1,985 | -0.7  | 3.4      | 1,967 | 0.0   |
| 2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>                                         | 0.3      | 1,430 | 0.7   | 0.0       | 24    | -    | 0.2        | 619   | 0.5   | 1.4      | 787   | 0.7   |
| 2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma                                                   | 0.1      | 591   | 0.4   | 0.0       | 0     | -    | 0.1        | 208   | -3.4  | 0.7      | 383   | 2.4   |
| 2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma                                       | 0.0      | 82    | -     | -         | -     | -    | 0.0        | 50    | -     | 0.0      | 18    | -     |
| 2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type                             | 0.2      | 745   | -2.6* | 0.1       | 90    | -    | 0.2        | 411   | -0.3  | 0.4      | 244   | -7.0* |
| 2(b) 2.2.5. Hepatosplenic T-cell lymphoma                                                        | 0.0      | 26    | -     | -         | -     | -    | 0.0        | 22    | -     | -        | -     | -     |
| 2(b) 2.2.6. Enteropathy-type T-cell lymphoma                                                     | 0.0      | 55    | -     | 0.0       | 0     | -    | 0.0        | 29    | -     | 0.0      | 26    | -     |
| 2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>                                          | 0.2      | 803   | 1.0   | -         | -     | -    | 0.2        | 428   | 1.3   | 0.6      | 363   | 0.4   |
| 2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma                                     | 0.1      | 374   | -2.1  | -         | -     | -    | 0.1        | 218   | -4.2  | 0.2      | 143   | 0.2   |
| 2(b) 2.3. Adult T-cell leukemia/lymphoma                                                         | 0.1      | 608   | 12.3* | 0.2       | 219   | -    | 0.1        | 261   | 11.5* | 0.2      | 128   | -     |
| 2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia | 0.1      | 248   | 2.8   | -         | -     | -    | 0.1        | 167   | -     | 0.1      | 76    | -     |
| 2(b) 2.5. T-cell large granular lymphocytic leukemia                                             | 0.0      | 91    | -     | -         | -     | -    | 0.0        | 42    | -     | 0.1      | 48    | -     |
| 2(b) 2.6. Prolymphocytic leukemia, T-cell                                                        | 0.0      | 133   | -     | 0.0       | 0     | -    | 0.0        | 55    | -     | 0.1      | 78    | -     |
| 2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell                                          | 0.0      | 47    | -     | -         | -     | -    | 0.0        | 26    | -     | 0.0      | 20    | -     |
| 2(c) Non-Hodgkin lymphoma, unknown lineage                                                       | 0.3      | 1,391 | -     | 0.2       | 285   | -    | 0.1        | 360   | -     | 1.2      | 746   | -     |
| 2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage                               | 0.1      | 526   | -     | 0.2       | 279   | -    | 0.0        | 130   | -     | 0.2      | 117   | -     |
| 2(c) 2. Prolymphocytic leukemia, unknown lineage                                                 | 0.0      | 39    | -     | -         | -     | -    | -          | -     | -     | 0.0      | 27    | -     |
| 2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage                                 | 0.2      | 826   | -     | -         | -     | -    | 0.1        | 219   | -     | 1.0      | 602   | -     |
| 2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>                                           | 1.5      | 6,125 | -0.2  | 3.1       | 3,523 | 0.1  | 0.7        | 1,827 | -0.8  | 1.3      | 775   | -0.9  |
| 3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma                                            | 0.0      | 111   | -     | -         | -     | -    | 0.0        | 53    | -     | 0.1      | 57    | -     |
| 4 Lymphoid neoplasm, NOS <sup>c</sup>                                                            | 0.8      | 3,908 | -5.1* | 0.0       | 44    | -    | 0.4        | 1,114 | -3.3* | 4.5      | 2,750 | -6.2* |

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.29  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2006-2012

| Site                                                                          | Count   | All Ages             |  | Ages 0-19            |  | Ages 20-64           |  | Ages 65+             |  |
|-------------------------------------------------------------------------------|---------|----------------------|--|----------------------|--|----------------------|--|----------------------|--|
|                                                                               |         | Percent ( 95% C.I. ) |  | Percent ( 95% C.I. ) |  | Percent ( 95% C.I. ) |  | Percent ( 95% C.I. ) |  |
| Lymphoid Neoplasm                                                             | 175,423 | 69.9 ( 69.6 , 70.1 ) |  | 90.1 ( 89.4 , 90.7 ) |  | 77.3 ( 77.0 , 77.7 ) |  | 59.4 ( 58.9 , 59.9 ) |  |
| 1 Hodgkin Lymphoma                                                            | 14,954  | 86.2 ( 85.6 , 86.9 ) |  | 96.9 ( 95.8 , 97.6 ) |  | 90.2 ( 89.5 , 90.9 ) |  | 54.3 ( 51.3 , 57.3 ) |  |
| 2 Non-Hodgkin lymphoma                                                        | 156,176 | 68.7 ( 68.4 , 69.1 ) |  | 88.2 ( 87.4 , 89.0 ) |  | 75.7 ( 75.3 , 76.1 ) |  | 60.1 ( 59.6 , 60.7 ) |  |
| 2(a) Non-Hodgkin lymphoma, B-cell                                             | 144,111 | 69.1 ( 68.8 , 69.4 ) |  | 88.8 ( 87.8 , 89.6 ) |  | 76.5 ( 76.1 , 76.9 ) |  | 60.7 ( 60.1 , 61.2 ) |  |
| 2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell                                | 7,914   | 68.6 ( 67.4 , 69.8 ) |  | 88.4 ( 87.3 , 89.4 ) |  | 38.9 ( 36.5 , 41.3 ) |  | 17.3 ( 13.7 , 21.2 ) |  |
| 2(a) 2. Mature Non-Hodgkin lymphoma, B-cell                                   | 129,173 | 69.2 ( 68.8 , 69.5 ) |  | 89.9 ( 87.8 , 91.7 ) |  | 78.0 ( 77.6 , 78.4 ) |  | 60.9 ( 60.4 , 61.5 ) |  |
| 2(a) 2.1. Chronic/Small/Prolymphocytic/<br>Mantle B-cell Non-Hodgkin lymphoma | 30,939  | 78.4 ( 77.6 , 79.1 ) |  | - ( - , - )          |  | 86.7 ( 85.8 , 87.5 ) |  | 72.6 ( 71.5 , 73.7 ) |  |
| 2(a) 2.1.1. Chronic/Small lymphocytic<br>leukemia/lymphoma                    | 27,182  | 81.5 ( 80.7 , 82.3 ) |  | - ( - , - )          |  | 89.6 ( 88.7 , 90.4 ) |  | 76.1 ( 74.9 , 77.2 ) |  |
| 2(a) 2.1.2. Prolymphocytic leukemia, B-cell                                   | 97      | 43.2 ( 29.8 , 55.9 ) |  | - ( - , - )          |  | 52.8 ( 31.9 , 70.0 ) |  | 37.0 ( 20.6 , 53.6 ) |  |
| 2(a) 2.1.3. Mantle-cell lymphoma                                              | 3,660   | 55.9 ( 53.6 , 58.1 ) |  | - ( - , - )          |  | 68.3 ( 65.3 , 71.0 ) |  | 45.5 ( 42.2 , 48.6 ) |  |
| 2(a) 2.2. Lymphoplasmacytic lymphoma/<br>Waldenstrom macroglobulinemia        | 2,806   | 82.0 ( 79.4 , 84.4 ) |  | - ( - , - )          |  | 89.8 ( 87.0 , 92.0 ) |  | 77.2 ( 73.3 , 80.6 ) |  |
| 2(a) 2.2.1. Lymphoplasmacytic lymphoma                                        | 1,273   | 77.7 ( 73.6 , 81.2 ) |  | - ( - , - )          |  | 85.3 ( 80.6 , 89.0 ) |  | 72.7 ( 66.8 , 77.8 ) |  |
| 2(a) 2.2.2. Waldenstrom macroglobulinemia                                     | 1,533   | 85.7 ( 82.1 , 88.6 ) |  | - ( - , - )          |  | 93.2 ( 89.5 , 95.6 ) |  | 80.9 ( 75.5 , 85.2 ) |  |
| 2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)                               | 33,755  | 62.0 ( 61.3 , 62.6 ) |  | 88.3 ( 84.7 , 91.0 ) |  | 71.2 ( 70.4 , 72.0 ) |  | 52.5 ( 51.4 , 53.6 ) |  |
| 2(a) 2.3.1. DLBCL, NOS <sup>c</sup>                                           | 33,322  | 61.8 ( 61.2 , 62.5 ) |  | 89.2 ( 85.6 , 91.9 ) |  | 71.1 ( 70.2 , 71.9 ) |  | 52.5 ( 51.4 , 53.6 ) |  |
| 2(a) 2.3.2. Intravascular large B-cell<br>lymphoma                            | 54      | 51.3 ( 33.4 , 66.5 ) |  | - ( - , - )          |  | 59.2 ( 35.1 , 76.9 ) |  | 44.2 ( 20.7 , 65.5 ) |  |
| 2(a) 2.3.3. Primary effusion lymphoma                                         | 54      | 23.1 ( 11.6 , 37.0 ) |  | - ( - , - )          |  | 23.8 ( 11.1 , 39.1 ) |  | - ( - , - )          |  |
| 2(a) 2.3.4. Mediastinal large B-cell<br>lymphoma                              | 325     | 83.9 ( 78.1 , 88.2 ) |  | 69.4 ( 43.8 , 85.1 ) |  | 86.8 ( 81.0 , 90.9 ) |  | - ( - , - )          |  |
| 2(a) 2.4. Burkitt lymphoma/leukemia                                           | 2,202   | 60.2 ( 57.9 , 62.4 ) |  | 89.7 ( 86.4 , 92.1 ) |  | 56.9 ( 53.9 , 59.7 ) |  | 36.4 ( 30.4 , 42.5 ) |  |
| 2(a) 2.5. Marginal-zone lymphoma (MZL)                                        | 9,414   | 89.7 ( 88.5 , 90.8 ) |  | 98.5 ( 89.7 , 99.8 ) |  | 93.1 ( 91.9 , 94.2 ) |  | 86.3 ( 84.2 , 88.2 ) |  |
| 2(a) 2.5.1. Splenic MZL                                                       | 831     | 85.6 ( 80.8 , 89.2 ) |  | - ( - , - )          |  | 85.6 ( 79.8 , 89.8 ) |  | 85.4 ( 78.1 , 90.4 ) |  |
| 2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type                            | 5,667   | 93.9 ( 92.4 , 95.1 ) |  | 97.8 ( 85.0 , 99.7 ) |  | 96.0 ( 94.6 , 97.0 ) |  | 91.6 ( 88.6 , 93.9 ) |  |
| 2(a) 2.5.3. Nodal MZL                                                         | 2,916   | 82.7 ( 80.3 , 84.8 ) |  | - ( - , - )          |  | 88.9 ( 86.2 , 91.1 ) |  | 77.4 ( 73.6 , 80.7 ) |  |
| 2(a) 2.6. Follicular lymphoma                                                 | 17,971  | 87.5 ( 86.7 , 88.2 ) |  | 97.3 ( 80.1 , 99.7 ) |  | 91.7 ( 90.9 , 92.4 ) |  | 81.6 ( 80.0 , 83.1 ) |  |
| 2(a) 2.7. Hairy-cell leukemia                                                 | 1,511   | 92.6 ( 89.9 , 94.5 ) |  | - ( - , - )          |  | 96.8 ( 94.6 , 98.1 ) |  | 81.4 ( 73.4 , 87.2 ) |  |
| 2(a) 2.8. Plasma cell neoplasms                                               | 30,545  | 48.4 ( 47.6 , 49.2 ) |  | - ( - , - )          |  | 61.4 ( 60.3 , 62.5 ) |  | 38.1 ( 37.1 , 39.2 ) |  |
| 2(a) 2.8.1. Plasmacytoma                                                      | 1,893   | 66.8 ( 63.7 , 69.6 ) |  | - ( - , - )          |  | 77.9 ( 74.4 , 81.0 ) |  | 51.4 ( 46.0 , 56.4 ) |  |
| 2(a) 2.8.2. Multiple myeloma/<br>plasma-cell leukemia                         | 28,652  | 47.2 ( 46.4 , 48.0 ) |  | - ( - , - )          |  | 60.0 ( 58.8 , 61.1 ) |  | 37.5 ( 36.4 , 38.6 ) |  |
| 2(a) 2.9. Heavy chain disease                                                 | 30      | 59.8 ( 34.0 , 78.3 ) |  | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  |
| 2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>                        | 7,024   | 68.4 ( 66.8 , 70.0 ) |  | 92.7 ( 83.1 , 96.9 ) |  | 76.2 ( 74.1 , 78.1 ) |  | 63.2 ( 60.8 , 65.5 ) |  |

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.29 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2006-2012

| Site                                                                                             | Count  | All Ages             |  | Ages 0-19            |  | Ages 20-64           |  | Ages 65+             |  |
|--------------------------------------------------------------------------------------------------|--------|----------------------|--|----------------------|--|----------------------|--|----------------------|--|
|                                                                                                  |        | Percent ( 95% C.I. ) |  | Percent ( 95% C.I. ) |  | Percent ( 95% C.I. ) |  | Percent ( 95% C.I. ) |  |
| 2(b) Non-Hodgkin lymphoma, T-cell                                                                | 10,585 | 65.1 ( 63.9 , 66.2 ) |  | 86.5 ( 84.3 , 88.4 ) |  | 68.4 ( 67.0 , 69.7 ) |  | 51.4 ( 49.0 , 53.8 ) |  |
| 2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell                                                   | 498    | 66.1 ( 61.6 , 70.2 ) |  | 87.5 ( 82.6 , 91.1 ) |  | 50.1 ( 43.0 , 56.7 ) |  | 7.5 ( 1.3 , 21.2 )   |  |
| 2(b) 2. Mature Non-Hodgkin lymphoma, T-cell                                                      | 10,034 | 65.2 ( 64.0 , 66.3 ) |  | 86.2 ( 83.6 , 88.4 ) |  | 69.3 ( 67.9 , 70.7 ) |  | 52.1 ( 49.7 , 54.5 ) |  |
| 2(b) 2.1. Mycosis fungoides/Sezary syndrome                                                      | 2,507  | 90.1 ( 87.9 , 91.9 ) |  | 94.8 ( 76.6 , 98.9 ) |  | 92.1 ( 89.9 , 93.8 ) |  | 85.5 ( 79.6 , 89.8 ) |  |
| 2(b) 2.1.1. Mycosis fungoides                                                                    | 2,429  | 91.7 ( 89.5 , 93.5 ) |  | 94.8 ( 76.6 , 98.9 ) |  | 93.0 ( 90.8 , 94.7 ) |  | 88.7 ( 82.5 , 92.8 ) |  |
| 2(b) 2.1.2. Sezary syndrome                                                                      | 78     | 35.9 ( 21.2 , 50.8 ) |  | - ( - , - )          |  | 47.8 ( 26.8 , 66.2 ) |  | 20.8 ( 4.6 , 44.8 )  |  |
| 2(b) 2.2. Peripheral T-cell lymphoma                                                             | 5,623  | 57.7 ( 56.0 , 59.2 ) |  | 83.6 ( 78.4 , 87.7 ) |  | 65.1 ( 63.2 , 67.0 ) |  | 43.5 ( 40.7 , 46.3 ) |  |
| 2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>                                         | 1,928  | 38.9 ( 36.2 , 41.5 ) |  | 69.5 ( 52.3 , 81.6 ) |  | 46.0 ( 42.4 , 49.5 ) |  | 28.5 ( 24.4 , 32.6 ) |  |
| 2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma                                                   | 753    | 43.7 ( 39.3 , 48.0 ) |  | - ( - , - )          |  | 55.4 ( 49.0 , 61.3 ) |  | 34.2 ( 28.3 , 40.2 ) |  |
| 2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma                                       | 74     | 88.4 ( 76.9 , 94.4 ) |  | - ( - , - )          |  | 88.8 ( 73.2 , 95.6 ) |  | - ( - , - )          |  |
| 2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type                             | 1,145  | 59.6 ( 56.2 , 62.8 ) |  | 84.9 ( 78.1 , 89.7 ) |  | 65.0 ( 60.9 , 68.8 ) |  | 30.9 ( 23.8 , 38.2 ) |  |
| 2(b) 2.2.5. Hepatosplenic T-cell lymphoma                                                        | 52     | 26.6 ( 14.4 , 40.5 ) |  | - ( - , - )          |  | 29.0 ( 14.4 , 45.3 ) |  | - ( - , - )          |  |
| 2(b) 2.2.6. Enteropathy-type T-cell lymphoma                                                     | 59     | 13.2 ( 4.6 , 26.6 )  |  | - ( - , - )          |  | 8.8 ( 0.9 , 28.3 )   |  | 16.6 ( 3.6 , 37.7 )  |  |
| 2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>                                          | 1,088  | 83.8 ( 80.3 , 86.7 ) |  | 96.2 ( 75.5 , 99.5 ) |  | 88.1 ( 84.3 , 91.0 ) |  | 76.3 ( 70.0 , 81.4 ) |  |
| 2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma                                     | 524    | 89.5 ( 84.5 , 93.0 ) |  | - ( - , - )          |  | 95.1 ( 90.7 , 97.4 ) |  | 78.0 ( 65.1 , 86.6 ) |  |
| 2(b) 2.3. Adult T-cell leukemia/lymphoma                                                         | 1,210  | 62.0 ( 58.5 , 65.2 ) |  | 86.7 ( 83.4 , 89.4 ) |  | 41.0 ( 35.0 , 46.9 ) |  | 14.8 ( 7.4 , 24.7 )  |  |
| 2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia | 435    | 43.2 ( 37.6 , 48.7 ) |  | - ( - , - )          |  | 43.4 ( 37.2 , 49.4 ) |  | 39.1 ( 26.3 , 51.6 ) |  |
| 2(b) 2.5. T-cell large granular lymphocytic leukemia                                             | 99     | 68.8 ( 56.6 , 78.3 ) |  | - ( - , - )          |  | 78.8 ( 62.7 , 88.5 ) |  | 57.8 ( 39.4 , 72.4 ) |  |
| 2(b) 2.6. Prolymphocytic leukemia, T-cell                                                        | 160    | 13.6 ( 7.1 , 22.4 )  |  | - ( - , - )          |  | 18.3 ( 8.9 , 30.3 )  |  | 9.0 ( 1.9 , 22.9 )   |  |
| 2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell                                          | 53     | 38.1 ( 24.8 , 51.4 ) |  | - ( - , - )          |  | 51.0 ( 31.8 , 67.3 ) |  | - ( - , - )          |  |
| 2(c) Non-Hodgkin lymphoma, unknown lineage                                                       | 1,480  | 59.4 ( 56.5 , 62.2 ) |  | 86.2 ( 82.1 , 89.4 ) |  | 57.5 ( 52.7 , 62.0 ) |  | 44.1 ( 39.1 , 49.0 ) |  |
| 2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage                               | 609    | 65.0 ( 60.9 , 68.8 ) |  | 86.5 ( 82.4 , 89.7 ) |  | 39.4 ( 31.1 , 47.6 ) |  | 21.7 ( 13.5 , 31.2 ) |  |
| 2(c) 2. Prolymphocytic leukemia, unknown lineage                                                 | 44     | 51.2 ( 34.1 , 66.0 ) |  | - ( - , - )          |  | - ( - , - )          |  | 42.2 ( 23.1 , 60.1 ) |  |
| 2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage                                 | 827    | 55.6 ( 51.5 , 59.6 ) |  | - ( - , - )          |  | 65.1 ( 59.4 , 70.3 ) |  | 48.3 ( 42.5 , 53.9 ) |  |
| 2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>                                           | 9,021  | 68.3 ( 67.2 , 69.3 ) |  | 88.3 ( 87.3 , 89.3 ) |  | 40.1 ( 38.0 , 42.3 ) |  | 17.8 ( 14.6 , 21.3 ) |  |
| 3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma                                            | 117    | 67.8 ( 55.4 , 77.5 ) |  | - ( - , - )          |  | 77.9 ( 64.1 , 86.9 ) |  | 44.6 ( 20.8 , 65.9 ) |  |
| 4 Lymphoid neoplasm, NOS <sup>c</sup>                                                            | 4,176  | 50.0 ( 48.0 , 51.9 ) |  | 84.6 ( 73.2 , 91.4 ) |  | 61.9 ( 59.1 , 64.5 ) |  | 41.0 ( 38.3 , 43.7 ) |  |

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

Table 19.30  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2006-2012

| Site                                                                          |        | All Ages             |                      | Ages 0-19            |                      | Ages 20-64           |                      | Ages 65+ |  |
|-------------------------------------------------------------------------------|--------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------|--|
|                                                                               |        | Count                | Percent ( 95% C.I. ) | Percent ( 95% C.I. ) | Percent ( 95% C.I. ) | Percent ( 95% C.I. ) | Percent ( 95% C.I. ) |          |  |
| Lymphoid Neoplasm                                                             | 97,136 | 69.4 ( 69.0 , 69.8 ) | 89.7 ( 88.8 , 90.6 ) | 75.6 ( 75.2 , 76.1 ) | 59.0 ( 58.2 , 59.7 ) |                      |                      |          |  |
| 1 Hodgkin Lymphoma                                                            | 8,168  | 85.4 ( 84.4 , 86.3 ) | 96.7 ( 95.2 , 97.8 ) | 88.7 ( 87.7 , 89.6 ) | 54.3 ( 50.0 , 58.4 ) |                      |                      |          |  |
| 2 Non-Hodgkin lymphoma                                                        | 86,731 | 68.3 ( 67.9 , 68.8 ) | 88.0 ( 86.9 , 89.0 ) | 74.1 ( 73.6 , 74.6 ) | 59.6 ( 58.9 , 60.4 ) |                      |                      |          |  |
| 2(a) Non-Hodgkin lymphoma, B-cell                                             | 79,652 | 68.8 ( 68.3 , 69.2 ) | 88.5 ( 87.2 , 89.7 ) | 75.1 ( 74.5 , 75.6 ) | 60.2 ( 59.4 , 61.0 ) |                      |                      |          |  |
| 2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell                                | 4,284  | 68.6 ( 67.0 , 70.2 ) | 87.9 ( 86.4 , 89.3 ) | 38.5 ( 35.3 , 41.7 ) | 19.3 ( 14.0 , 25.2 ) |                      |                      |          |  |
| 2(a) 2. Mature Non-Hodgkin lymphoma, B-cell                                   | 71,668 | 68.9 ( 68.4 , 69.4 ) | 90.5 ( 87.9 , 92.5 ) | 76.4 ( 75.9 , 77.0 ) | 60.6 ( 59.7 , 61.3 ) |                      |                      |          |  |
| 2(a) 2.1. Chronic/Small/Prolymphocytic/<br>Mantle B-cell Non-Hodgkin lymphoma | 18,803 | 77.4 ( 76.4 , 78.3 ) | - ( - , - )          | 85.5 ( 84.4 , 86.5 ) | 70.9 ( 69.4 , 72.4 ) |                      |                      |          |  |
| 2(a) 2.1.1. Chronic/Small lymphocytic<br>leukemia/lymphoma                    | 16,158 | 81.0 ( 79.9 , 82.0 ) | - ( - , - )          | 88.7 ( 87.5 , 89.8 ) | 75.0 ( 73.3 , 76.5 ) |                      |                      |          |  |
| 2(a) 2.1.2. Prolymphocytic leukemia, B-cell                                   | 67     | 48.5 ( 30.9 , 64.0 ) | - ( - , - )          | 61.6 ( 34.5 , 80.3 ) | 40.5 ( 20.4 , 59.8 ) |                      |                      |          |  |
| 2(a) 2.1.3. Mantle-cell lymphoma                                              | 2,578  | 55.5 ( 52.8 , 58.1 ) | - ( - , - )          | 67.6 ( 64.2 , 70.9 ) | 43.9 ( 40.0 , 47.8 ) |                      |                      |          |  |
| 2(a) 2.2. Lymphoplasmacytic lymphoma/<br>Waldenstrom macroglobulinemia        | 1,598  | 81.9 ( 78.2 , 84.9 ) | - ( - , - )          | 88.4 ( 84.5 , 91.4 ) | 77.4 ( 72.0 , 81.9 ) |                      |                      |          |  |
| 2(a) 2.2.1. Lymphoplasmacytic lymphoma                                        | 683    | 77.9 ( 72.2 , 82.6 ) | - ( - , - )          | 84.0 ( 77.3 , 88.8 ) | 73.4 ( 65.0 , 80.1 ) |                      |                      |          |  |
| 2(a) 2.2.2. Waldenstrom macroglobulinemia                                     | 915    | 84.9 ( 79.9 , 88.7 ) | - ( - , - )          | 91.3 ( 85.6 , 94.8 ) | 80.6 ( 73.1 , 86.2 ) |                      |                      |          |  |
| 2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)                               | 18,472 | 62.0 ( 61.0 , 62.9 ) | 89.8 ( 85.1 , 93.0 ) | 69.0 ( 67.9 , 70.1 ) | 52.7 ( 51.1 , 54.3 ) |                      |                      |          |  |
| 2(a) 2.3.1. DLBCL, NOS <sup>c</sup>                                           | 18,267 | 62.0 ( 61.1 , 62.9 ) | 90.3 ( 85.6 , 93.5 ) | 69.0 ( 67.9 , 70.1 ) | 52.8 ( 51.2 , 54.4 ) |                      |                      |          |  |
| 2(a) 2.3.2. Intravascular large B-cell<br>lymphoma                            | 27     | 39.2 ( 16.8 , 61.1 ) | - ( - , - )          | - ( - , - )          | - ( - , - )          |                      |                      |          |  |
| 2(a) 2.3.3. Primary effusion lymphoma                                         | 50     | 23.4 ( 11.6 , 37.7 ) | - ( - , - )          | 22.6 ( 10.4 , 37.7 ) | - ( - , - )          |                      |                      |          |  |
| 2(a) 2.3.4. Mediastinal large B-cell<br>lymphoma                              | 128    | 79.0 ( 68.1 , 86.5 ) | - ( - , - )          | 84.4 ( 73.1 , 91.2 ) | - ( - , - )          |                      |                      |          |  |
| 2(a) 2.4. Burkitt lymphoma/leukemia                                           | 1,586  | 62.1 ( 59.4 , 64.7 ) | 89.4 ( 85.7 , 92.3 ) | 57.7 ( 54.3 , 60.9 ) | 36.2 ( 27.6 , 44.7 ) |                      |                      |          |  |
| 2(a) 2.5. Marginal-zone lymphoma (MZL)                                        | 4,353  | 89.6 ( 87.7 , 91.2 ) | 100.0 ( - , - )      | 92.4 ( 90.5 , 93.9 ) | 86.5 ( 83.2 , 89.1 ) |                      |                      |          |  |
| 2(a) 2.5.1. Splenic MZL                                                       | 378    | 88.5 ( 81.2 , 93.0 ) | - ( - , - )          | 83.4 ( 74.7 , 89.4 ) | 89.9 ( 80.5 , 94.9 ) |                      |                      |          |  |
| 2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type                            | 2,561  | 93.8 ( 91.3 , 95.6 ) | 100.0 ( - , - )      | 95.5 ( 93.3 , 97.0 ) | 91.5 ( 86.1 , 94.9 ) |                      |                      |          |  |
| 2(a) 2.5.3. Nodal MZL                                                         | 1,414  | 82.0 ( 78.4 , 85.0 ) | - ( - , - )          | 88.0 ( 84.0 , 91.1 ) | 76.4 ( 70.3 , 81.3 ) |                      |                      |          |  |
| 2(a) 2.6. Follicular lymphoma                                                 | 8,896  | 86.5 ( 85.3 , 87.6 ) | 96.5 ( 75.8 , 99.6 ) | 90.2 ( 89.0 , 91.3 ) | 80.5 ( 78.0 , 82.7 ) |                      |                      |          |  |
| 2(a) 2.7. Hairy-cell leukemia                                                 | 1,224  | 93.1 ( 90.1 , 95.3 ) | - ( - , - )          | 96.5 ( 93.8 , 98.0 ) | 83.7 ( 74.4 , 89.8 ) |                      |                      |          |  |
| 2(a) 2.8. Plasma cell neoplasms                                               | 16,714 | 49.3 ( 48.2 , 50.3 ) | - ( - , - )          | 60.8 ( 59.4 , 62.2 ) | 39.2 ( 37.7 , 40.7 ) |                      |                      |          |  |
| 2(a) 2.8.1. Plasmacytoma                                                      | 1,172  | 67.6 ( 63.7 , 71.2 ) | - ( - , - )          | 76.5 ( 72.2 , 80.3 ) | 53.2 ( 45.8 , 60.1 ) |                      |                      |          |  |
| 2(a) 2.8.2. Multiple myeloma/<br>plasma-cell leukemia                         | 15,542 | 47.9 ( 46.8 , 49.0 ) | - ( - , - )          | 59.2 ( 57.7 , 60.7 ) | 38.4 ( 36.9 , 40.0 ) |                      |                      |          |  |
| 2(a) 2.9. Heavy chain disease                                                 | -      | - ( - , - )          | - ( - , - )          | - ( - , - )          | - ( - , - )          |                      |                      |          |  |
| 2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>                        | 3,700  | 66.6 ( 64.3 , 68.9 ) | 91.9 ( 79.4 , 96.9 ) | 73.3 ( 70.4 , 76.0 ) | 60.9 ( 57.3 , 64.3 ) |                      |                      |          |  |

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.30 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2006-2012

| Site                                                                                             | Count | All Ages             |  | Ages 0-19            |  | Ages 20-64           |  | Ages 65+             |  |
|--------------------------------------------------------------------------------------------------|-------|----------------------|--|----------------------|--|----------------------|--|----------------------|--|
|                                                                                                  |       | Percent ( 95% C.I. ) |  | Percent ( 95% C.I. ) |  | Percent ( 95% C.I. ) |  | Percent ( 95% C.I. ) |  |
| 2(b) Non-Hodgkin lymphoma, T-cell                                                                | 6,288 | 64.2 ( 62.7 , 65.7 ) |  | 86.9 ( 84.3 , 89.1 ) |  | 65.7 ( 63.9 , 67.5 ) |  | 50.4 ( 47.1 , 53.6 ) |  |
| 2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell                                                   | 350   | 65.6 ( 60.2 , 70.5 ) |  | 86.0 ( 79.9 , 90.3 ) |  | 47.5 ( 39.0 , 55.5 ) |  | - ( - , - )          |  |
| 2(b) 2. Mature Non-Hodgkin lymphoma, T-cell                                                      | 5,914 | 64.2 ( 62.6 , 65.7 ) |  | 87.2 ( 84.2 , 89.7 ) |  | 66.7 ( 64.8 , 68.5 ) |  | 51.1 ( 47.8 , 54.4 ) |  |
| 2(b) 2.1. Mycosis fungoides/Sezary syndrome                                                      | 1,389 | 88.3 ( 85.0 , 90.9 ) |  | 100.0 ( - , - )      |  | 90.9 ( 87.7 , 93.3 ) |  | 81.8 ( 73.1 , 87.9 ) |  |
| 2(b) 2.1.1. Mycosis fungoides                                                                    | 1,341 | 90.3 ( 86.9 , 92.8 ) |  | 100.0 ( - , - )      |  | 91.9 ( 88.8 , 94.2 ) |  | 85.7 ( 76.4 , 91.5 ) |  |
| 2(b) 2.1.2. Sezary syndrome                                                                      | 48    | 31.3 ( 13.7 , 50.8 ) |  | - ( - , - )          |  | - ( - , - )          |  | 14.3 ( 1.0 , 43.7 )  |  |
| 2(b) 2.2. Peripheral T-cell lymphoma                                                             | 3,285 | 56.3 ( 54.2 , 58.4 ) |  | 82.7 ( 75.9 , 87.8 ) |  | 62.3 ( 59.6 , 64.8 ) |  | 43.2 ( 39.3 , 47.0 ) |  |
| 2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>                                         | 1,176 | 38.6 ( 35.1 , 42.2 ) |  | 72.0 ( 49.9 , 85.6 ) |  | 44.6 ( 40.0 , 49.1 ) |  | 28.5 ( 23.1 , 34.2 ) |  |
| 2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma                                                   | 396   | 40.2 ( 34.1 , 46.1 ) |  | - ( - , - )          |  | 49.2 ( 40.5 , 57.3 ) |  | 31.6 ( 23.3 , 40.2 ) |  |
| 2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma                                       | 29    | 83.2 ( 62.5 , 93.1 ) |  | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  |
| 2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type                             | 701   | 57.1 ( 52.8 , 61.2 ) |  | 85.7 ( 77.0 , 91.3 ) |  | 60.7 ( 55.4 , 65.6 ) |  | 29.5 ( 20.5 , 39.0 ) |  |
| 2(b) 2.2.5. Hepatosplenic T-cell lymphoma                                                        | 36    | 26.5 ( 12.1 , 43.4 ) |  | - ( - , - )          |  | 34.1 ( 16.1 , 53.0 ) |  | - ( - , - )          |  |
| 2(b) 2.2.6. Enteropathy-type T-cell lymphoma                                                     | 29    | 19.3 ( 6.0 , 38.1 )  |  | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  |
| 2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>                                          | 622   | 83.7 ( 79.0 , 87.5 ) |  | - ( - , - )          |  | 87.2 ( 81.9 , 91.1 ) |  | 75.8 ( 67.1 , 82.4 ) |  |
| 2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma                                     | 296   | 88.8 ( 81.5 , 93.3 ) |  | - ( - , - )          |  | 95.1 ( 89.5 , 97.8 ) |  | 77.1 ( 59.4 , 87.8 ) |  |
| 2(b) 2.3. Adult T-cell leukemia/lymphoma                                                         | 836   | 66.5 ( 62.4 , 70.2 ) |  | 88.4 ( 84.6 , 91.3 ) |  | 44.1 ( 36.9 , 51.1 ) |  | 5.0 ( 0.4 , 19.9 )   |  |
| 2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia | 280   | 42.7 ( 36.0 , 49.3 ) |  | - ( - , - )          |  | 41.0 ( 33.5 , 48.4 ) |  | 40.4 ( 24.0 , 56.2 ) |  |
| 2(b) 2.5. T-cell large granular lymphocytic leukemia                                             | 39    | 59.0 ( 39.3 , 74.2 ) |  | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  |
| 2(b) 2.6. Prolymphocytic leukemia, T-cell                                                        | 85    | 17.7 ( 8.3 , 29.9 )  |  | - ( - , - )          |  | 21.4 ( 8.8 , 37.5 )  |  | 14.2 ( 3.2 , 33.0 )  |  |
| 2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell                                          | -     | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  |
| 2(c) Non-Hodgkin lymphoma, unknown lineage                                                       | 791   | 58.0 ( 54.0 , 61.7 ) |  | 84.4 ( 78.4 , 88.8 ) |  | 55.8 ( 49.7 , 61.5 ) |  | 39.9 ( 32.7 , 47.1 ) |  |
| 2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage                               | 340   | 62.9 ( 57.3 , 67.9 ) |  | 84.0 ( 78.0 , 88.5 ) |  | 38.5 ( 28.0 , 48.9 ) |  | 21.3 ( 10.5 , 34.6 ) |  |
| 2(c) 2. Prolymphocytic leukemia, unknown lineage                                                 | -     | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  |
| 2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage                                 | 433   | 54.3 ( 48.6 , 59.6 ) |  | - ( - , - )          |  | 62.9 ( 55.6 , 69.4 ) |  | 43.8 ( 35.2 , 52.1 ) |  |
| 2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>                                           | 4,974 | 68.1 ( 66.6 , 69.5 ) |  | 87.6 ( 86.2 , 88.8 ) |  | 39.7 ( 36.9 , 42.6 ) |  | 18.9 ( 14.2 , 24.1 ) |  |
| 3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma                                            | 71    | 77.1 ( 60.9 , 87.3 ) |  | - ( - , - )          |  | 81.1 ( 64.9 , 90.3 ) |  | - ( - , - )          |  |
| 4 Lymphoid neoplasm, NOS <sup>c</sup>                                                            | 2,166 | 49.0 ( 46.3 , 51.6 ) |  | 84.6 ( 69.5 , 92.6 ) |  | 58.1 ( 54.5 , 61.6 ) |  | 39.7 ( 35.7 , 43.7 ) |  |

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

Table 19.31  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2006-2012

| Site                                                                          | All Ages |                      | Ages 0-19            |                      | Ages 20-64           |                      | Ages 65+ |  |
|-------------------------------------------------------------------------------|----------|----------------------|----------------------|----------------------|----------------------|----------------------|----------|--|
|                                                                               | Count    | Percent ( 95% C.I. ) | Percent ( 95% C.I. ) | Percent ( 95% C.I. ) | Percent ( 95% C.I. ) | Percent ( 95% C.I. ) |          |  |
| Lymphoid Neoplasm                                                             | 78,287   | 70.4 ( 70.0 , 70.8 ) | 90.5 ( 89.5 , 91.5 ) | 79.8 ( 79.3 , 80.3 ) | 59.9 ( 59.2 , 60.6 ) |                      |          |  |
| 1 Hodgkin Lymphoma                                                            | 6,786    | 87.3 ( 86.3 , 88.2 ) | 97.0 ( 95.4 , 98.0 ) | 92.0 ( 91.1 , 92.9 ) | 54.2 ( 49.9 , 58.3 ) |                      |          |  |
| 2 Non-Hodgkin lymphoma                                                        | 69,445   | 69.3 ( 68.8 , 69.7 ) | 88.6 ( 87.2 , 89.8 ) | 78.0 ( 77.4 , 78.6 ) | 60.7 ( 59.9 , 61.4 ) |                      |          |  |
| 2(a) Non-Hodgkin lymphoma, B-cell                                             | 64,459   | 69.5 ( 69.0 , 70.0 ) | 89.1 ( 87.6 , 90.4 ) | 78.7 ( 78.0 , 79.3 ) | 61.1 ( 60.4 , 61.9 ) |                      |          |  |
| 2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell                                | 3,630    | 68.6 ( 66.8 , 70.3 ) | 89.1 ( 87.4 , 90.5 ) | 39.4 ( 35.8 , 42.9 ) | 15.4 ( 10.8 , 20.8 ) |                      |          |  |
| 2(a) 2. Mature Non-Hodgkin lymphoma, B-cell                                   | 57,505   | 69.5 ( 69.0 , 70.1 ) | 88.7 ( 84.7 , 91.8 ) | 80.3 ( 79.6 , 80.9 ) | 61.3 ( 60.5 , 62.1 ) |                      |          |  |
| 2(a) 2.1. Chronic/Small/Prolymphocytic/<br>Mantle B-cell Non-Hodgkin lymphoma | 12,136   | 79.9 ( 78.7 , 81.1 ) | - ( - , - )          | 89.0 ( 87.7 , 90.3 ) | 75.0 ( 73.2 , 76.6 ) |                      |          |  |
| 2(a) 2.1.1. Chronic/Small lymphocytic<br>leukemia/lymphoma                    | 11,024   | 82.3 ( 81.0 , 83.5 ) | - ( - , - )          | 91.2 ( 89.8 , 92.4 ) | 77.5 ( 75.6 , 79.1 ) |                      |          |  |
| 2(a) 2.1.2. Prolymphocytic leukemia, B-cell                                   | 30       | 32.3 ( 14.9 , 51.2 ) | - ( - , - )          | - ( - , - )          | - ( - , - )          |                      |          |  |
| 2(a) 2.1.3. Mantle-cell lymphoma                                              | 1,082    | 56.9 ( 52.7 , 61.0 ) | - ( - , - )          | 70.2 ( 64.2 , 75.4 ) | 48.4 ( 42.6 , 54.0 ) |                      |          |  |
| 2(a) 2.2. Lymphoplasmacytic lymphoma/<br>Waldenstrom macroglobulinemia        | 1,208    | 82.3 ( 78.3 , 85.6 ) | - ( - , - )          | 91.5 ( 87.2 , 94.4 ) | 76.8 ( 70.9 , 81.6 ) |                      |          |  |
| 2(a) 2.2.1. Lymphoplasmacytic lymphoma                                        | 590      | 77.3 ( 71.2 , 82.3 ) | - ( - , - )          | 86.6 ( 79.1 , 91.5 ) | 71.9 ( 63.1 , 79.0 ) |                      |          |  |
| 2(a) 2.2.2. Waldenstrom macroglobulinemia                                     | 618      | 86.8 ( 81.2 , 90.8 ) | - ( - , - )          | 95.1 ( 89.6 , 97.7 ) | 81.3 ( 72.7 , 87.4 ) |                      |          |  |
| 2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)                               | 15,283   | 62.0 ( 61.0 , 63.0 ) | 86.0 ( 79.8 , 90.4 ) | 74.6 ( 73.3 , 75.8 ) | 52.2 ( 50.8 , 53.7 ) |                      |          |  |
| 2(a) 2.3.1. DLBCL, NOS <sup>c</sup>                                           | 15,055   | 61.6 ( 60.6 , 62.6 ) | 87.4 ( 81.1 , 91.7 ) | 74.2 ( 72.9 , 75.4 ) | 52.2 ( 50.7 , 53.6 ) |                      |          |  |
| 2(a) 2.3.2. Intravascular large B-cell<br>lymphoma                            | 27       | 63.0 ( 38.7 , 79.9 ) | - ( - , - )          | - ( - , - )          | - ( - , - )          |                      |          |  |
| 2(a) 2.3.3. Primary effusion lymphoma                                         | -        | - ( - , - )          | - ( - , - )          | - ( - , - )          | - ( - , - )          |                      |          |  |
| 2(a) 2.3.4. Mediastinal large B-cell<br>lymphoma                              | 197      | 86.3 ( 79.7 , 90.9 ) | - ( - , - )          | 88.2 ( 81.5 , 92.5 ) | - ( - , - )          |                      |          |  |
| 2(a) 2.4. Burkitt lymphoma/leukemia                                           | 616      | 55.1 ( 50.6 , 59.3 ) | 90.3 ( 82.7 , 94.7 ) | 54.3 ( 48.2 , 60.0 ) | 34.5 ( 27.0 , 42.2 ) |                      |          |  |
| 2(a) 2.5. Marginal-zone lymphoma (MZL)                                        | 5,061    | 89.8 ( 88.1 , 91.2 ) | - ( - , - )          | 93.9 ( 92.2 , 95.1 ) | 86.2 ( 83.4 , 88.5 ) |                      |          |  |
| 2(a) 2.5.1. Splenic MZL                                                       | 453      | 81.8 ( 74.9 , 87.0 ) | - ( - , - )          | 87.5 ( 79.0 , 92.7 ) | 77.2 ( 66.2 , 85.1 ) |                      |          |  |
| 2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type                            | 3,106    | 94.0 ( 92.0 , 95.6 ) | - ( - , - )          | 96.2 ( 94.4 , 97.5 ) | 91.7 ( 87.7 , 94.4 ) |                      |          |  |
| 2(a) 2.5.3. Nodal MZL                                                         | 1,502    | 83.1 ( 79.8 , 85.9 ) | - ( - , - )          | 89.7 ( 85.8 , 92.6 ) | 78.3 ( 73.2 , 82.5 ) |                      |          |  |
| 2(a) 2.6. Follicular lymphoma                                                 | 9,075    | 88.4 ( 87.3 , 89.4 ) | - ( - , - )          | 93.3 ( 92.3 , 94.2 ) | 82.5 ( 80.3 , 84.4 ) |                      |          |  |
| 2(a) 2.7. Hairy-cell leukemia                                                 | 287      | 89.9 ( 82.3 , 94.4 ) | - ( - , - )          | 97.2 ( 92.4 , 99.0 ) | 73.2 ( 54.4 , 85.3 ) |                      |          |  |
| 2(a) 2.8. Plasma cell neoplasms                                               | 13,831   | 47.3 ( 46.2 , 48.4 ) | - ( - , - )          | 62.3 ( 60.6 , 63.9 ) | 37.0 ( 35.5 , 38.5 ) |                      |          |  |
| 2(a) 2.8.1. Plasmacytoma                                                      | 721      | 65.4 ( 60.4 , 70.0 ) | - ( - , - )          | 80.3 ( 74.1 , 85.2 ) | 48.5 ( 40.8 , 55.8 ) |                      |          |  |
| 2(a) 2.8.2. Multiple myeloma/<br>plasma-cell leukemia                         | 13,110   | 46.3 ( 45.1 , 47.5 ) | - ( - , - )          | 61.0 ( 59.3 , 62.7 ) | 36.5 ( 34.9 , 38.0 ) |                      |          |  |
| 2(a) 2.9. Heavy chain disease                                                 | -        | - ( - , - )          | - ( - , - )          | - ( - , - )          | - ( - , - )          |                      |          |  |
| 2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>                        | 3,324    | 70.4 ( 68.0 , 72.6 ) | - ( - , - )          | 80.1 ( 77.1 , 82.8 ) | 65.3 ( 62.0 , 68.4 ) |                      |          |  |

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.31 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2006-2012

| Site                                                                                             | Count | All Ages             |  | Ages 0-19            |  | Ages 20-64           |  | Ages 65+             |  |
|--------------------------------------------------------------------------------------------------|-------|----------------------|--|----------------------|--|----------------------|--|----------------------|--|
|                                                                                                  |       | Percent ( 95% C.I. ) |  | Percent ( 95% C.I. ) |  | Percent ( 95% C.I. ) |  | Percent ( 95% C.I. ) |  |
| 2(b) Non-Hodgkin lymphoma, T-cell                                                                | 4,297 | 66.3 ( 64.5 , 68.0 ) |  | 85.3 ( 80.7 , 88.8 ) |  | 72.2 ( 70.1 , 74.2 ) |  | 52.5 ( 49.0 , 55.8 ) |  |
| 2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell                                                   | 148   | 67.1 ( 58.6 , 74.2 ) |  | 92.0 ( 81.8 , 96.6 ) |  | 55.7 ( 42.7 , 67.0 ) |  | - ( - , - )          |  |
| 2(b) 2. Mature Non-Hodgkin lymphoma, T-cell                                                      | 4,120 | 66.5 ( 64.7 , 68.3 ) |  | 83.7 ( 78.3 , 87.9 ) |  | 73.2 ( 71.0 , 75.2 ) |  | 53.0 ( 49.6 , 56.4 ) |  |
| 2(b) 2.1. Mycosis fungoides/Sezary syndrome                                                      | 1,118 | 92.1 ( 89.0 , 94.3 ) |  | 91.4 ( 84.6 , 98.2 ) |  | 93.5 ( 90.2 , 95.7 ) |  | 88.3 ( 82.3 , 92.3 ) |  |
| 2(b) 2.1.1. Mycosis fungoides                                                                    | 1,088 | 93.3 ( 90.1 , 95.5 ) |  | 91.4 ( 84.6 , 98.2 ) |  | 94.2 ( 90.9 , 96.3 ) |  | 90.0 ( 83.9 , 93.9 ) |  |
| 2(b) 2.1.2. Sezary syndrome                                                                      | 30    | 42.7 ( 20.2 , 63.6 ) |  | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  |
| 2(b) 2.2. Peripheral T-cell lymphoma                                                             | 2,338 | 59.4 ( 56.9 , 61.7 ) |  | 84.8 ( 75.3 , 90.8 ) |  | 69.3 ( 66.3 , 72.1 ) |  | 43.4 ( 39.2 , 47.5 ) |  |
| 2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>                                         | 752   | 38.9 ( 34.8 , 43.0 ) |  | - ( - , - )          |  | 48.2 ( 42.4 , 53.8 ) |  | 28.1 ( 22.1 , 34.3 ) |  |
| 2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma                                                   | 357   | 47.0 ( 40.7 , 53.1 ) |  | - ( - , - )          |  | 62.8 ( 53.5 , 70.7 ) |  | 35.8 ( 27.7 , 44.1 ) |  |
| 2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma                                       | 45    | 91.1 ( 74.7 , 97.1 ) |  | - ( - , - )          |  | 89.1 ( 67.2 , 96.7 ) |  | - ( - , - )          |  |
| 2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type                             | 444   | 63.4 ( 57.9 , 68.4 ) |  | 82.9 ( 69.5 , 90.8 ) |  | 71.5 ( 65.0 , 77.0 ) |  | 32.6 ( 21.5 , 44.1 ) |  |
| 2(b) 2.2.5. Hepatosplenic T-cell lymphoma                                                        | -     | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  |
| 2(b) 2.2.6. Enteropathy-type T-cell lymphoma                                                     | 30    | 10.2 ( 2.0 , 26.6 )  |  | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  |
| 2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>                                          | 466   | 83.9 ( 78.5 , 88.1 ) |  | - ( - , - )          |  | 89.3 ( 83.6 , 93.1 ) |  | 74.3 ( 63.4 , 82.4 ) |  |
| 2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma                                     | 228   | 90.4 ( 82.3 , 94.9 ) |  | - ( - , - )          |  | 94.5 ( 87.5 , 97.6 ) |  | 78.8 ( 56.5 , 90.5 ) |  |
| 2(b) 2.3. Adult T-cell leukemia/lymphoma                                                         | 374   | 51.8 ( 45.4 , 57.8 ) |  | 81.6 ( 73.4 , 87.5 ) |  | 34.4 ( 24.0 , 45.0 ) |  | 20.9 ( 10.8 , 33.3 ) |  |
| 2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia | 155   | 43.7 ( 33.7 , 53.3 ) |  | - ( - , - )          |  | 48.2 ( 37.6 , 58.0 ) |  | 37.1 ( 18.2 , 56.2 ) |  |
| 2(b) 2.5. T-cell large granular lymphocytic leukemia                                             | 60    | 75.0 ( 58.6 , 85.7 ) |  | - ( - , - )          |  | 82.4 ( 62.5 , 92.3 ) |  | 63.8 ( 37.5 , 81.4 ) |  |
| 2(b) 2.6. Prolymphocytic leukemia, T-cell                                                        | 75    | 8.9 ( 2.1 , 22.2 )   |  | - ( - , - )          |  | 13.5 ( 2.8 , 32.8 )  |  | 6.4 ( 0.5 , 24.3 )   |  |
| 2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell                                          | 29    | 35.6 ( 18.7 , 53.0 ) |  | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  |
| 2(c) Non-Hodgkin lymphoma, unknown lineage                                                       | 689   | 61.1 ( 56.8 , 65.2 ) |  | 88.5 ( 82.3 , 92.7 ) |  | 60.2 ( 52.3 , 67.3 ) |  | 47.1 ( 40.6 , 53.3 ) |  |
| 2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage                               | 269   | 67.6 ( 61.4 , 73.0 ) |  | 89.7 ( 83.6 , 93.6 ) |  | 40.9 ( 27.8 , 53.5 ) |  | 21.9 ( 10.8 , 35.5 ) |  |
| 2(c) 2. Prolymphocytic leukemia, unknown lineage                                                 | 26    | 54.1 ( 28.4 , 74.1 ) |  | - ( - , - )          |  | - ( - , - )          |  | - ( - , - )          |  |
| 2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage                                 | 394   | 57.1 ( 50.9 , 62.9 ) |  | - ( - , - )          |  | 69.2 ( 59.3 , 77.1 ) |  | 51.5 ( 44.0 , 58.4 ) |  |
| 2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>                                           | 4,047 | 68.5 ( 66.9 , 70.1 ) |  | 89.2 ( 87.7 , 90.6 ) |  | 40.6 ( 37.3 , 43.9 ) |  | 16.8 ( 12.5 , 21.6 ) |  |
| 3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma                                            | 46    | 55.4 ( 36.4 , 70.9 ) |  | - ( - , - )          |  | 72.3 ( 45.4 , 87.6 ) |  | - ( - , - )          |  |
| 4 Lymphoid neoplasm, NOS <sup>c</sup>                                                            | 2,010 | 51.1 ( 48.2 , 53.9 ) |  | 84.3 ( 61.5 , 94.1 ) |  | 67.4 ( 63.0 , 71.4 ) |  | 42.1 ( 38.4 , 45.7 ) |  |

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).


<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

Figure 19.1

# SEER Observed Incidence, SEER Delay Adjusted Incidence and US Death Rates<sup>a</sup> Non-Hodgkin Lymphoma, by Race and Sex



Source: SEER 9 areas and US Mortality Files (National Center for Health Statistics, CDC).

<sup>a</sup> Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines and APCs are calculated using the Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute.


The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.

\* The APC is significantly different from zero ( $p < 0.05$ ).

Figure 19.2

# SEER Incidence and US Death Rates<sup>a</sup> Non-Hodgkin Lymphoma, Both Sexes

## Joinpoint Analyses for Whites and Blacks from 1975-2013 and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2013



Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

<sup>a</sup> Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2013 period allow a maximum of 5 joinpoints. Analyses for other ethnic groups during the period 1992-2013 allow a maximum of 4 joinpoints.


<sup>b</sup> API = Asian/Pacific Islander.

<sup>c</sup> AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>d</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from New Hampshire and Oklahoma.

Figure 19.3


# Non-Hodgkin Lymphoma Incidence Rates, 1980 vs 2013 Males by Age at Diagnosis and SEER area



Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103).

Figure 19.4


# Non-Hodgkin Lymphoma SEER Incidence by Age 1975-1977 vs 2011-2013 All Races, Males



Source: SEER 9 areas. Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103).

Figure 19.5

# SEER Observed Incidence and SEER Delay Adjusted Incidence Rates<sup>a</sup> SEER 9 Areas Compared to SEER 13 Areas Non-Hodgkin Lymphoma, Male, by Race



Source: SEER 9 areas and SEER 13 areas.

<sup>a</sup> Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).


Regression lines and APCs are calculated using the Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute.

The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.

\* The APC is significantly different from zero ( $p < 0.05$ ).

Figure 19.6

# SEER Observed Incidence and SEER Delay Adjusted Incidence Rates<sup>a</sup> SEER 9 Areas Compared to SEER 13 Areas Non-Hodgkin Lymphoma, Female, by Race



Source: SEER 9 areas and SEER 13 areas.

<sup>a</sup> Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).


Regression lines and APCs are calculated using the Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute.

The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.

\* The APC is significantly different from zero ( $p < 0.05$ ).

Figure 19.7

**Non-Hodgkin Lymphoma**  
**5-Year SEER Conditional Relative Survival and**  
**95% Confidence Intervals**  
 Probability of surviving the next 5 years given the cohort  
 has already survived 0, 1, or 3 years  
 1998-2012 by stage at diagnosis



Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG contribute cases for diagnosis years 2000 and later. The remaining 13 SEER Areas contribute cases for the entire time period. Percent surviving is not shown if based on less than 25 cases. Confidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error.